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(Tables 7 and 8). Part 2 contains graphs and maps that depict 
summary data for selected notifiable infectious diseases and 
conditions described in tabular form in Part 1. Historical 
notifiable disease data, annotated as Part 3 in previous releases 
of this summary, will no longer be included in this report. 
Historical notifiable disease data during 1944–2013 are 
available online in previous years’ summaries (http://www.
cdc.gov/mmwr/mmwr_nd). The Selected Reading section 
presents general and disease-specific references for notifiable 
infectious diseases and conditions. These references provide 
additional information on surveillance and epidemiologic 
concerns, diagnostic concerns, and infectious disease-control 
activities. To increase the usefulness of future editions, 
comments regarding the current report and descriptions of 
how information is or could be used are invited. Comments 
should be e-mailed to NNDSSweb@cdc.gov with the following 
subject line: “Annual Summary”.
Background
The infectious diseases and conditions designated by CSTE 
and CDC as nationally notifiable during 2014 are listed in 
this section. A notifiable infectious disease or condition is one 
for which regular, frequent, and timely information regarding 
individual cases is considered necessary for the prevention 
and control of the disease or condition. A brief history of 
the reporting of nationally notifiable infectious diseases and 
conditions in the United States is available at https://wwwn.cdc.
gov/nndss/history.aspx. In 1961, CDC assumed responsibility 
for the collection of data on nationally notifiable diseases and 
deaths in 122 U.S. cities. Data are collected through NNDSS, 
which is neither a single surveillance system nor a method of 
reporting. Rather, it is a “system of systems”, which is coordinated 
by CDC at the national level across disease-specific programs 
to optimize data compilation, analysis, and dissemination of 
notifiable disease data. Monitoring surveillance data enables 
public health authorities to detect sudden changes in disease 
* No cases of anthrax; dengue hemorrhagic fever (and dengue shock syndrome), 
eastern equine encephalitis, nonneuroinvasive disease; poliomyelitis, paralytic; 
poliovirus infection, nonparalytic; severe acute respiratory syndrome-associated 
coronavirus disease (SARS-CoV); smallpox; vancomycin-resistant Staphylococcus 
aureus (VRSA); western equine encephalitis, neuroinvasive and nonneuroinvasive 
disease; and yellow fever were reported in the United States during 2014.
Preface
The Summary of Notifiable Infectious Diseases and Conditions—
United States, 2014 (hereafter referred to as the summary) contains 
the official statistics, in tabular and graphic form, for the reported 
occurrence of nationally notifiable infectious diseases and conditions 
in the United States for 2014. Unless otherwise noted, data are final 
totals for 2014 reported as of June 30, 2015. These statistics are 
collected and compiled from reports sent by U.S. state and territory, 
New York City, and District of Columbia health departments to 
the National Notifiable Diseases Surveillance System (NNDSS), 
which is operated by CDC in collaboration with the Council of 
State and Territorial Epidemiologists (CSTE). This summary is 
available at http://www.cdc.gov/mmwr/mmwr_nd/index.html. 
This site also includes summary publications from previous years.
The Highlights section presents noteworthy epidemiologic 
and prevention information for 2014 for selected infectious 
diseases and conditions and additional information to aid 
in the interpretation of surveillance and infectious diseases- 
and conditions-trend data. Part 1 contains tables showing 
incident (new) cases and incidence rates for the nationally 
notifiable infectious diseases and conditions reported during 
2014; these tables do not include rows for conditions with 
zero cases reported in 2014 (Tables 1,2,3,4,5, and 6).* The 
tables provide the number of cases reported to CDC for 2014 
and the distribution of cases by MMWR month, geographic 
location, and demographic characteristics (e.g., age, sex, race, 
and ethnicity). Part 1 also includes a table with the reported 
incidence of notifiable diseases during 2004–2014 and a 
table enumerating deaths associated with specified notifiable 
infectious diseases and conditions reported to CDC’s National 
Center for Health Statistics (NCHS) during 2008–2014 
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or condition occurrence and distribution, identify changes 
in agents and host factors, and detect changes in health-care 
practices. National level surveillance data are compiled from case 
notification reports of nationally notifiable infectious diseases 
and conditions submitted from the state, territory, and selected 
local health departments to CDC.
Cases are first identified through reports of infectious diseases 
and conditions from the local level to the state or territory. 
Legislation, regulation, or other rules in those jurisdictions 
require health-care providers, hospitals, laboratories, and 
others to provide information on reportable conditions to 
public health authorities or their agents. Case reporting at the 
local level protects the public’s health by ensuring the proper 
identification and follow-up of cases. Public health workers 
ensure that persons who are already ill receive appropriate 
treatment; trace contacts who need vaccines, treatment, 
quarantine, or education; investigate and control outbreaks; 
eliminate environmental hazards; and close premises where 
disease transmission is believed to be ongoing.
Although infectious disease and condition reporting is 
mandated at the state, territory, and local levels by legislation 
or regulation, state and territory notification to CDC is 
voluntary. All U.S. state health departments, five territorial 
health departments, and two local health departments 
(New York City and District of Columbia) voluntarily notify 
CDC about nationally notifiable infectious diseases and 
conditions which are reportable in their jurisdictions; the data 
in these case notifications that CDC receives are collected by 
staff working on reportable disease and condition surveillance 
systems in local, state, and territorial health departments. 
Case notification of nationally notifiable infectious diseases 
and conditions helps public health authorities monitor the 
effect of these diseases and conditions, measure the disease 
and condition trends, assess the effectiveness of control and 
prevention measures, identify populations or geographic 
areas at high risk, allocate resources appropriately, formulate 
prevention strategies, and develop public health policies.
The list of nationally notifiable infectious diseases and 
conditions is revised periodically (Box 1). An infectious 
disease or condition might be added to the list as a new 
pathogen emerges, or a disease or condition might be removed 
as its incidence declines. Public health officials at state and 
territorial health departments collaborate with CDC staff 
in determining which infectious diseases and conditions 
should be considered nationally notifiable. CSTE, with input 
from CDC, makes recommendations annually for additions 
and deletions to the list. The list of infectious diseases and 
conditions considered reportable in each jurisdiction varies 
over time and across jurisdictions. Current and historic 
national public health surveillance case definitions used 
for classifying and enumerating cases consistently at the 
national level across reporting jurisdictions are available 
at https://wwwn.cdc.gov/nndss/conditions.
Data Sources
Provisional data on the reported occurrence of nationally 
notifiable infectious diseases and conditions are published 
weekly in MMWR. After each reporting year, staff in state and 
territory health departments finalize reports of cases for that 
year with local or county health departments and reconcile the 
data with reports previously sent to CDC throughout the year. 
These data are compiled in final form in this summary, which 
represents the official and archival counts of cases for each year. 
The data in these reports are approved by the appropriate chief 
epidemiologist from each submitting state or territory before 
being published in this summary. Data published in MMWR 
Surveillance Summaries or other surveillance reports produced 
by CDC programs might differ from data reported in this 
summary because of differences in the timing of reports, the 
source of the data, or surveillance methodology.
Data in this summary were derived primarily from reports 
transmitted to CDC from health departments in the 50 states, 
five territories, New York City, and the District of Columbia 
(reporting jurisdictions). Data were reported for MMWR 
weeks 1–53, which correspond to the period for the week 
ending January 4, 2014 through the week ending January 3, 
2015. More information regarding notifiable infectious diseases 
and conditions, including national surveillance case definitions, 
is available at https://wwwn.cdc.gov/nndss/conditions. Policies 
for reporting notifiable infectious disease and condition cases 
can vary by disease, condition, or reporting jurisdiction. The 
case-status categories used to determine which cases reported 
to NNDSS are published in the tables are listed by infectious 
disease or condition in the publication criteria column of the 
2014 NNDSS event code list (Box 2).
For a report of a nationally notifiable disease or condition to 
be published in MMWR (formerly described as “print criteria” 
and currently described as “publication criteria”), the reporting 
state or territory must have designated the infectious disease 
or condition reportable in their state or territory for the year 
corresponding to the year of report to CDC. After this criterion 
is met, the infectious disease- or condition-specific criteria listed 
in the Exhibit are applied. Where the Exhibit indicates that all 
reports will be published, this means that cases designated with 
unknown or suspect case confirmation status will be included 
in the counts along with probable and confirmed cases. Data 
for new nationally notifiable infectious diseases or conditions 
are not usually available from reporting jurisdictions until 
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January of the year following the approval of the CSTE position 
statement. In addition, CDC must have Office of Management 
and Budget Paperwork Reduction Act approval to request data 
from reporting jurisdictions (1). As a result, there is usually a 
delay between the time CSTE recommends a condition be made 
nationally notifiable and the time CDC can aggregate the data 
submitted by reporting jurisdictions.
BOX 1. Infectious Diseases and Conditions Designated by CSTE and CDC as Nationally Notifiable During 2014*
Anthrax
Arboviral diseases, neuroinvasive and nonneuroinvasive†
California serogroup viruses
Eastern equine encephalitis virus
Powassan virus
St. Louis encephalitis virus
West Nile virus

























Haemophilus influenzae, invasive disease
Hansen’s disease (Leprosy)
Hantavirus pulmonary syndrome





Hepatitis B, perinatal infection
Hepatitis C, acute
Hepatitis C, past or present
Human Immunodeficiency Virus (HIV) diagnoses§
Influenza-associated pediatric mortality
Invasive pneumococcal disease (Streptococcus pneumoniae, invasive disease)






Meningococcal disease (Neisseria meningitidis)
Mumps















Severe acute respiratory syndrome-associated coronavirus disease 
(SARS-CoV)












Typhoid fever (caused by Salmonella enterica serotype Typhi)
Vancomycin-intermediate Staphylococcus aureus (VISA) infection
Vancomycin-resistant Staphylococcus aureus (VRSA) infection
Varicella (morbidity)
Varicella (mortality)
Vibriosis (any species of the family Vibrionaceae, other than toxigenic 
Vibrio cholerae O1 or O139)
Viral Hemorrhagic Fever





New World Arenaviruses (Guanarito, Machupo, Junin, and Sabia viruses)
Yellow fever
* This list reflects position statements approved in 2013 (or 2012, in the case of leptospirosis) by the Council of State and Territorial Epidemiologists (CSTE) for 
national surveillance, which were implemented in January 2014. In 2012, CSTE recommended that Leptospirosis be made nationally notifiable, but because 
of delays in Office of Management and Budget Paperwork Reduction Act approval, it was not added to the list of nationally notifiable conditions until 2014. 
National surveillance case definitions for these infectious diseases and conditions are available at http://wwwn.cdc.gov/nndss/conditions.
† The year 2014 reflects a modified surveillance case definition for this disease per approved 2013 CSTE position statements.
§ AIDS (Acquired Immunodeficiency Syndrome) has been reclassified as HIV stage III.
¶ Includes the following categories: primary, secondary, latent (including early latent and late latent) and late syphilis with clinical manifestations (including late 
benign syphilis and cardiovascular syphilis).
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BOX 2. EXHIBIT: Publication criteria and CDC organization responsible for finalizing the data with reporting jurisdictions for notifiable conditions 
reported to the National Notifiable Diseases Surveillance System, 2014
Code Notifiable condition Publication criteria*,†,§
CDC Organization responsible 
for finalizing the data
11090 Anaplasma phagocytophilum Confirmed and probable OPHSS
10350 Anthrax Confirmed and probable OPHSS
12010 Babesiosis Confirmed and probable OPHSS
10530 Botulism, foodborne Confirmed OPHSS
10540 Botulism, infant Confirmed OPHSS
10550 Botulism, other (includes wound) Confirmed OPHSS
10548 Botulism, other (unspecified) Confirmed OPHSS
10549 Botulism, wound Confirmed OPHSS
10020 Brucellosis Confirmed and probable OPHSS
10054 California serogroup virus diseases, neuroinvasive Confirmed and probable NCEZID; DVBD
10061 California serogroup virus diseases, nonneuroinvasive Confirmed and probable NCEZID; DVBD
10273 Chancroid All reports NCHHSTP; DSTDP
10274 Chlamydia trachomatis infection All reports NCHHSTP; DSTDP
10470 Cholera (toxigenic Vibrio cholerae O1 or O139) Confirmed OPHSS
11900 Coccidioidomycosis Confirmed OPHSS
11580 Cryptosporidiosis Confirmed and probable OPHSS
11575 Cyclosporiasis Confirmed and probable OPHSS
10680 Dengue fever (DF) Confirmed and probable NCEZID; DVBD
10685 Dengue hemorrhagic fever (DHF) (and Dengue shock syndrome (DSS) Confirmed and probable NCEZID; DVBD
10040 Diphtheria Confirmed, probable, and unknown OPHSS
10053 Eastern equine encephalitis virus disease, neuroinvasive Confirmed and probable NCEZID; DVBD
10062 Eastern equine encephalitis virus disease, nonneuroinvasive Confirmed and probable NCEZID; DVBD
11088 Ehrlichia chaffeensis Confirmed and probable OPHSS
11089 Ehrlichia ewingii Confirmed and probable OPHSS
11091 Ehrlichiosis/Anaplasmosis, undetermined Confirmed and probable OPHSS
11570 Giardiasis Confirmed and probable OPHSS
10280 Gonorrhea All reports NCHHSTP; DSTDP
10590 Haemophilus influenzae, invasive disease Confirmed, probable, and unknown OPHSS
10380 Hansen’s disease (leprosy) Confirmed OPHSS
11590 Hantavirus pulmonary syndrome (HPS) Confirmed NCEZID; DHCPP
11550 Hemolytic uremic syndrome, postdiarrheal (HUS) Confirmed and probable OPHSS
10110 Hepatitis A, acute Confirmed NCHHSTP; DVH
10100 Hepatitis B, acute Confirmed NCHHSTP; DVH
10105 Hepatitis B, chronic Confirmed and probable NCHHSTP; DVH
10104 Hepatitis B perinatal infection Confirmed NCHHSTP; DVH
10101 Hepatitis C, acute Confirmed NCHHSTP; DVH
10106 Hepatitis C, past or present Confirmed and probable NCHHSTP; DVH
HIV diagnoses Confirmed NCHHSTP; DHAP
11061 Influenza-associated pediatric mortality Confirmed NCIRD; ID
11723 Invasive Pneumococcal Disease (IPD)/Streptococcus pneumoniae, 
invasive disease (all ages)
Confirmed OPHSS
10490 Legionellosis Confirmed OPHSS
10390 Leptospirosis Confirmed and probable OPHSS
10640 Listeriosis Confirmed OPHSS
11080 Lyme disease Confirmed and probable OPHSS
10130 Malaria Confirmed OPHSS
10140 Measles (rubeola), total Confirmed and unknown OPHSS
10150 Meningococcal disease (Neisseria meningitidis) Confirmed and probable OPHSS
10180 Mumps Confirmed, probable, and unknown OPHSS
11062 Novel influenza A virus infections, initial detections of Confirmed NCIRD; ID
10190 Pertussis (Whooping Cough) Confirmed, probable, and unknown OPHSS
10440 Plague All reports OPHSS
10410 Poliomyelitis, paralytic Confirmed OPHSS
10405 Poliovirus infection, nonparalytic Confirmed OPHSS
10057 Powassan virus disease, neuroinvasive Confirmed and probable NCEZID; DVBD
10063 Powassan virus disease, nonneuroinvasive Confirmed and probable NCEZID; DVBD
10450 Psittacosis (Ornithosis) Confirmed and probable OPHSS
10257 Q fever, acute Confirmed and probable OPHSS
10258 Q fever, chronic Confirmed and probable OPHSS
10340 Rabies, animal Confirmed NCEZID; DHCPP
10460 Rabies, human Confirmed NCEZID; DHCPP
10200 Rubella Confirmed and unknown OPHSS
10370 Rubella, congenital syndrome (CRS) Confirmed, probable, and unknown OPHSS
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Final data for certain infectious diseases and conditions are 
derived from the surveillance records of the CDC program. 
Requests for further information regarding these data should 
be directed to the appropriate program. The CDC organization 
responsible for finalizing the data used for the final MMWR 
tables for each condition is listed in the Exhibit.
Population estimates were obtained from the NCHS 
postcensal estimates of the resident population of the 
United States during July 1, 2013–July 1, 2014, by year, county, 
single year of age (range: 0 to ≥85 years), bridged-race (white, 
black or African American, American Indian or Alaska Native, 
Asian, or Pacific Islander), Hispanic ethnicity (not Hispanic or 
BOX 2. EXHIBIT: (Continued) Publication criteria and CDC organization responsible for finalizing the data with reporting jurisdictions for 
notifiable conditions reported to the National Notifiable Diseases Surveillance System, 2014
Code Notifiable condition Publication criteria*,†,§
CDC Organization responsible 
for finalizing the data
11000 Salmonellosis Confirmed and probable OPHSS
10575 Severe acute respiratory syndrome-associated coronavirus 
(SARS-CoV) disease
Confirmed and probable OPHSS
11563 Shiga toxin-producing Escherichia coli (STEC) Confirmed and probable OPHSS
11010 Shigellosis Confirmed and probable OPHSS
11800 Smallpox Confirmed and probable OPHSS
10250 Spotted fever rickettsiosis Confirmed, probable, and unknown OPHSS
10051 St. Louis encephalitis virus disease, neuroinvasive Confirmed and probable NCEZID; DVBD
10064 St. Louis encephalitis virus disease, nonneuroinvasive Confirmed and probable NCEZID; DVBD
11700 Streptococcal toxic shock syndrome (STSS) Confirmed and probable OPHSS
10316 Syphilis, congenital All reports NCHHSTP; DSTDP
10313 Syphilis, early latent All reports NCHHSTP; DSTDP
10314 Syphilis, late latent All reports NCHHSTP; DSTDP
10319 Syphilis, late with clinical manifestations (including late benign syphilis 
and cardiovascular syphilis)
All reports NCHHSTP; DSTDP
10311 Syphilis, primary All reports NCHHSTP; DSTDP
10312 Syphilis, secondary All reports NCHHSTP; DSTDP
10310 Syphilis, total primary and secondary All reports NCHHSTP; DSTDP
10210 Tetanus All reports OPHSS
10520 Toxic shock syndrome (staphylococcal) (TSS) Confirmed and probable OPHSS
10270 Trichinellosis Confirmed and probable OPHSS
10220 Tuberculosis Confirmed NCHHSTP; DTE
10230 Tularemia Confirmed and probable OPHSS
10240 Typhoid fever (caused by Salmonella typhi) Confirmed and probable OPHSS
11663 Vancomycin-intermediate Staphylococcus aureus (VISA) Confirmed OPHSS
11665 Vancomycin-resistant Staphylococcus aureus (VRSA) Confirmed OPHSS
10030 Varicella morbidity (Chickenpox) Confirmed and probable OPHSS
 Varicella mortality Confirmed and probable¶ NCIRD; DVD
11545 Vibriosis (any species of the family Vibrionaceae, other than toxigenic 
Vibrio cholerae O1 or O139)
Confirmed and probable OPHSS
11647 Viral hemorrhagic fevers (VHF) Confirmed OPHSS
10056 West Nile virus disease, neuroinvasive Confirmed and probable NCEZID; DVBD
10049 West Nile virus disease, nonneuroinvasive Confirmed and probable NCEZID; DVBD
10052 Western equine encephalitis virus disease, neuroinvasive Confirmed and probable NCEZID; DVBD
10065 Western equine encephalitis virus disease, nonneuroinvasive Confirmed and probable NCEZID; DVBD
10660 Yellow fever Confirmed and probable NCEZID; DVBD
Abbreviations: OPHSS = Office of Public Health Scientific Services; NCEZID = National Center for Emerging and Zoonotic Infectious Diseases; DVBD = Division of 
Vector-Borne Diseases; NCHHSTP = National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention; DSTDP = Division of STD Prevention; DHCPP = Division 
of High Consequence Pathogens and Pathology; DVH = Division of Viral Hepatitis; DHAP = Division of HIV/AIDS Prevention; NCIRD = National Center for Infectious 
and Respiratory Diseases; ID = Influenza Division; DTE = Division of Tuberculosis Elimination; DVD = Division of Viral Diseases.
* An unknown case classification status is used when a reporting jurisdiction sends aggregate counts of cases or when the surveillance information system of a 
reporting jurisdiction does not capture case classification data. In both situations, cases are verified to meet the case classification (e.g., confirmed, probable, 
and suspected) specified in the publication criteria.
† Publication criteria for the National Notifiable Diseases Surveillance System (NNDSS): for a case report of a nationally notifiable disease to be published in MMWR, 
the reporting state or territory must have designated the disease reportable in their state or territory for the year corresponding to the year of report to CDC. 
After this criterion is met, the disease-specific criteria listed in the Exhibit are applied. When the above-listed table indicates that all reports will be earmarked 
for publication, this means that cases designated with unknown or suspect case confirmation status will be published just as probable and confirmed cases will 
be published. Because Council of State and Territorial (CSTE) position statements customarily are not finalized until July of each year, NNDSS data for the newly 
added conditions usually are not available from all reporting jurisdictions until January of the year following the approval of the CSTE position statement.
§ Based on case classification status.
¶ Publication criteria determined by reporting jurisdictions. In 2014 Varicella deaths were reported from four jurisdictions with the following publication criteria; 
Texas (probable), Florida (confirmed), Virginia (confirmed), and Georgia (confirmed).
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Latino, Hispanic or Latino), and sex (Vintage 2014), prepared 
under a collaborative arrangement with the U.S. Census 
Bureau. Population estimates for states as of June 25, 2015 are 
available at http://www.cdc.gov/nchs/nvss/bridged_race/data_
documentation.htm#vintage2014. Population estimates for 
territories are from the 2014 U.S. Census Bureau International 
Data Base, available at http://www.census.gov/population/
international/data/idb/informationGateway.php. The choice of 
population denominators for incidence reported in MMWR is 
based on the availability of census population data at the time 
of preparation for publication and the desire for consistent use 
of the same population data to compute incidence reported 
by different CDC programs.
Incidence in this summary was calculated as the number 
of reported cases for each infectious disease or condition 
divided by either the U.S. resident population for the specified 
demographic population or the total U.S. resident population, 
multiplied by 100,000. For Territories, incidence in this 
summary was calculated as the number of reported cases for 
each infectious disease or condition divided by either the 
territorial resident population for the specified demographic 
population or the total territorial resident population, 
multiplied by 100,000. When a nationally notifiable infectious 
disease or condition is associated with a specific age restriction, 
the same age restriction was applied to the population in 
the denominator of the incidence calculation. In addition, 
population data from states in which the disease or condition 
was not reportable or was not available are excluded from 
incidence calculations. Unless otherwise stated, disease totals 
for the United States do not include data for American Samoa, 
Guam, Puerto Rico, the Commonwealth of the Northern 
Mariana Islands, or the U.S. Virgin Islands.
Interpreting Data
The completeness of information on notifiable infectious diseases 
and conditions was highly variable and related to the disease or 
condition being reported (2–9). Incidence data in this summary 
are presented by the MMWR week and year (https://wwwn.cdc.
gov/nndss/document/MMWR_Week_overview.pdf) assigned by 
the state or territorial health department, with some exceptions, 
including human immunodeficiency virus (HIV) (presented 
by date of diagnosis), tuberculosis (presented by date CDC 
surveillance staff verified that the case met the criteria in the national 
surveillance case definition), domestic arboviral diseases (presented 
by date of illness onset), and varicella deaths (presented by date of 
death). Data were reported by the jurisdiction of the person’s “usual 
residence” at the time of disease or condition onset (https://wwwn.
cdc.gov/nndss/document/11-SI-04.pdf). For certain nationally 
notifiable infectious diseases and conditions, surveillance data are 
reported independently to various CDC programs. For this reason, 
surveillance data reported by other CDC programs might vary 
from data reported in this summary because of differences in 1) the 
date used to aggregate data (e.g., date of report or date of disease 
or condition occurrence), 2) the timing of reports, 3) the source of 
the data, 4) surveillance case definitions, and 5) policies regarding 
case jurisdiction (i.e., which jurisdiction should submit the case 
notification to CDC). In addition, the “date of disease occurrence” 
of conditions might vary. For infectious diseases, the meaning of 
the “date of disease occurrence” varies across jurisdictions and by 
disease and might be a date of symptom or disease onset, diagnosis, 
laboratory result, reporting of a case to a jurisdiction, or notification 
of a case to CDC.
Data reported in this summary are useful for analyzing 
infectious disease or condition trends and determining relative 
infectious disease or condition numbers. However, reporting 
practices affect how these data should be interpreted. Infectious 
disease and condition reporting is likely incomplete, and 
completeness might vary depending on the infectious disease 
or condition and reporting state. The degree of completeness 
of data reporting also might be influenced by the diagnostic 
facilities available, control measures in effect, public awareness 
of a specific infectious disease or condition, and the resources 
and priorities of state and local officials responsible for public 
health surveillance and for controlling infectious diseases and 
conditions. Finally, factors such as changes in methods for 
public health surveillance, introduction of new diagnostic tests, 
or discovery of new infectious disease or condition entities can 
cause changes in reporting that are independent of the actual 
incidence of infectious disease or condition.
Public health surveillance data are published for selected 
racial/ethnic populations because these characteristics can 
be risk markers for certain notifiable infectious diseases 
or conditions. Race and ethnicity data also can be used to 
highlight populations for focused prevention programs. 
However, caution must be used when drawing conclusions 
from reported race and ethnicity. Different racial/ethnic 
populations might have different patterns of access to health 
care, potentially resulting in data that are not representative of 
actual infectious disease or condition incidence among specific 
population groups. In addition, not all race and ethnicity data 
are collected or reported uniformly for all infectious diseases 
and conditions; for example, the recommended standard for 
classifying a person’s race or ethnicity is based on self-reporting. 
However, this procedure might not always be followed.
Surveillance data reported to NNDSS are in either individual 
case-specific form or summary form (i.e., aggregated data 
for a group of cases). Summary data often lack demographic 
information (e.g., race); therefore, the demographic-specific 
rates presented in this summary might be underestimated.
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Transitions in NNDSS Data Collection
Data collection in NNDSS has undergone various transitions 
over time. Before 1990, data were reported to CDC as 
cumulative counts rather than as individual case reports. In 
1990, using the National Electronic Telecommunications 
System for Surveillance (or NETSS), states began electronically 
capturing and reporting individual cases to CDC without 
personal identifiers.  In 2001, CDC launched the National 
Electronic Disease Surveillance System (NEDSS) to 
promote the use of data and information system standards 
that advance the development of efficient, integrated, and 
interoperable surveillance information systems at the local, 
state, territorial, and national levels. Reporting jurisdictions 
now use integrated surveillance information systems based on 
NEDSS architectural standards to submit NNDSS data to 
CDC. Additional information concerning NEDSS is available 
at https://wwwn.cdc.gov/nndss/nedss.aspx.
In 2013, CDC began to conceptualize improvements 
to strengthen and modernize the technical infrastructure 
supporting NNDSS. In 2014, CDC and selected states 
began work on the NNDSS Modernization Initiative (NMI), 
a multiyear commitment to enhance NNDSS surveillance 
capabilities. An important benefit for public health decision 
making will be the ability to acquire higher quality data that 
are more comprehensive and timely. Through NMI, CDC and 
its state partners will increase the robustness of the NNDSS 
technological infrastructure so that it is based on interoperable, 
standardized data and data exchange mechanisms. Additional 
information is available at http://www.cdc.gov/nmi.
Method for Identifying which 
Nationally Notifiable Infectious 
Diseases and Conditions are 
Reportable
States and jurisdictions are sovereign entities. Reportable 
conditions are determined by the laws and regulations of 
each state, territory, or local jurisdiction. Some infectious 
diseases and conditions deemed nationally notifiable by CSTE 
might not be designated as reportable in certain states or 
jurisdictions. Only data from reporting states, territories, and 
jurisdictions that designated the infectious disease or condition 
as reportable are included in the summary tables. This ensures 
the data displayed in this summary are from population-based 
surveillance efforts and are generally comparable across states, 
territories, and other jurisdictions. When a CSTE- and CDC-
recommended nationally notifiable disease or condition is not 
reportable by state, territory, or other jurisdiction officials, 
an “N” indicator for “not reportable” is inserted in the table 
for the specified reporting state, territory, or jurisdiction 
and applicable year. Each year, the NNDSS Data Processing 
Team solicits information from each NNDSS reporting state, 
territory, and jurisdiction (all 50 U.S. states, the District of 
Columbia, New York City, and five U.S. territories) about 
whether reporting is mandated by law or regulation for each 
nationally notifiable condition.
International Health Regulations
At its annual meeting in June 2007, CSTE approved 
a position statement that supports implementation of 
International Health Regulations (IHR) in the United States 
(10). CSTE approval followed the adoption of revised IHR in 
May 2005 by the World Health Assembly (11) that went into 
effect in the United States on July 18, 2007. This international 
legal instrument governs the role of the World Health 
Organization (WHO) and its member countries, including 
the United States, in identifying, responding to, and sharing 
information about events that might constitute a Public Health 
Emergency of International Concern (PHEIC). A PHEIC is 
an extraordinary event that constitutes a public health risk to 
other countries through international spread of disease and 
potentially requires a coordinated international response. All 
WHO member countries are required to notify WHO of a 
potential PHEIC. WHO makes the final determination about 
the existence of a PHEIC.
Health care providers in the United States are required to 
report diseases, conditions, and outbreaks determined to be 
reportable by local, state, or territorial law or regulation. In 
addition, all health care providers should work with their local, 
state, or territorial health agencies to identify and report events 
occurring in their location that might constitute a PHEIC. U.S. 
state and territorial departments of health report information 
about a potential PHEIC to the most relevant federal agency 
responsible for monitoring such an event. In the case of human 
infectious disease, the U.S. state or territorial departments of 
health notifies CDC through existing formal and informal 
reporting mechanisms (10). CDC further analyzes the event by 
use of the decision algorithm in Annex 2 of the IHR and notifies 
the U.S. Department of Health and Human Services (HHS) 
Secretary’s Operations Center (SOC), as appropriate. The HHS 
SOC is responsible for reporting a potential PHEIC to WHO.
In the United States, HHS has the lead role in carrying out 
IHR, in cooperation with multiple federal departments and 
agencies. When a potential PHEIC is identified, the United 
States has 48 hours to assess the risk of the reported event. If 
authorities determine that a potential PHEIC exists, the United 
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States, as with all WHO member countries, has 24 hours to 
report the event to WHO. The HHS SOC is responsible for 
reporting a potential PHEIC to WHO.
An IHR decision algorithm (Annex 2 of the IHR) was 
developed to help countries determine whether an event should 
be reported. If any two of the following four questions are 
answered in the affirmative, then a potential PHEIC exists 
and WHO should be notified:
• Is the public health impact of the event serious?
• Is the event unusual or unexpected?
• Is there a significant risk of international spread?
• Is there a significant risk for international travel or 
trade restrictions?
The revised IHR reflects a conceptual shift from the use 
of a predefined disease list to a framework of reporting and 
responding to events on the basis of an assessment of public 
health criteria, including seriousness, unexpectedness, and 
international travel and trade implications. A PHEIC is an 
event that falls within those criteria (further defined in a 
decision algorithm in Annex 2 of the revised IHR); however, 
any one of the following four conditions always constitutes 
a PHEIC and do not require the use of the IHR decision 
instrument in Annex 2:
• severe acute respiratory syndrome (SARS),
• smallpox,
• poliomyelitis caused by wild-type poliovirus, and
• human influenza caused by a new subtype.
Examples of events that require the use of the decision 
instrument include, but are not limited to cholera, pneumonic 
plague, yellow fever, West Nile fever, viral hemorrhagic fevers, 
and meningococcal disease. Other biologic, chemical, or 
radiologic events that fit the decision algorithm also must be 
reported to WHO.




CSTE also approved a position statement that added initial 
detections of novel influenza A virus infections to the list of 
nationally notifiable infectious diseases, beginning in January 
2007, to in part support the implementation of the revised 
IHR in the United States to identify human influenza caused 
by a new subtype (12).
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Anthrax
The U.S. Food and Drug Administration (FDA) has 
approved two antitoxin treatments for inhalation anthrax: 
anthrax immune globulin intravenous (human) (i.e., Anthrasil) 
(1) and raxibacumab (2). These therapeutics are held in the 
Strategic National Stockpile, and requests for use must be 
made to CDC. Antitoxins, in combination with antimicrobials 
and supportive therapies, are recommended for treatment 
of systemic anthrax. In addition, anthrax vaccine adsorbed 
(i.e., BioThrax) is FDA-approved as a 3-dose postexposure 
prophylaxis (PEP) series, along with antimicrobials, to prevent 
anthrax in adults exposed to Bacillus anthracis (3). PEP and 
treatment recommendations exist for multiple populations, 
including children, pregnant and postpartum women, and 
adults for conventional and mass casualty settings (4–7).
1. Food and Drug Administration. FDA approves treatment for 
inhalation anthrax. 2015. http://www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/ucm439752.htm
2. Food and Drug Administration. FDA approves raxibacumab to treat 
inhalational anthrax. 2012. http://www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/ucm332341.htm
3. Food and Drug Administration. FDA approves vaccine for use after known 
or suspected anthrax exposure. 2015. http://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm474027.htm
4. Bradley JS, Peacock G, Krug SE, et al. Pediatric anthrax clinical 
management. Pediatrics 2014;133:e1411–36. http://dx.doi.org/10.1542/
peds.2014-0563
5. Hendricks KA, Wright ME, Shadomy SV, et al. Centers for disease control 
and prevention expert panel meetings on prevention and treatment of 
anthrax in adults. Emerg Infect Dis 2014. http://dx.doi.org/10.3201/
eid2002.130687
6. Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations 
for prophylaxis for and treatment of anthrax in pregnant and postpartum 
women. Emerg Infect Dis 2014. http://dx.doi.org/10.3201/eid2002.130611
7. Bower WA, Hendricks K, Pillai S, Guarnizo J, Meaney-Delman D. 
Clinical framework and medical countermeasure use during an anthrax 
mass-casualty incident. MMWR Recomm Rep 2015;64(No. RR-4).
Domestic Arboviral Disease, 
Neuroinvasive and Nonneuroinvasive
In 2014, a total of 2,205 West Nile virus (WNV) disease cases 
were reported, including 1,347 cases of neuroinvasive disease 
(e.g., meningitis, encephalitis, and acute flaccid paralysis) and 
97 deaths (1). WNV disease cases were reported from 42 states 
and the District of Columbia. Three states reported two thirds 
(66%) of the WNV neuroinvasive disease cases: California 
(561 cases), Texas (253), and Arizona (80). The incidence 
of neuroinvasive disease was similar to the median incidence 
during 2002–2013 (median = 0.40; range = 0.13–1.02). 
However, California reported a record 561 neuroinvasive 
disease cases, 83% more than the next highest year (2005). In 
California, 70% of all neuroinvasive disease cases were reported 
from two counties (Los Angeles and Orange). These findings 
underscore the focal nature of WNV outbreaks.
After WNV, the next most commonly reported cause of 
neuroinvasive arboviral disease was La Crosse virus, followed by 
Jamestown Canyon virus, St. Louis encephalitis virus, Powassan 
virus, and Eastern equine encephalitis virus. Jamestown Canyon 
virus disease cases continue to be reported from new locations (e.g., 
Tennessee) following the implementation of routine Jamestown 
Canyon virus antibody testing at CDC in 2013 (2). Although 
rare, Eastern equine encephalitis virus disease remained the most 
severe arboviral disease, with two deaths among eight patients.
1. Lindsey NP, Lehman JA, Staples JE, Fischer M. West Nile virus and other 
nationally notifiable arboviral diseases—United States, 2014. MMWR 
Morb Mortal Wkly Rep 2015;64:929–34. http://dx.doi.org/10.15585/
mmwr.mm6434a1
2. Pastula DM, Hoang Johnson DK, White JL, Dupuis AP 2nd, 
Fischer M, Staples JE. Jamestown Canyon virus disease in the 
United States—2000–2013. Am J Trop Med Hyg 2015;93:384–9. http://
dx.doi.org/10.4269/ajtmh.15-0196
Babesiosis
Babesiosis is caused by protozoan parasites of the genus Babesia, 
which infect red blood cells. Babesia infection can range from 
asymptomatic to life threatening. Clinical manifestations can 
include fever, chills, other nonspecific influenza-like symptoms, 
and hemolytic anemia. Babesia parasites usually are tickborne but 
also can be transmitted via blood transfusion or congenitally (1).
In 2014, a total of 1,744* cases of babesiosis were reported 
to CDC. Babesiosis cases were reported by 22 of the 31 
states in which babesiosis was a reportable condition; 94% 
(1,636) of the reported cases occurred in residents of seven 
states (Connecticut, Massachusetts, Minnesota, New Jersey, 
New York, Rhode Island, and Wisconsin). The median age 
of patients was 63 years (range: <1–96 years); 65% (1,131) 
were male, and sex was unknown for <1% (six). Among the 
1,340 patients for whom data were available, 84% (1,124) had 
symptom onset dates during June–August.
1. Herwaldt BL, Linden JV, Bosserman E, Young C, Olkowska D, 
Wilson M. Transfusion-associated babesiosis in the United States: a 
description of cases. Ann Intern Med 2011;155:509–19. http://dx.doi.
org/10.7326/0003-4819-155-8-201110180-00362
Highlights for 2014
* This number differs slightly from the denominator of 1,760 presented in Table 2, 
which includes 22 erroneous reports not retracted before the deadline for 
finalizing the data. In addition, six cases that were reported after the deadline 
are included at the request of the pertinent health departments.
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Botulism
Botulism is a severe paralytic illness caused by toxins produced 
by Clostridium botulinum. Exposure to the toxin can occur 
by ingestion (foodborne botulism), in situ production from 
C. botulinum colonization of either a wound (wound botulism) 
or the gastrointestinal tract (infant botulism and adult intestinal 
colonization botulism), or overdose of botulinum toxin used for 
cosmetic or therapeutic purposes (1). In 2014, a total of 161 
cases of botulism were reported, including 127 cases in infants, 
15 foodborne cases, and 19 cases classified as other, including 
wound botulism. During 2014, four outbreaks (events with 
two or more cases) of foodborne botulism were reported. One 
outbreak was associated with stinkheads (fermented whitefish 
heads, a traditional Alaska Native food) (three cases), one with 
seal oil (three cases), one with home-canned tomato sauce (two 
cases), and one with pasta and jarred pesto (two cases). The jarred 
pesto was produced in a home kitchen, sold commercially, and 
then mixed with the pasta by one of the cases; the only leftovers 
available for testing were the pesto and pasta mixed together.
All states maintain 24-hour telephone services for reporting of 
botulism and other public health emergencies. Health care providers 
should report suspected botulism cases immediately to their state 
health departments. CDC maintains intensive surveillance for cases 
of botulism in the United States and provides consultation and 
antitoxin for suspected cases. State health departments can reach the 
CDC botulism duty officer on call 24 hours a day, 7 days a week via 
the CDC Emergency Operations Center (telephone: 770-488-7100).
1. Sobel J. Botulism. Clin Infect Dis 2005;41:1167–73. http://dx.doi.
org/10.1086/444507
Brucellosis
During 2014, a total of 92 human brucellosis cases were 
reported in the United States; 58 were among men. Cases 
were distributed throughout the United States, with the South 
Atlantic and Pacific regions having the highest number of 
reported cases (19 and 25, respectively). Persons who consume 
raw (unpasteurized) dairy products might be at increased risk 
for exposure to Brucella spp., which can cause brucellosis (1). 
Feral swine hunters also are considered an at-risk population (2).
1. CDC. Risks from unpasteurized dairy products. http://www.cdc.gov/
brucellosis/exposure/unpasteurized-dairy-products.html
2. CDC. Hunters risks. http://www.cdc.gov/brucellosis/exposure/hunters.html
Chlamydia
Chlamydia trachomatis is the most commonly reported 
nationally notifiable infectious disease in the United States; 
1,441,789 cases were reported to CDC in 2014. Following a 
slight decline during 2012–2013, the national rate of reported 
chlamydial infection increased 2.8% during 2013–2014,* from 
443.5 to 456.1 per 100,000 population (1). Rates were highest 
among females aged 15–19 years (2,941.0 cases per 100,000 
females) and 20–24 years (3,651.1). The rate among women 
aged 15–19 years increased steadily during 2000–2011, but 
decreased 4.4% during 2011–2012, 7.9% during 2012–2013, 
and 4.2% during 2013–2014. As in previous years, rates of 
reported chlamydia were highest among non-Hispanic blacks. 
The rate of reported chlamydia among black females aged 
15–19 years was 4.9 times the rate among white females in the 
same age group. Most chlamydial infections are asymptomatic, 
and rates of reported cases are affected by the diagnostic 
test used and the proportion of the population screened. 
Consequently, increases in case rates might reflect expanded 
screening coverage, use of more sensitive diagnostic tests, and 
increases in incidence of infection. Likewise, decreases in rates 
of reported chlamydial infections might suggest decreases in 
incidence of infection or decreases in screening coverage.
1. CDC. Sexually transmitted disease surveillance 2014. Atlanta, GA: US 
Department of Health and Human Services, CDC; 2015.
Cholera
Cholera continues to be rare in the United States and is most 
often acquired during travel in countries where toxigenic Vibrio 
cholerae O1 or O139 is circulating (1‒3). Of the five cholera 
infections in 2014, all were travel-associated (two with travel 
to Cuba, two to India, and one to Ghana). Although cholera 
is endemic in many African countries, the patient who traveled 
to Ghana is the first since 2011 to be associated with travel to 
an African country (4).
1. Steinberg EB, Greene KD, Bopp CA, Cameron DN, Wells JG, 
Mintz ED. Cholera in the United States, 1995–2000: trends at the end 
of the twentieth century. J Infect Dis 2001;184:799–802. http://dx.doi.
org/10.1086/322989
2. Newton AE, Heiman KE, Schmitz A, et al. Cholera in United States 
associated with epidemic in Hispaniola. Emerg Infect Dis 2011;17:2166–
8. http://dx.doi.org/10.3201/eid1711.110808
3. Loharikar A, Newton AE, Stroika S, et al. Cholera in the United States, 
2001–2011: a reflection of patterns of global epidemiology and travel. 
Epidemiol Infect 2015;143:695–703. http://dx.doi.org/10.1017/
S0950268814001186
4. Mintz ED, Guerrant RL. A lion in our village—the unconscionable 
tragedy of cholera in Africa. N Engl J Med 2009;360:1060–3. http://
dx.doi.org/10.1056/NEJMp0810559
* Rates for 2014 were calculated using the 2013 population estimates and differ 
from 2014 rates presented in the figures and table 7 (calculated using 2014 
population estimates).
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Coccidioidomycosis
Coccidioidomycosis (i.e., Valley fever) is a fungal infection 
caused by inhalation of Coccidioides spp. spores that are present 
in the arid soil of the southwestern United States, California, 
and parts of Central and South America. Coccidioides also 
was recently identified in soil in south-central Washington in 
association with cases of human disease (1). After a substantial 
increase during 1998–2011 (2), the number of cases has 
decreased each year since then, including a 13% decrease in 
the number of cases from 2013 to 2014 (9,438 and 8,232, 
respectively). Historically, Arizona and California have had the 
highest number of reported coccidioidomycosis cases. Arizona, 
which reported the most cases (5,624) of any state in 2014, 
experienced a 4% decrease in the number of cases compared 
with 2013 (5,861 cases). California reported the second-highest 
number of cases (2,243) of any state in 2014 and experienced 
a 31% decrease compared with 2013 (3,272 cases).
Reasons for the overall decrease in reported cases might, in 
part, be related to changes in the environment or changes in 
the at-risk population. Physicians should continue to maintain 
a high suspicion for acute coccidioidomycosis in patients who 
live in or have traveled to areas in which the disease is endemic 
and should be aware of the possibility for coccidioidomycosis 
outside of its previously recognized geographic range.
1. Litvintseva AP, Marsden-Haug N, Hurst S, et al. Valley fever: finding new 
places for an old disease: Coccidioides immitis found in Washington State 
soil associated with recent human infection. Clin Infect Dis 2015;60:e1–3. 
http://dx.doi.org/10.1093/cid/ciu681
2. CDC. Increase in reported coccidioidomycosis—United States, 1998–
2011. MMWR Morb Mortal Wkly Rep 2013;62:217–21.
Cryptosporidiosis
Approximately 95% of human cryptosporidiosis is caused by 
the numerous Cryptosporidium parvum and Cryptosporidium 
hominis subtypes. Although cryptosporidiosis affects persons 
of all age groups, cases are most frequently reported in children 
aged 1–4 years (1). A substantial increase in transmission 
of Cryptosporidium occurs during summer, coinciding with 
increased use of recreational water, a well-established risk 
factor for cryptosporidiosis. Cryptosporidium has emerged as 
the leading cause of nationally notified recreational water–
associated outbreaks and waterborne disease outbreaks overall 
(2). Transmission through recreational water is facilitated 
by the substantial number (up to 108–109) of immediately 
infectious Cryptosporidium oocysts that can be shed in a single 
bowel movement (3), the extended time (days to weeks) that 
oocysts can be shed (4), the low (≤10 oocysts) infectious dose 
(5), and the extreme tolerance of Cryptosporidium oocysts to 
chlorine (6). In 2014, the increased reporting observed after 
2004 continued. In addition, the proportion of probable cases 
has increased to 36% of all reported cases, primarily because 
of changes in the 2011 and 2012 national case definitions.
Conventional diagnostics (e.g., microscopy and immunoassays) 
cannot discriminate among the Cryptosporidium species and 
their subtypes. CDC has launched CryptoNet, a molecular-
based surveillance system that will integrate traditional and 
molecular data to help elucidate Cryptosporidium transmission 
pathways and thus the epidemiology of cryptosporidiosis in 
the United States. CryptoNet has successfully differentiated 
clusters of illness caused by different Cryptosporidium species 
and detected outbreaks caused by rare subtypes. Additional 
information about CryptoNet is available at http://www.cdc.
gov/parasites/crypto/cryptonet.html.
To reduce the burden of cryptosporidiosis associated with 
recreational water, enhanced prevention measures are needed. 
In the United States, public health codes for public aquatic 
facilities are written, enacted, implemented, and enforced by 
state or local officials; no federal agency regulates the design, 
construction, operation, and maintenance of these venues. 
To provide support to state and local jurisdictions, CDC led 
the development and revision of the Model Aquatic Health 
Code (MAHC) (http://www.cdc.gov/mahc/editions/current.
html). This guidance document integrates the latest science 
and best practices with specific code language and explanatory 
materials covering the design, construction, operation, and 
maintenance of public swimming pools, hot tubs/spas, and 
other aquatic venues. The MAHC is updated every 2 years 
through an all-stakeholder–driven process via the Council for 
the Model Aquatic Health Code (www.cmahc.org/index.php) 
to ensure its continued relevance and to respond to the latest 
scientific data and aquatics sector innovations.
1. Painter JE, Hlavsa MC, Collier SA, Xiao L, Yoder JS. Cryptosporidiosis 
surveillance—United States, 2011–2012. MMWR Suppl 2015;64(No. SS-3).
2. Hlavsa MC, Roberts VA, Kahler AM, et al. Outbreaks of illness associated 
with recreational water—United States, 2011–2012. MMWR Morb 
Mortal Wkly Rep 2015;64:668–72.
3. Goodgame RW, Genta RM, White AC, Chappell CL. Intensity of infection 
in AIDS-associated cryptosporidiosis. J Infect Dis 1993;167:704–9. 
http://dx.doi.org/10.1093/infdis/167.3.704
4. Chappell CL, Okhuysen PC, Sterling CR, DuPont HL. Cryptosporidium 
parvum: intensity of infection and oocyst excretion patterns in healthy 
volunteers. J Infect Dis 1996;173:232–6. http://dx.doi.org/10.1093/
infdis/173.1.232
5. Chappell CL, Okhuysen PC, Langer-Curry R, et al. Cryptosporidium 
hominis: experimental challenge of healthy adults. Am J Trop Med Hyg 
2006;75:851–7.
6. Murphy JL, Arrowood MJ, Lu X, Hlavsa MC, Beach MJ, Hill VR. Effect 
of cyanuric acid on the inactivation of Cryptosporidium parvum under 
hyperchlorination conditions. Environ Sci Technol 2015;49:7348–55. 
http://dx.doi.org/10.1021/acs.est.5b00962
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Cyclosporiasis
Of the 398 cyclosporiasis cases reported in 2014, a total of 
275 (69%) were domestically acquired (i.e., they occurred in 
persons with no known history of travel outside the United 
States and Canada during the 14-day incubation period), 77 
(19%) were associated with international travel, and 46 (12%) 
occurred in persons for whom the travel status was unknown 
or missing. Of the domestically acquired cases, 244 (89%) 
occurred in persons with onset of illness during May–August. 
Clusters of cases were identified in Michigan (June onset dates), 
Texas (June–July onsets), and South Carolina (July onsets) (1). 
In Michigan, a cluster of 14 cases identified among attendees 
of a conference included residents of Michigan and six other 
states. In Texas, 26 cluster-associated cases occurred among 
patrons of five different local Mexican-style restaurants. In 
South Carolina, one temporospatial cluster of 13 cases was 
investigated, although the exact location(s) of exposure was not 
identified. A vehicle of infection (i.e., fresh cilantro imported 
from Mexico) was implicated only for the 26 cluster-associated 
cases in Texas, marking the second consecutive year in which 
fresh cilantro from Mexico was implicated as the vehicle of 
infection for at least some of the reported cyclosporiasis cases 
in Texas. The vehicle(s) of infection was not identified for the 
remaining 218 (89% of 244) domestically acquired cases with 
onsets during May–August 2014. No molecular subtyping 
methods are available that could facilitate linking cases of 
cyclosporiasis to each other and to particular vehicles and 
sources of infection.
1. CDC. U.S. foodborne outbreaks of cyclosporiasis—2000–2014. Atlanta, 
GA: US Department of Health and Human Services, CDC; 2014.
Dengue
Dengue is an acute febrile illness characterized by myalgia, 
headache, leukopenia, and minor bleeding manifestations 
(1). Patients with severe dengue experience plasma leakage 
resulting in fluid accumulation, hemorrhage, and/or major 
organ impairment (e.g., liver failure, myocarditis, and impaired 
consciousness). Dengue is endemic throughout much of the 
tropics and subtropics, where an estimated 50–100 million 
cases and 9,200 deaths occur annually (2). With proper clinical 
management, the case-fatality rate of hospitalized dengue 
patients can be <0.5% (3). Efforts to improve outcomes among 
persons with dengue include an online clinical education course 
developed by CDC (http://www.cdc.gov/dengue/training/
cme.html).
In 2014, a total 680 laboratory-positive, travel-associated 
dengue cases were reported from 44 of the 50 states, two of 
the five territories, and the District of Columbia. Most (65%) 
persons with travel-associated dengue had a history of travel to 
the Caribbean or Americas, where chikungunya had recently 
emerged. Because dengue and chikungunya often have a similar 
clinical presentation, the increase in reported dengue cases 
compared to previous years, when dengue was not epidemic in 
the region, might be attributable to increased diagnostic testing 
to differentiate between these diseases among patients with 
acute febrile illness. The states with the most travel-associated 
dengue cases reported were California (130), Arizona (97), and 
Florida and New Jersey (84 each). Concomitant with a dengue 
epidemic in northern Mexico, an outbreak of travel-associated 
dengue occurred in Arizona, and all reported case-patients had 
recently traveled to Mexico; enhanced surveillance revealed 
no locally acquired cases (4). Florida reported seven locally 
acquired dengue cases. In the dengue-endemic Caribbean 
territories of Puerto Rico and the U.S. Virgin Island, reports of 
laboratory-positive dengue cases were substantially lower than 
in previous years (525 and 19 cases, respectively). No cases of 
dengue hemorrhagic fever were reported in 2014 in travelers 
or residents of U.S. territories.
1. World Health Organization. Dengue: guidelines for diagnosis, treatment, 
prevention and control. Geneva, Switzerland: World Health Organization; 2009.
2. Stanaway JD, Shepard DS, Undurrage EA, et al. The global burden of 
dengue: an analysis from the Global Burden of Disease Study 2013. Lancet 
Infect Dis 2016;16:712–23.
3. Lam PK, Tam DT, Diet TV, et al. Clinical characteristics of Dengue shock 
syndrome in Vietnamese children: a 10-year prospective study in a single 
hospital. Clin Infect Dis 2013;57:1577–86. http://dx.doi.org/10.1093/
cid/cit594
4. Jones JM, Lopez B, Adams L, et al. Binational dengue outbreak along 
the United States–Mexico border—Yuma County, Arizona, and Sonora, 
Mexico, 2014. MMWR Morb Mortal Wkly Rep 2016;65:495–9. http://
dx.doi.org/10.15585/mmwr.mm6519a3
Diphtheria
During 2014, a nonfatal case of diphtheria caused by 
nontoxigenic Corynebacterium diphtheriae was reported to 
CDC. The case occurred in a 17-year-old white female resident 
of Ohio. The patient was fully vaccinated. No other family 
member or close contact was ill.
Giardiasis
Giardiasis is the most common enteric parasitic infection in 
the United States, infecting an estimated 1.2 million persons 
annually (1). Symptomatology is variable, but giardiasis 
is normally characterized by diarrhea, abdominal cramps, 
bloating, weight loss, and malabsorption; extraintestinal 
symptoms are possible (2). Infected persons can shed Giardia 
for several weeks, and recent studies indicate a potential for 
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chronic sequelae from giardiasis (3). Giardia is endemic 
worldwide, including in the United States, and is the most 
commonly diagnosed pathogen among travelers returning 
to the United States from other countries (4). Giardia is 
commonly detected in internationally adopted children 
screened in the United States; often, these children do not have 
gastrointestinal symptoms (5). In 2014, the reported incidence 
of giardiasis appeared to decrease compared with 2013, which 
could reflect changes in reporting practices or changes in the 
actual occurrence of giardiasis.
Giardia is transmitted through the fecal-oral route with 
the ingestion of environmentally stable Giardia cysts. Most 
information on giardiasis transmission is from outbreak 
investigations; 242 giardiasis outbreaks reported to CDC for 
1971–2011 resulted from waterborne (74.8%), foodborne 
(15.7%), person-to-person (2.5%) and animal contact (1.2%) 
transmission (6). On the basis of outbreak trends, investigators 
identified groundwater and distribution system vulnerabilities 
in drinking water systems, inadequate pool disinfection, 
fruit and vegetable contamination, and poor food handler 
hygiene as possible targets for giardiasis prevention measures. 
However, the majority of reported giardiasis cases are not 
linked to known outbreaks. Among reported cases, <2% are 
documented as outbreak-associated (7). An ecological study 
of sporadic giardiasis in the United States indicated that high 
county-level reliance on private wells was associated with 
higher giardiasis rates (8). Prospective epidemiologic studies 
and continued outbreak and case surveillance are needed to 
understand transmission pathways and to identify effective 
public health prevention measures.
Population studies of Giardia seroprevalence would 
contribute substantially to understanding the prevalence of 
giardiasis in the United States (9). Enhanced genotyping 
methods would increase knowledge of the molecular 
epidemiology of Giardia, including elucidating species-
specific subassemblages (10). Application of these tools to 
epidemiologic studies and surveillance has the potential 
to improve understanding of giardiasis risk factors, enable 
researchers to identify outbreaks by linking cases currently 
classified as sporadic infections, and provide risk factor 
information needed to inform prevention strategies.
1. Scallan E, Hoekstra RM, Angulo FJ, et al. Foodborne illness acquired in 
the United States—major pathogens. Emerg Infect Dis 2011;17:7–15. 
http://dx.doi.org/10.3201/eid1701.P11101
2. Cantey PT, Roy S, Lee B, et al. Study of nonoutbreak giardiasis: novel 
findings and implications for research. Am J Med 2011;124:1175.e1–8. 
http://dx.doi.org/10.1016/j.amjmed.2011.06.012
3. Hanevik K, Wensaas KA, Rortveit G, Eide GE, Mørch K, Langeland N. 
Irritable bowel syndrome and chronic fatigue 6 years after giardia infection: 
a controlled prospective cohort study. Clin Infect Dis 2014;59:1394–400. 
http://dx.doi.org/10.1093/cid/ciu629
 4. Harvey K, Esposito DH, Han P, et al. Surveillance for travel-related 
disease—GeoSentinel Surveillance System, United States, 1997–2011. 
MMWR Surveill Summ 2013;62(No. SS-9).
 5. Staat MA, Rice M, Donauer S, et al. Intestinal parasite screening 
in internationally adopted children: importance of multiple stool 
specimens. Pediatrics 2011;128:e613–22.
 6. Adam EA, Yoder JS, Gould H, Hlavsa MC. Giardiasis outbreaks in the 
United States, 1971–2011. Epidemiol Infect 2016. http://www.ncbi.
nlm.nih.gov/pubmed/26750152
 7. Schnell K, Collier S, Derado G, Yoder J, Gargano JW. Giardiasis in 
the United States—an epidemiologic and geospatial analysis of county-
level drinking water and sanitation data, 1993–2010. J Water Health 
2016;14:267–79.
 8. Yoder JS, Gargano JW, Wallace RM, Beach MJ Giardiasis surveillance—
United States, 2009–2010. MMWR Surveill Summ 2012;61(No. SS-5).
 9. Priest JW, Moss DM, Visvesvara GS, Jones CC, Li A, Isaac-Renton JL. 
Multiplex assay detection of immunoglobulin G antibodies that recognize 
Giardia intestinalis and Cryptosporidium parvum antigens. Clin Vaccine 
Immunol 2010;17:1695–707. http://dx.doi.org/10.1128/CVI.00160-10
 10. Feng Y, Xiao L. Zoonotic potential and molecular epidemiology of 
Giardia species and giardiasis. Clin Microbiol Rev 2011;24:110–40. 
http://dx.doi.org/10.1128/CMR.00033-10
Gonorrhea
Following a historically low rate in 2009 (98.1 cases per 
100,000 population), the national rate of reported gonorrhea 
cases increased 12.8% to 110.7 cases per 100,000 population 
in 2014* (1). The rate among men steadily increased during 
this period, including a 10.5% increase during 2013–2014; 
the rate among women decreased 0.4% during 2013–2014. 
The increase among men, coinciding with the decrease among 
women, suggests increased transmission and/or or increased 
case detection, including expanded extragenital gonorrhea 
screening, among gay, bisexual, and other men who have sex 
with men. As in previous years, the highest rates of gonorrhea 
were among persons aged 15–24 years, among non-Hispanic 
blacks, and in the South. In 2014, the gonorrhea rate among 
non-Hispanic blacks was 10.6 times the rate among non-
Hispanic whites. Although the highest rate overall was in the 
South, including a 3.1% increase during 2013–2014, the rate 
of reported gonorrhea cases increased by 22.2% in the West 
during the same time.
Treatment for gonorrhea has been complicated by the 
repeated acquisition of antimicrobial resistance by Neisseria 
gonorrhoeae. The emergence of fluoroquinolone resistance 
during 2000–2007 and subsequent declining cefixime 
susceptibility (2006–2011) resulted in changes in the CDC 
treatment guidelines in 2007, 2010, and 2012. The only 
CDC-recommended treatment regimen for gonorrhea is dual 
therapy with intramuscular ceftriaxone and oral azithromycin 
(2). In CDC’s sentinel surveillance system (Gonococcal Isolate 
* Rates for 2014 were calculated using the 2013 population estimates and differ 
from 2014 rates presented in the figures and table 7 (calculated using 2014 
population estimates).
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Surveillance Project), the percentage of isolates with reduced 
cefixime susceptibility decreased from 1.4% in 2011 to 0.4% 
in 2013, and then increased to 0.8% in 2014. During this time, 
the percentage of isolates with elevated ceftriaxone minimum 
inhibitory concentrations (MICs) ranged from 0.05% (2013) 
to 0.4% (2011). During 2013–2014, the percentage with 
elevated azithromycin MICs increased from 0.6% to 2.5% (1).
1. CDC. Sexually transmitted disease surveillance 2014. Atlanta, GA: US 
Department of Health and Human Services, CDC; 2015.
2. CDC. Sexually transmitted diseases treatment guidelines, 2015. MMWR 
Recomm Rep 2015;64(No. RR-3).
Hansen’s Disease (Leprosy)
Hansen’s Disease (HD) (i.e., leprosy) is a chronic 
infectious disease caused by the obligate intracellular 
bacterium Mycobacterium leprae. Growing optimally at 
27°–30°C (80.6°–86.0°F), HD primarily affects the skin and 
superficial peripheral nerves, most notably the posterior tibial 
and lateral popliteal nerves of the lower leg and foot, the ulnar, 
median, and radial nerves of the forearm and hand, and the facial 
nerve (1). HD is highly responsive to treatment but requires a 
prolonged multidrug therapy of 1–2 years of dapsone, rifampin, 
and clofazamine to result in cure (2). However, untreated disease 
can result in sensory and motor neuropathy, with eventual 
permanent disability of the eyes, hands, and feet (3).
An average of 89 HD cases have been reported to CDC per 
year since 2000, with a low of 66 in 2006 and a high of 105 
in 2004; not all states list HD as a reportable disease, which 
might account for the higher numbers reported annually by 
the National Hansen’s Disease Programs (4). By race, white 
and Asian/Pacific Islanders accounted for the majority of new 
reported cases (36 [54%] of 67 cases and 24 [36%] of 67 cases, 
respectively). Similar to 2013, the majority of new cases in 
2014 were reported from Texas (19 [22%] of 88), Hawaii (14 
[16%] of 88), and New York City and Florida (10 [11%] of 88 
each). In addition to the 88 cases reported in the United States, 
13 cases were reported from Guam and two from Puerto Rico.
1. Eichelmann K, González González SE, Salas-Alanis JC, Ocampo-Candiani J. 
Leprosy. An update: definition, pathogenesis, classification, diagnosis, 
and treatment. Actas Dermosifiliogr 2013;104:554–63. http://dx.doi.
org/10.1016/j.adengl.2012.03.028
2. Worobec SM. Current approaches and future directions in the treatment 
of leprosy. Res Rep Trop Med 2012;3:79–91. http://dx.doi.org/10.2147/
RRTM.S27395
3. Walker SL, Lockwood DNJ. Leprosy. Clin Dermatol 2007;25:165–72. 
http://dx.doi.org/10.1016/j.clindermatol.2006.05.012
4. Hansen’s Disease Data & Statistics. Washington, DC: US Department of 
Health and Human Services; 2015. http://www.hrsa.gov/hansensdisease/
dataandstatistics.html
Hantavirus Pulmonary Syndrome
Hantavirus pulmonary syndrome (HPS), a severe and 
sometimes fatal pulmonary disease resembling acute 
respiratory distress syndrome, is caused by hantavirus infection. 
Hantaviruses are transmitted by inhalation or direct contact 
with virus-containing particles or through direct contact 
with rodents who harbor the virus, such as the deer mouse 
(Peromyscus maniculatus). Most HPS cases occur in the western 
United States (1,2). In 2014, a total of 34* cases of HPS 
occurred in 13 states, of which 33 (97%) occurred in western 
states. Median age of patients was 38 years (range: 5–84). The 
2014 case fatality rate was 38%, similar to previous reports.
Although HPS is a rare disease in the United States, it is 
associated with severe illness and high rates of death. Persons 
should avoid contact with deer mice or their droppings and 
use personal protective equipment when cleaning rodent 
infested environments.
1. MacNeil A, Ksiazek TG, Rollin PE. Hantavirus pulmonary syndrome, 
United States, 1993–2009. Emerg Infect Dis 2011;17:1195–201.
2. Knust B, Rollin PE. Twenty-year summary of surveillance for human 
hantavirus infections, United States. Emerg Infect Dis 2013;19:1934–7. 
http://dx.doi.org/10.3201/eid1912.131217
Hemolytic Uremic Syndrome, 
Postdiarrheal
Hemolytic uremic syndrome (HUS) is characterized by 
the triad of hemolytic anemia, thrombocytopenia, and renal 
insufficiency. The most common etiology of postdiarrheal 
HUS in the United States is infection with Shiga toxin-
producing  Escherichia coli  (STEC), principally STEC 
O157:H7 (1,2). Children aged <5 years progress to HUS 
more often than all other persons infected with STEC 
O157:H7 (15.3% vs. 6.3%) (3). In 2014, as in previous years 
of surveillance, the age group with the most reported cases was 
children aged 1‒4 years (117 of 250 cases).
1. Banatvala N, Griffin PM, Greene KD, et al. The United States National 
Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, 
clinical, and epidemiologic findings. J Infect Dis 2001;183:1063–70. 
http://dx.doi.org/10.1086/319269
2. Mody RK, Luna-Gierke RE, Jones TF, et al. Infections in pediatric 
postdiarrheal hemolytic uremic syndrome: factors associated with 
identifying shiga toxin-producing Escherichia coli. Arch Pediatr Adolesc Med 
2012;166:902–9. http://dx.doi.org/10.1001/archpediatrics.2012.471
3. Gould LH, Demma L, Jones TF, et al. Hemolytic uremic syndrome and 
death in persons with Escherichia coli O157:H7 infection, foodborne 
diseases active surveillance network sites, 2000–2006. Clin Infect Dis 
2009;49:1480–5. http://dx.doi.org/10.1086/644621
* Although 32 cases were reported in table 1, two cases were subsequently added.
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Human Immunodeficiency Virus 
Infections
CDC requires states to report Human Immunodeficiency 
Virus Infections (HIV) case data through the enhanced HIV/
AIDS Reporting System (eHARS), which is a browser-based 
system deployed at 54 state/local and territorial public health 
departments in the United States. HIV surveillance data are not 
reported through NNDSS. De-identified data are transmitted 
monthly from health departments through the secure access 
management system (SAMS) directly to CDC’s Division of 
HIV/AIDS Prevention, National Center for HIV/AIDS, Viral 
Hepatitis, STD, and TB Prevention, and are incorporated into 
the National HIV Surveillance System database.
As of April 2008, all 50 states, the District of Columbia, 
and six U.S. dependent areas required confidential name-
based reporting for HIV infection, in addition to reporting 
persons whose disease has been classified as stage 3 (acquired 
immunodeficiency syndrome [AIDS]). In 2008, CDC 
published a revised surveillance case definition for HIV 
infection that includes AIDS and incorporates the HIV 
infection classification (1). Laboratory-confirmed evidence 
of HIV infection is required to meet the surveillance case 
definition for HIV infection, including stage 3 (AIDS).
In 2014, the HIV surveillance case definition was revised to 
adapt to changes in diagnostic criteria used by laboratories and 
clinicians (2). The laboratory criteria for defining a confirmed 
case of HIV infection were changed to accommodate multitest 
algorithms that do not include previously required tests (e.g., 
Western blot). New to the case definition is the inclusion of 
criteria for differentiating HIV-1 and HIV-2 infections and 
for recognizing early HIV infection (stage 0), during which 
viral loads might be high enough and CD4 T-lymphocyte 
counts low enough to be confused with stage 3 (AIDS). In 
addition, the revised definition consolidates the staging systems 
for adults/adolescents and children, simplifies surveillance 
criteria for opportunistic illnesses indicative of stage 3, and 
incorporates revisions of clinical criteria (i.e., medical record 
documentation) for reporting diagnoses without laboratory 
evidence. Because retroactive implementation of some features 
(e.g., the new staging system) of the 2014 case definition would 
be impractical, for this report, cases diagnosed before 2014 
were classified according to the 2008 HIV case definition and 
cases diagnosed in 2014 were classified according to the 2014 
HIV case definition.
A total of 35,606 cases of HIV infection were diagnosed 
in the United States during 2014 and reported to CDC as of 
December 2014. Blacks had the highest rate of diagnoses of 
HIV infection of all racial/ethnic groups (40.1 per 100,000 
population) and accounted for 44.5% of diagnoses in 2014. 
Although HIV affects persons in all age groups, cases were 
most frequently diagnosed in adults aged 25–39 years. Areas 
with the highest rates (≥15.0) of diagnoses during 2014 were 
the District of Columbia, Florida, Louisiana, Mississippi, New 
York, South Carolina, and the U.S. Virgin Islands.
1. Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna 
MT. Revised surveillance case definitions for HIV infection among adults, 
adolescents, and children aged <18 months and for HIV infection and 
AIDS among children aged 18 months to <13 years—United States, 2008. 
MMWR Recomm Rep 2008;57(No. RR-10).
2. CDC. Revised surveillance case definition for HIV infection—United 
States, 2014. MMWR Recomm Rep 2014;63(No. RR-3).
Influenza-Associated Pediatric 
Mortality
In 2004, the Council of State and Territorial Epidemiologists 
added influenza-associated pediatric mortality to the list of 
conditions reportable to the National Notifiable Diseases 
Surveillance System (1). A pediatric influenza-associated death 
is defined for surveillance purposes as a death resulting from a 
clinically compatible illness that was confirmed to be influenza 
by an appropriate laboratory or rapid diagnostic test in a 
person aged <18 years. From December 29, 2013 to January 3, 
2015*, a total of 141 influenza-associated pediatric deaths were 
reported to CDC from 34 states and New York City.
Of the 141 influenza-associated pediatric deaths reported to 
CDC during 2014, four deaths occurred during the 2008–09 
influenza season, six deaths during the 2009–10 influenza 
season, two deaths during the 2011–12 influenza season, 
103 during the 2013–14 influenza season, and 26 during the 
2014–15 influenza season. An influenza season spans the time 
period between MMWR week 40 of a calendar year to MMWR 
week 39 of the following year. A total of 117 (83%) cases were 
associated with influenza A viruses, 20 (14%) with influenza B 
viruses, three (2.1%) with an influenza virus for which the type 
was not determined, and one (0.7%) death was associated with 
influenza A virus and influenza B virus co-infection. Of 117 
influenza A viruses, subtype was determined for 70 (60%); 
52 were influenza A (H1N1)pdm09 viruses and 18 were 
influenza A (H3N2) viruses.
Among the 141 deaths reported in 2014, a total of 18 
(13%) occurred among children aged <6 months, 46 (33%) 
among those aged 6–59 months, 43 (31%) among those aged 
5–11 years, and 34 (24%) among those aged 12–17 years; 
the median age at the time of death was 6.1 years (range: 
3 days–17 years). The median age in 2014 is similar to 
previous influenza seasons during nonpandemic periods, but 
* For 2014, only influenza-associated pediatric deaths that were reported during 
MMWR week 1 through MMWR week 53 (December 29, 2013–January 3, 
2015) are included in this summary.
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is lower than the median age of deaths observed during the 
2009 pandemic.
Information on the location of death was available for 131 
(93%) of the 141 children: 81 (62%) children died after being 
admitted to the hospital (73 were admitted to the intensive care 
unit), 30 (23%) died in the emergency department, and 20 
(15%) died outside the hospital. Information on pre-existing 
medical conditions was reported for 136 (96%) children: 
73 (54%) children had one or more underlying medical 
condition known to confer increased risk for complications 
from influenza (2). The most common group of underlying 
conditions was neurologic disorders (e.g., moderate to 
severe developmental delay, seizure disorders, cerebral palsy, 
mitochondrial disorders, neuromuscular disorders, and 
neurologic conditions), which was reported for 48 (35.3%) 
of 136 children. Eleven (8.1%) of 136 children had cardiac 
disease or congenital heart disease, 19 (14%) had chromosomal 
abnormalities and/or genetic syndromes, and 33 (24%) had a 
chronic pulmonary condition (e.g., asthma, cystic fibrosis, or 
other chronic pulmonary disease).
Among the 141 deaths in children, 69 children had specimens 
collected for bacterial culture from normally sterile sites. Of 
these, 24 (35%) had positive cultures, and two (8.3%) of the 
24 were positive for more than one pathogen. Staphylococcus 
aureus was detected in five (21%) of 24 positive cultures; three 
were methicillin-resistant, and for two specimens methicillin-
sensitivity testing was not done. Three cultures (13%) were 
positive for Streptococcus pneumoniae, six (25%) were positive 
for Group A Streptococcus, three (13%) were positive for 
Pseudomonas aeruginosa, and two (8.3%) were positive for 
Escherichia coli. Other bacterial pathogens identified included 
one each with Haemophilus influenzae, Klebsiella pneumoniae, 
and Streptococcus species.
Of 93 children aged ≥6 months at the time of illness onset 
for whom seasonal vaccination status was known, 20 (22%) 
had been vaccinated against influenza as recommended by 
the Advisory Committee on Immunization Practices (2,3). 
Twenty-three children were aged <6 months at the time of 
illness onset and ineligible for vaccination.
The number of influenza-associated pediatric deaths reported 
during 2014 was higher than that in nine of the previous 
10 seasons, excluding the 2009 influenza A (H1N1)pdm09 
pandemic. Influenza seasons typically span portions of two 
calendar years and can vary widely in terms of severity and 
timing of peak activity, thus affecting the number of deaths 
reported in a calendar year. The 2014–15 influenza season 
was moderately severe and peaked in late December 2014 
(4). Continued surveillance for influenza-associated mortality 
is important to monitor the effects of seasonal and novel 
influenza, factors contributing to severe influenza-associated 
disease, and the influence of interventions among children.
1. Council of State and Territorial Epidemiologists. Influenza-associated 
pediatric mortality. Position statement 04-ID-04. http://c.ymcdn.com/
sites/www.cste.org/resource/resmgr/PS/04-ID-04-FINAL.pdf
2. Grohskopf LA, Olsen SJ, Sokolow LZ, et al. Prevention and control 
of seasonal influenza with vaccines: Recommendations of the Advisory 
Committee on Immunization Practices—United States, 2014–2015. 
MMWR Morb Mortal Wkly Rep 2014;63:691–7.
3. Advisory Committee on Immunization Practices. Prevention and control 
of influenza with vaccines: interim recommendations of the Advisory 
Committee on Immunization Practices (ACIP), 2013. MMWR Morb 
Mortal Wkly Rep 2013;62:356.
4. Appiah GD, Blanton L, D’Mello T, et al. Influenza activity—United States, 
2014–15 season and composition of the 2015–16 influenza vaccine. 
MMWR Morb Mortal Wkly Rep 2015;64:583–90.
Leptospirosis
Leptospirosis is a zoonotic disease caused by bacteria of the 
genus Leptospira. Infection in humans occurs through direct 
or indirect contact with the urine of infected host animals 
including rodents (1,2), livestock (3), dogs (4), and many 
wildlife species. Initial signs and symptoms might mimic 
certain other febrile illnesses, making recognition difficult 
(5). Some cases of leptospirosis progress to severe, potentially 
fatal, disease with signs of multiorgan involvement that can 
include aseptic meningitis, jaundice, renal failure, pulmonary 
involvement, and hemorrhage (1,2).
Exposure risks for leptospirosis include recreational water 
activities (2,6), such as wading, swimming, rafting and kayaking, 
especially after heavy rainfall; contact with floodwaters; 
occupational exposures related to farming (6) and contact with 
host animals, such as occurs with slaughterhouse workers and 
veterinarians (2,7); and living in areas with rodent infestation 
(8). Cases of leptospirosis in the United States also have been 
linked to adventure racing and multisport events (9,10) and 
with travel to countries where leptospirosis is endemic.
The emergence of new risk groups; the lack of dynamic 
data on incidence, distribution, and risk factors; and the likely 
underestimation of disease incidence led to the reinstatement 
of leptospirosis to the list of nationally notifiable diseases by 
the Council of State and Territorial Epidemiologists in 2013. 
CDC officially began receiving case notifications through the 
National Notifiable Diseases Surveillance System (NNDSS) in 
January 2014. Leptospirosis is reportable in 46 jurisdictions, 
states, and territories.
In 2014, a total of 107 cases of leptospirosis were reported 
to NNDSS from 11 states and one territory. Sixty-nine (64%) 
cases were from Puerto Rico and 23 (21%) were from Hawaii. 
In the 50 states and the District of Columbia, of 38 total cases, 
30 (79%) were male, a trend identified in previous reports (6). 
Of 35 cases with reported age, 31 (89%) were aged 15–64 years. 
After 19 years without standardized reporting of leptospirosis 
cases, increasing the awareness of leptospirosis among health 
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care providers and improving the detection and reporting of 
leptospirosis cases is essential for improving understanding of 
the disease’s epidemiology in the United States.
 1. Bharti AR, Nally JE, Ricaldi JN, et al. Leptospirosis: a zoonotic disease 
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Listeriosis
Listeria monocytogenes infection (listeriosis) is rare but can 
cause severe invasive disease (e.g., bacteremia and meningitis). 
Listeriosis is predominately acquired through contaminated 
food and occurs most frequently among older adults, persons 
with certain immunocompromising conditions, and pregnant 
women and their newborns. Pregnancy-associated listeriosis is 
usually a relatively mild illness for women, but can result in 
fetal loss or severe neonatal disease.
Listeriosis has been nationally notifiable since 2000. In 
2014, the incidence of listeriosis reported to the National 
Notifiable Diseases Surveillance System (NNDSS) was 0.24 
infections per 100,000 population. Progress toward the 2020 
national target of 0.2 infections (1) is measured through the 
Foodborne Diseases Active Surveillance Network (FoodNet), 
which conducts active, population-based surveillance for 
listeriosis in 10 U.S. states. FoodNet reported a preliminary 
annual incidence of Listeria monocytogenes in 2014 of 0.24 
infections, the same rate reported to NNDSS (2).
The Listeria Initiative is an enhanced surveillance system 
designed to aid in the rapid investigation of listeriosis outbreaks 
by combining molecular subtyping results with epidemiologic 
data collected by state and local health departments (3). As 
part of the Listeria Initiative, CDC recommends that all 
clinical isolates of L. monocytogenes be forwarded routinely to 
a public health laboratory for pulsed-field gel electrophoresis 
(PFGE) subtyping and that these PFGE subtyping results be 
submitted to PulseNet, the National Molecular Subtyping 
Network for Foodborne Disease Surveillance (4); clinical 
isolates also should be promptly sent to CDC for further 
characterization. In addition, communicable disease programs 
are asked to interview all patients with listeriosis promptly 
using the standard Listeria Initiative questionnaire, which is 
available in English and Spanish (http://www.cdc.gov/listeria/
surveillance.html).
Beginning in September 2013, whole genome sequencing 
has been performed on all clinical isolates as part of a project 
conducted by CDC, state and local health departments, the 
Food and Drug Administration, the U.S. Department of 
Agriculture’s Food Safety and Inspection Service, the National 
Institutes of Health, and international partners (5). All isolate 
sequences are deposited in publicly available databases at 
the National Center for Biotechnology Information of the 
National Institutes of Health. The Listeria Initiative has aided 
in the timely identification and removal of contaminated food 
during several listeriosis investigations, including a multistate 
outbreak of 35 illnesses that was linked to commercially 
produced, prepackaged caramel apples in 2014 (6).
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Lyme Disease
In 2014, the number of confirmed Lyme disease cases 
reported to CDC decreased compared with the number 
reported in 2013, but was higher compared to the number 
reported during 2010–2012. On the basis of reports to the 
National Notifiable Diseases Surveillance System (NNDSS), 
the geographic distribution of high incidence areas has 
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expanded over time (1), with 381 counties reporting an 
incidence of ≥10 confirmed cases per 100,000 persons in 2014, 
compared with 324 counties in 2008. In addition, during 
2013–2014, CDC and state and county health departments 
investigated several sudden cardiac deaths associated with 
Lyme carditis through case series, death certificate analysis, 
and review of NNDSS surveillance data (2,3). This rare but 
very serious complication of Lyme disease underscores the 
importance of reducing exposure to ticks and tick habitat.
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Measles
Measles was declared eliminated from the United States 
in 2000. Since then, elimination has been maintained 
through high population immunity along with adequate 
disease surveillance and public health response capacity (1,2). 
Nonetheless, because measles remains endemic in much of the 
world, importations continue to result in sporadic cases and 
outbreaks in the United States, which can be costly to control 
(3). As in the other years since elimination, most measles cases 
(99%) were import-associated (4).
A measles outbreak is defined as a chain of transmission 
involving three or more cases. A total of 23 outbreaks occurred 
in 2014, accounting for 81% of the total cases. There were 
63 international importations, the most since 2011, and 
43% of importations originated from the Philippines. The 
largest outbreak accounted for 57% of the cases. In each of 
these outbreaks, transmission occurred after a U.S. resident 
traveler introduced measles into communities with pockets 
of persons unvaccinated because of philosophical or religious 
beliefs. This allowed for spread to occur, mainly in households 
and community gatherings, before public health interventions 
could be implemented (CDC, unpublished data, 2014).
The largest outbreak occurred in Ohio, which started when 
unvaccinated travelers visited the Philippines where a large 
outbreak of measles was occurring. The travelers returned to 
Ohio and spread the disease to other unvaccinated persons 
(89% unvaccinated, 10% unknown, and 1% with 1 dose). 
This outbreak was the largest outbreak in the United States 
since 1992.
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Meningococcal Disease
Neisseria meningitidis is an important cause of bacterial 
meningitis and sepsis in the United States. In 2014, rates of 
meningococcal disease continued to be at historic lows in the 
United States (0.18 cases per 100,000 population). CDC’s 
Advisory Committee on Immunization Practices (ACIP) 
recommends routine use of quadrivalent (serogroup A, C, W, 
and Y) meningococcal conjugate vaccine in adolescents and 
others at increased risk for disease (1–3). In 2014, coverage with 
at least 1 dose of meningococcal conjugate vaccine was 79.3% 
among adolescents aged 13–17 years in the United States; 
however, by state, coverage ranged from 46.0%–95.2%, 
including the District of Columbia (4). Coverage with ≥2 doses 
of meningococcal conjugate vaccine among adolescents aged 
17 years was 28.5% (4).
Two serogroup B meningococcal vaccines were licensed for 
use in the United States in 2014 and 2015. Both vaccines are 
approved for use in persons aged 10–25 years. In 2015, ACIP 
recommended routine use of serogroup B meningococcal 
vaccine in certain groups at increased risk for disease (5). 
A serogroup B meningococcal vaccine series also can be 
administered to adolescents and young adults aged 16–23 years 
to provide short-term protection against most strains of 
serogroup B meningococcal disease. The preferred age for 
serogroup B meningococcal vaccination is 16–18 years (6).
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Mumps
In 2014, a total of 1,223 cases of mumps were reported in 
the United States with an overall incidence rate of 0.38 cases 
per 100,000 persons. Most (N = 883 [72%]) mumps cases 
reported in the United States during 2014 were from three 
states (Ohio, Illinois, and Wisconsin) and New York City, all 
of which experienced university-based outbreaks. University-
based outbreaks are known to occur despite high 2-dose vaccine 
coverage (1). Reported median vaccine-effectiveness for mumps 
vaccine is 78% for 1-dose and 88% for 2-doses (2). Close and 
prolonged contact likely facilitates mumps transmission.
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Novel Influenza A Viruses
In 2007, the Council of State and Territorial Epidemiologists 
added human infection with a novel influenza A virus to 
the list of conditions reportable to the National Notifiable 
Diseases Surveillance System (1). Novel influenza A virus 
infections are human infections with influenza A viruses 
that are different from currently circulating human seasonal 
influenza viruses. These viruses include those that are subtyped 
as nonhuman in origin and those that cannot be subtyped with 
standard methods and reagents used for currently circulating 
influenza viruses.
Influenza viruses that normally circulate in swine are called 
swine influenza viruses when isolated from swine, but are 
called variant viruses when isolated from humans. During 
2005–2014, all reported novel influenza A human infections 
in the United States involved variant viruses rather than avian-
origin influenza viruses. Although most persons identified with 
variant influenza virus infection report contact with swine 
preceding their illness, suggesting swine-to-human spread, 
limited human-to-human transmission of these viruses has 
occurred (2). Because the implications of ongoing transmission 
of these viruses between humans are potentially severe, prompt 
and thorough investigation of human infections with novel 
influenza viruses is critical so that risk for infection can be 
more fully understood and appropriate public health measures 
can be taken (3).
In 2014, three human infections with novel influenza A viruses 
were reported from two states (Ohio [two] and Wisconsin 
[one]) (4,5). All three cases involved infection with an 
influenza A (H3N2) variant virus (H3N2v). The median age of 
patients was seven years (range: 2–10 years), and all three were 
female. Reported symptoms associated with infection were fever 
(100%), cough (100%), fatigue (100%), shortness of breath 
(67%), muscle aches (67%), vomiting or diarrhea (67%), and 
conjunctivitis (33%); all three cases reported influenza-like 
illness (e.g. fever (≥100°F [37.8°C] with cough and/or sore 
throat). None had an underlying medical condition known to 
confer increased risk for complications from influenza (6). All 
three patients sought health care for their illness and one was 
hospitalized; all three fully recovered. All three reported direct 
contact with (e.g., touching or handling) or proximity to (e.g., 
walking through an area or coming within 6 feet of ) swine in 
the week preceding illness onset. No likely human-to-human 
transmission of novel influenza A viruses was identified.
Transmission of variant influenza A viruses to humans 
usually occurs among persons with direct, unprotected 
contact with swine or environments where swine are or 
have been present (e.g., agricultural fairs, farms, and petting 
zoos). CDC conducts surveillance for human infections with 
novel influenza A viruses in conjunction with state and local 
public health laboratories year-round and conducts extensive 
epidemiologic investigations on each case. Any specimen with 
results suggestive of the presence of a novel influenza A virus or 
that cannot be subtyped using standard methods and reagents 
at a public health laboratory is immediately submitted to CDC 
for further testing. Surveillance for human infections with 
novel influenza A viruses is essential, and early identification 
and investigation of human infections with novel influenza A 
viruses are critical so that risk for infection can be more fully 
understood and appropriate public health measures taken.
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Pertussis
Reported pertussis cases in the United States increased 15% 
from 2013 (incidence: 9.0 per 100,000 population) to 2014 
(10.4). Despite the national increase in reporting, a majority 
of states reported fewer cases in 2014 than in 2013 (32). 
However, in 2014, California reported the largest number 
of cases observed (8,723) since its 2010 pertussis epidemic 
(7,195) (1). Six additional states reported a ≥50% increase in 
cases (Connecticut, Delaware, Idaho, Maine, Nebraska, and 
South Dakota). Although the age distribution of reported cases 
is similar to that reported for 2013, peak incidence has shifted 
from children aged 10 years in 2013 to those aged 15 years 
in 2014, likely the effect of waning immunity among aging 
cohorts of adolescents vaccinated exclusively with acellular 
pertussis vaccines (2–4). A total of 13 deaths occurred among 
all age groups; eight of the deaths occurred among infants 
aged <1 year, who account for most pertussis-related deaths 
reported in the United States. Maternal Tdap vaccination 
during the third trimester of pregnancy remains the primary 
recommendation for prevention of pertussis in infants (5).
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Plague
Plague is a highly virulent fleaborne zoonosis caused by 
Yersinia pestis. A median of eight cases are reported each year 
in the United States (1). Most human plague infections result 
from an infectious flea bite; however, domestic animals can 
become infected and transmit plague to humans. Bubonic 
and septicemic plague are common clinical forms of plague 
and are not transmissible to others. In contrast, persons with 
pneumonic plague can transmit infection to others via infective 
respiratory droplets (2).
During 2014, an outbreak of pneumonic plague occurred 
in Colorado involving four patients. All four had exposure to 
a dog with confirmed pneumonic plague; however, person-to-
person transmission between two of these patients could not be 
excluded (3). This is the first documented transmission from 
a domestic dog to humans in the United States. Furthermore, 
this event represents the largest outbreak and the first instance 
of possible human-to-human transmission in the United States 
since 1924 (1,2).
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Q-Fever
Q fever is a zoonosis caused by the obligate intracellular 
bacterium Coxiella burnetii. The primary route of exposure is 
inhalation of aerosolized birth products from livestock (e.g., 
cows, goats, or sheep). In addition, other routes of exposure, 
such as ingestion, tick bite, and sexual transmission, are 
possible. In 2014, a cluster of five suspect Q fever cases in New 
York was associated with a history of travel to Germany for 
live cell therapy (injections of cells from the organs or fetuses 
of nonhuman animals) (1). A case from Canada was also 
associated with the New York cluster. Health care providers 
should be aware of medical tourism for this live cell therapy 
and the associated risks.
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22 MMWR / Published October 14, 2016, for 2014 / Vol. 63 / No. 54
Morbidity and Mortality Weekly Report
US Department of Health and Human Services/Centers for Disease Control and Prevention
Rabies
During 2014, one case of human rabies was reported in 
the United States. The case was reported from Missouri. The 
patient presented with neck pain that radiated down the left 
arm that progressed to left arm numbness and tingling, bilateral 
upper body tremors, anxiousness, and hallucinations. Because 
of the unexplained rapidly progressive encephalitis and self-
reported hydrophobia, rabies was suspected. CDC antemortem 
testing confirmed a rabies virus variant associated with the 
tri-colored bat Perimyotis subflavus. Following diagnosis, life 
support was withdrawn and the patient died.
During 2014, the number of animals submitted to state and 
local laboratories for rabies diagnosis (104,313) increased 7.8% 
compared with 2013. A total of 5,988 animals were confirmed 
positive. Increases in the number of animals reported rabid 
were observed for the following species: sheep/goats (10.0%), 
skunks (9.8%), cats (9.2%), and bats (9.0%). The number of 
reported rabid dogs (50.8%), foxes (10.6%), cattle (8.9%), 
raccoons (4.2%) and horses/mules (3.3%) also decreased 
compared with 2013.
Salmonellosis
In 2014, the incidence of salmonellosis in the United 
States was 16.3 laboratory-confirmed infections per 100,000 
population, approximately one and a half times the 2020 
national health objectives target of 11.4 (1). Data from the 
Foodborne Diseases Active Surveillance Network (FoodNet), 
which conducts active surveillance for salmonellosis in 10 U.S. 
states, are used to measure progress towards Healthy People 
2020 objectives. In 2014, FoodNet reported a preliminary 
annual incidence of Salmonella of 15.5, slightly lower than the 
rate reported to the National Notifiable Diseases Surveillance 
System (2). During 2014, as in previous years of surveillance, 
children aged <5 years had the highest reported incidence rates 
of salmonellosis. Salmonellosis is reported most frequently in 
late summer and early fall; in 2014, this seasonality was evident, 
with most reports during July–October.
Accounting for underdiagnosis, Salmonella causes an estimated 
1.2 million illnesses annually in the United States; of these, an 
estimated 1 million are transmitted by food consumed in the 
United States (3). Salmonella  can contaminate a wide range 
of foods, and different serotypes tend to have different animal 
reservoirs and food sources, making control challenging. The 
largest multistate outbreak of  Salmonella  infections in 2014 
(serotypes Infantis, Newport, and Hadar) was traced to live 
poultry in backyard flocks; other notable outbreaks in 2014 
were linked to cucumbers (serotype Newport), bean sprouts 
(serotype Enteritidis), nut butter (serotype Braenderup), clinical 
and college and university teaching microbiology laboratories 
(serotype Typhimurium), organic sprouted chia powder 
(serotypes Newport, Hartford, and Oranienburg), frozen feeder 
rodents (serotype Typhimurium), pet bearded dragons (serotypes 
Cotham and Kisarawe), mechanically separated chicken (serotype 
Heidelberg), and raw cashew cheese (serotype Stanley) (4).
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Shiga Toxin-Producing Escherichia coli
In 2014, the incidence of laboratory-confirmed Shiga 
toxin-producing Escherichia coli (STEC) infections in the 
United States was 2.0 cases per 100,000 population. FoodNet, 
an active, population-based surveillance system for enteric 
diseases, reported STEC incidence of 2.4 in 2014 (1). As 
in all previous years of surveillance, the age group with the 
highest incidence of reported STEC infections was children 
aged 1–4 years (9.0). In 2014, multistate outbreaks of STEC 
infection linked to foods included raw clover sprouts (STEC 
O121) and ground beef (STEC O157:H7) (2).
Public health actions to monitor, prevent, and control 
STEC infections are based on serogroup characterization. 
Development of postdiarrheal hemolytic uremic syndrome 
(HUS), a severe complication of STEC infection, is most 
strongly associated with STEC O157. Non-O157 STEC, 
a diverse group that varies in virulence, comprises over 50 
other serogroups. Increased use of assays for the detection of 
Shiga toxins in clinical laboratories in recent years has led to 
increased reporting of non-O157 STEC infection (3). STEC 
can produce Shiga toxins (Stx): Stx1, Stx2, or both. In general, 
strains that produce certain types of Stx2 are the most virulent 
(4). Accounting for underdiagnosis, an estimated 96,000 
illnesses are caused by STEC O157 and 168,000 illnesses by 
non-O157 STEC each year (5,6).
Stool specimens from patients with community-acquired 
diarrhea submitted to clinical laboratories should be tested 
routinely both by culture for STEC O157 and by an assay that 
detects Shiga toxins (or the genes that encode them). Detection 
of Shiga toxin alone is inadequate for clinical management 
and public health investigation; characterizing STEC isolates 
by serogroup and by pulsed-field gel electrophoresis pattern is 
important to detect, investigate, and control outbreaks.
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Shigellosis
In 2014, the incidence of reported shigellosis in the 
United States was 6.5 infections per 100,000 population. 
This is comparable to the incidence of laboratory-confirmed 
shigellosis reported by FoodNet, an active, population-based 
surveillance system for enteric diseases, in 2014 (5.8), and is 
in line with fairly stable incidence rates observed in FoodNet 
during the previous decade (1,2). In 2014, as in previous years, 
the highest number of reported cases of shigellosis occurred 
among children aged <10 years. S. sonnei infections account 
for approximately 75% of shigellosis in the United States (3). 
Shigellosis does not demonstrate marked seasonality, likely 
reflecting the importance of person-to-person transmission.
Accounting for underdiagnoses, Shigella causes an estimated 
500,000 illnesses annually in the United States; of these, an 
estimated 130,000 are transmitted by food consumed in 
the United States (3). Shigella is often transmitted person-
to-person, including through sexual contact between men 
who have sex with men (MSM), and can also be transmitted 
by contaminated food or by contaminated water used for 
drinking or recreational purposes (4). Some cases of shigellosis 
are acquired during international travel (5,6) and have caused 
multidrug-resistant outbreaks in the United States (7). 
Childcare-associated outbreaks are common and are often 
difficult to control (8).
MSM and persons infected with human immunodeficiency 
virus appear to be at the greatest risk for infection with Shigella 
with decreased susceptibility to azithromycin (9,10). In 2014, 
the majority of isolates known to be resistant to azithromycin 
harbored mphA or ermB, macrolide resistance genes that 
are typically plasmid-encoded. For adults with suspected 
shigellosis, clinicians should obtain sexual histories, collect 
stool specimens, test for antimicrobial susceptibility, and 
counsel patients about prevention.
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Syphilis, Congenital
From 2008 to 2012, the rate of reported congenital syphilis 
decreased from 10.5 to 8.4 reported cases per 100,000 live 
births (1). However, in 2013, the rate of reported congenital 
syphilis increased to 9.1. In 2014*, the rate increased to 11.6, 
a 27.5% increase relative to 2013. Historically, increases in 
congenital syphilis parallel increases in primary and secondary 
(P&S) syphilis among women. During 2013–2014, the 
reported P&S syphilis rate among women increased 22.7%.
During 2013–2014, the congenital syphilis rate increased 
in every region of the United States, but as in previous years, 
the highest rates in 2014 were reported from the South (15.5). 
* Rates for 2013 and 2014 were calculated using the 2012 live birth estimates 
and differ from the 2013 and 2014 rates presented in the figures and table 7 
(calculated using 2013 and 2014 live birth estimates, respectively).
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Similarly, during 2013–2014, the congenital syphilis rate increased 
among most race/ethnicity groups including whites, blacks, 
Hispanics, and Asians/Pacific Islanders, but race and ethnic 
disparities persisted in 2014. The rate of congenital syphilis among 
non-Hispanic blacks (38.2) was 10.3 times the rate among non-
Hispanic whites (3.7), and the rate among Hispanics (12.1) was 
3.3 times the rate among non-Hispanic whites.
1. CDC. Sexually transmitted disease surveillance 2014. Atlanta, GA: US 
Department of Health and Human Services, CDC; 2015.
Syphilis, Primary and Secondary
In 2000 and 2001, the national rate of reported primary and 
secondary (P&S) syphilis cases reached the lowest rate (2.1 
cases per 100,000 population) since reporting began in 1941. 
However, since 2000–2001, the P&S syphilis rate has increased 
almost every year. In 2014*, the rate was 6.3 in the United States, 
the highest rate reported since 1994 (1). Since 2000, increases 
in the P&S syphilis rate have primarily been attributable to 
increased cases among men, specifically among gay, bisexual, 
and other men who have sex with men (collectively referred to 
as MSM). In 2014, men accounted for the majority (90.7%) of 
all cases of P&S syphilis. Among male cases with known sex of 
sex partner(s), 82.9% occurred among MSM. However, during 
2013–2014, the P&S syphilis rate increased 22.7% among 
women (from 0.9 to 1.1) and 14.4% among men (from 10.2 
to 11.7). Increases in the overall, male, and female P&S syphilis 
rates were observed in every region of the country.
1. CDC. Sexually transmitted disease surveillance 2014. Atlanta, GA: US 
Department of Health and Human Services, CDC; 2015.
Trichinellosis
In 2014, a total of 11 confirmed and two probable 
trichinellosis cases were reported. Of these, a known or 
suspected source of Trichinella infection was documented for 
nine (69%) and included bear (six), free-range pork (one), 
pork from an unspecified source (one), and hamburger (one). 
No likely source of infection could be identified for four cases.
An outbreak of two confirmed (one each from Texas and 
Utah) and two probable cases (one each from Colorado and 
Washington) was reported among a group of six persons who 
hunted and consumed meat from a black bear in Alaska. 
The meat was consumed “somewhat rare” after being cooked 
on skewers over an open fire. The Washington State Public 
Health Laboratory detected Trichinella larvae in a sample of 
leftover bear meat via microscopy. The best way to prevent 
Trichinella infection is to thoroughly cook all meats to the 
USDA-recommended temperatures (as verified with a food 
thermometer) before consumption (1).
1. CDC. Trichinellosis. Atlanta, GA: US Department of Health and Human 
Services, CDC; 2013. http://www.cdc.gov/parasites/trichinellosis/prevent.html.
Tuberculosis
Tuberculosis (TB) is one of the world’s deadliest airborne 
diseases. It is the leading cause of death worldwide of persons 
living with human immunodeficiency virus (HIV), causing 
one fourth of all HIV-related deaths. In 2014, an estimated 
9.6 million persons worldwide developed TB, and 1.5 million 
died from the disease (1). One third of the world’s population 
has latent TB infection (LTBI), which can later develop into 
active disease (2). Many persons arrive in the United States 
annually from countries with high burdens of TB, including 
immigrants, refugees, students, or travelers.
In the United States, new cases of TB disease have been 
reported annually since 1953 to the National Tuberculosis 
Surveillance System (NTSS) in CDC’s Division of Tuberculosis 
Elimination (DTBE) (3). CDC receives data from 60 reporting 
jurisdictions (all 50 U.S. states, the District of Columbia, 
New York City, and eight U.S.-affiliated islands) through a 
standardized data collection form, the Report of Verified Case 
of Tuberculosis (RVCT). In 2009, the RVCT was revised and 
NTSS transitioned into a web-based reporting system.
The number and rate of TB cases have declined each year 
since 1993, representing steady progress toward the goal of 
TB elimination in the United States (<1 case per 1,000,000 
population). However, in 2014, the number (9,421) of new TB 
cases and rate of 3.0 per 100,000 population marked the smallest 
annual decline of incidence and TB case rate (-2.2%) in more 
than a decade (4).
Among all TB cases in the United States, racial/
ethnic minorities, especially foreign-born persons, are 
disproportionately affected. In 2014, the proportion of persons 
with TB who were foreign-born increased to 66% (6,215 of 
9,421) of total cases (4). Non-Hispanic Asians had the largest 
number of TB cases and the highest incidence rate in 2014. 
Compared with non-Hispanic whites, the TB rate among non-
Hispanic Asians in 2014 was approximately 30 times higher 
(17.8 versus 0.6).*
TB drug resistance continues to be a major concern. During 
1996–2014, the percentage of primary multidrug-resistant 
(MDR) TB cases, (i.e., patients with no previous history of TB 
* Race/ethnicity is presented differently than in tables 5 and 6. Persons of Hispanic 
ethnicity might be of any race.
* Rates for 2014 were calculated using the 2013 population estimates and differ 
from 2014 rates presented in the figures and table 7 (calculated using 2014 
population estimates).
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disease and resistant to at least isoniazid [INH] and rifampin 
[RIF]) has fluctuated between 1.3 and 0.9%. The percentage of 
U.S.-born patients with primary MDR TB has remained below 
1%. However, of the total number of reported primary MDR 
TB cases, the proportion occurring in foreign-born persons 
increased from 25% in 1993 to 85% in 2014. In addition, 15 
extensively drug-resistant TB cases (i.e., patients with resistance 
to INH and RIF, plus resistance to any fluoroquinolone and 
at least one of three injectable second-line anti-TB drugs [i.e., 
amikacin, kanamycin, or capreomycin]) have been reported 
since 2009; of these, 11 were among foreign-born persons (4).
To achieve TB elimination, intensified efforts are needed to 
address the persistent disparities that exist between U.S.-born 
and foreign-born persons and between whites and minorities in 
the United States. Improved awareness, testing, and treatment 
of LTBI and TB disease in minorities and foreign-born 
populations are essential to these efforts. DTBE is developing 
an initiative to enhance testing, monitoring, and treatment 
of LTBI to prevent progression to TB disease and accelerate 
the decline of TB.
1. World Health Organization. Global tuberculosis report 2015, 20th edition. 
http://www.who.int/tb/publications/global_report/en
2. World Health Organization. 10 facts about tuberculosis. http://www.
who.int/features/factfiles/tuberculosis/en
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4. CDC. Reported tuberculosis in the United States, 2014. Atlanta, GA: 
U.S. Department of Health and Human Services, CDC, October 2015. 
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Typhoid Fever
Typhoid fever is rare in the United States. Since 2009, an 
annual average of <400 cases has been reported. In 2014, a 
total of 349 cases were reported. Approximately 75% of U.S. 
cases are associated with international travel (1), and the risk 
for infection is highest for travelers visiting friends and relatives 
in countries where typhoid fever is endemic. These persons 
might stay for extended periods and are less likely than other 
travelers to seek pretravel vaccination and to observe strict safe 
water and food practices, possibly because of misperception 
of disease risk (2). The risk is also higher for travelers who 
visit areas where the disease is highly endemic, such as the 
Indian subcontinent, even for a short time (3). In 2011, CDC 
removed pretravel typhoid vaccination recommendations for 
26 low-risk destinations; pretravel vaccination guidelines are 
available at http://wwwnc.cdc.gov/travel (4).
1. Lynch MF, Blanton EM, Bulens S, et al. Typhoid fever in the United 
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org/10.7326/0003-4819-142-1-200501040-00013
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Varicella
As the 2-dose varicella vaccination program continues to 
mature and with the discontinuation of active surveillance for 
varicella, national surveillance is increasingly important for 
monitoring impact of the program. More states are reporting 
varicella cases to CDC through the National Notifiable 
Diseases Surveillance System; reporting of varicella cases to 
CDC from states and the District of Columbia increased from 
29 in 2006 (when the second dose of varicella vaccine was 
recommended for children [1]) to 40 as of 2014. Although the 
number of states reporting has increased, varicella incidence 
has declined 84.3% from an average of 25.4 per 100,000 
population during 2005–2006 to 4.0 in 2014.
To monitor impact of the varicella vaccination program, 
data from key variables such as age, vaccination status, 
disease severity (e.g., number of lesions), outcome of the case 
(e.g., hospitalized), and whether the case is associated with 
an outbreak, are used. In 2014, a total of 10,089 (99%) of 
10,172 cases reported to CDC from 40 states had data on at 
least one of the key variables important for monitoring the 
varicella vaccination program; completeness was 95% (9,622) 
for age, 60% (6,077) for vaccination status, 43% (4,344) for 
disease severity, 8% (802) for whether the case resulted in 
hospitalization, and 84% (8,493) for whether the case was 
associated with an outbreak. Of the cases with data reported 
for each of the key variables, 52% (4,975) was for persons 
aged 1–9 years, 22% (2,165) for those aged 10–19 years, and 
18% (1,726) for those aged ≥20 years; 55% (3,330) was for 
persons who had received at least 1 dose of varicella vaccine. 
Of those with information on number of doses, 56% (1,330 
of 2,358) had received 2 doses, 48% (2,081) had mild disease 
presentation (<50 lesions), 3% (25) resulted in hospitalization, 
and 11% (919) were associated with outbreaks. Laboratory 
testing for varicella was performed for 25% (1,159 of 
4,696) of reported cases, of which 79% (912 of 1,159) were 
laboratory confirmed.
Much of the varicella data should be interpreted with caution 
because of the large proportion of missing data. States continue 
improving varicella surveillance practices (2) and are working to 
increase completeness of reporting for the variables important 
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for monitoring the varicella vaccination program. As varicella 
incidence continues to decline, national surveillance data 
will provide the information needed to monitor progress and 
changing varicella epidemiology.
1. Marin M, Güris D, Chaves SS, Schmid S, Seward JF. Prevention of 
varicella: recommendations of the Advisory Committee on Immunization 
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Vibriosis
The incidence of vibriosis, defined as infection caused by 
a species from the family Vibrionaceae other than toxigenic 
Vibrio cholerae O1 or O139, has increased during 2007–2014 
(1). In 2012, an outbreak of V. parahaemolyticus infections 
was associated with consumption of shellfish harvested from 
Oyster Bay Harbor, New York (2). Now endemic on the 
Atlantic Coast, this same strain continued to cause illness in 
2013 and 2014 (3).
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Viral Hemorrhagic Fever
Viral Hemorrhagic Fever (VHF) is a group of acute febrile 
illnesses that are caused by approximately 30 viruses (1). Many 
are of substantial public health concern, particularly in Africa 
and South America, with the possibility of importation to 
the United States. Nationally notifiable VHFs are those with 
documented person to person transmission: Crimean-Congo 
hemorrhagic fever, Ebola virus disease (EVD), Lassa fever, 
Lujo, Marburg, and several New World Arenaviruses (Junin, 
Machupo, Guanarito, Sabia).
The 2014–16 West African EVD epidemic is the largest in 
history, with approximately 28,000 cases and 11,000 deaths 
(2). Such large numbers of cases presented new challenges in 
effectively diagnosing patients with EVD, caring for affected 
patients, and containing the epidemic. In 2014, a total of 10 
persons with EVD received medical care in the United States. 
Six were medically evacuated to the United States after having 
EVD diagnosed in West Africa (3–6); four had the disease 
diagnosed in the United States. The four EVD cases diagnosed 
in the United States consisted of traveler from Liberia with two 
subsequent nosocomial infections (7–11) and a medical aid 
worker who returned from Guinea (12). These were the first 
EVD cases to receive care in the United States. Previously, a 
patient with Marburg virus disease was cared for in Colorado 
in 2007 (13).
In response to the concern about importation of EVD to 
the United States, national and state level surveillance systems 
were enhanced in 2014 (14–18). In October 2014, all airline 
passengers who had traveled to Liberia, Sierra Leone, and 
Guinea within the previous 21 days were diverted to five 
airports for admittance to the United States using enhanced 
screening methods (19). At risk travelers and health care 
workers were required to complete a 21-day active monitoring 
period (17,18). In addition, CDC responded to inquiries from 
state and local health officials and health care providers and 
facilitated testing of persons under investigation (20,21).
One imported case of Lassa fever was reported in April 
2014. This is only the seventh known imported case to the 
United States (22). Lassa fever is endemic in West Africa, with an 
estimated 100,000 to 300,000 cases and 5,000 deaths annually.
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PART 1  
Summary of Notifiable Diseases  
in the United States, 2014
Abbreviations and Symbols Used in Tables
U  Data not available.
N  Not reportable (i.e., report of disease is not required in that    
  jurisdiction).
—  No reported cases.
Notes:  Rates <0.01 after rounding are listed as 0.
  Data in the MMWR Summary of Notifiable Diseases — United States,  
  2014 might differ from data in other CDC surveillance reports   
  because of differences in the timing of reports, the source of the  
  data, the use of different case definitions, and print criteria.
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TABLE 1. Number of reported cases of notifiable diseases,* by month,† excluding U.S. territories — United States, 2014





neuroinvasive — — 1 — 2 1 19 29 28 5 — — — 85
nonneuroinvasive — — — — — 2 4 4 1 — — — — 11
Eastern equine encephalitis virus
neuroinvasive — — — — — — 1 3 4 — — — — 8
Powassan virus
neuroinvasive — — — — 2 — 2 1 2 — — — — 7
nonneuroinvasive — — — — 1 — — — — — — — — 1
St. Louis encephalitis virus
neuroinvasive 1 — — — — — 2 3 — — — — — 6
nonneuroinvasive — — — 1 — — — 1 — 2 — — — 4
West Nile virus
neuroinvasive — 1 1 — 2 28 182 547 480 88 15 3 — 1,347
nonneuroinvasive — 1 — — 4 24 129 390 257 46 4 3 — 858
Babesiosis, total 8 8 15 11 45 221 526 535 158 72 72 89 — 1,760
confirmed 6 6 7 4 34 184 476 462 120 51 52 70 — 1,472
probable 2 2 8 7 11 37 50 73 38 21 20 19 — 288
Botulism, total 11 10 11 16 8 19 10 19 9 20 12 16 — 161
foodborne — 1 — — — 1 2 6 1 — — 4 — 15
infant 9 9 8 13 6 15 7 11 8 19 11 11 — 127
other (wound and unspecified) 2 — 3 3 2 3 1 2 — 1 1 1 — 19
Brucellosis 2 5 4 8 15 7 5 16 11 4 5 10 — 92
Chancroid¶ — 1 — — 1 1 — 1 2 — — — — 6
Chlamydia trachomatis infection¶ 97,157 109,226 142,149 110,169 132,858 111,251 107,315 144,706 114,508 114,227 132,164 126,059 — 1,441,789
Cholera — 1 — 1 — — — 2 — — 1 — — 5
Coccidioidomycosis** 761 847 890 676 956 671 483 619 542 483 600 704 — 8,232
Cryptosporidiosis, total 334 417 502 434 529 534 793 1,637 1,250 953 666 633 — 8,682
confirmed 224 253 292 264 311 314 490 1,138 838 612 406 423 — 5,565
probable 110 164 210 170 218 220 303 499 412 341 260 210 — 3,117
Cyclosporiasis — 5 2 3 13 36 135 152 22 15 7 8 — 398
Dengue fever§ 46 27 23 23 40 54 76 85 56 66 137 47 — 680
Diphtheria — — — 1 — — — — — — — — — 1
Ehrlichiosis/Anaplasmosis 
Anaplasma phagocytophilum 13 18 20 53 351 662 611 339 138 163 302 130 — 2,800
Ehrlichia chaffeensis 5 8 6 21 149 313 310 311 131 65 101 55 — 1,475
Ehrlichia ewingii — — 1 — 1 1 5 8 — 1 — — — 17
undetermined 3 1 4 5 21 47 38 34 20 8 9 6 — 196
Giardiasis 835 954 1,204 989 1,221 1,012 1,197 1,973 1,464 1,238 1,296 1,171 — 14,554
Gonorrhea¶ 24,079 25,407 31,899 25,395 31,273 27,111 27,073 35,376 28,522 27,492 33,167 33,268 — 350,062
Haemophilus influenzae, invasive disease 
all ages, serotypes 328 285 356 280 323 255 253 271 204 235 299 452 — 3,541
age <5 yrs 
serotype b 1 2 6 2 4 1 1 4 1 4 5 9 — 40
nontypeable 16 18 20 8 8 7 9 3 5 6 9 19 — 128
non-b serotype 6 2 7 1 2 5 1 3 3 3 4 1 — 38
unknown serotype 27 23 34 28 28 21 11 16 18 19 19 22 — 266
Hansen’s disease 1 10 7 7 5 8 9 9 6 5 5 16 — 88
Hantavirus pulmonary syndrome 2 1 2 3 5 4 6 1 1 2 3 2 — 32
Hemolytic uremic syndrome postdiarrheal 4 12 11 12 18 27 31 41 32 21 20 21 — 250
Hepatitis, virus 
A acute 62 96 107 83 142 86 87 151 117 86 99 123 — 1,239
B acute 205 206 282 222 280 199 188 264 217 189 258 281 — 2,791
B chronic 937 941 1,517 1,068 1,330 1,069 958 1,135 835 764 988 858 — 12,400
B infection perinatal 3 5 4 6 4 4 3 2 4 1 5 6 — 47
C acute 121 171 244 171 238 143 166 214 158 117 226 235 — 2,204
C past or present 9,256 11,158 15,679 12,670 15,395 13,707 12,401 15,532 12,269 13,030 15,758 16,008 — 162,863
Human immunodeficiency virus  
(HIV) diagnoses ††
3,602 3,209 3,528 3,552 3,506 3,470 3,512 3,247 3,100 2,812 1,664 401 3 35,606
Influenza-associated pediatric mortality§§ 31 24 21 9 6 3 5 13 2 2 4 21 — 141
Invasive pneumococcal disease 
all ages 1,722 1,575 1,955 1,481 1,585 832 626 588 706 802 1,200 2,284 — 15,356
age <5 yrs 77 89 140 111 100 61 44 46 58 85 104 150 — 1,065
Legionellosis 205 185 277 261 390 495 607 717 561 470 484 514 — 5,166
Leptospirosis 2 2 3 2 3 1 3 3 5 3 7 4 — 38
Listeriosis 39 21 42 45 56 63 81 104 89 69 80 80 — 769
Lyme disease, total 653 608 856 979 2,201 5,210 7,700 6,502 2,868 2,071 2,124 1,689 — 33,461
confirmed 438 434 604 682 1,523 4,100 6,227 5,088 2,124 1,454 1,482 1,203 — 25,359
probable 215 174 252 297 678 1,110 1,473 1,414 744 617 642 486 — 8,102
See table footnotes on next page.
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TABLE 1. (Continued) Number of reported cases of notifiable diseases,* by month,† excluding U.S. territories — United States, 2014
Disease Jan. Feb. Mar. Apr. May June July Aug. Sept. Oct. Nov. Dec.
Not 
stated Total
Malaria 110 86 91 84 170 177 191 246 154 112 121 111 — 1,653
Measles, total 15 46 49 27 196 210 31 15 4 10 7 57 — 667
indigenous 6 32 44 16 189 207 29 15 1 7 4 54 — 604
imported 9 14 5 11 7 3 2 — 3 3 3 3 — 63
Meningococcal disease 
all serogroups 53 44 55 36 39 30 14 28 27 32 29 46 — 433
serogroups ACWY 18 7 19 12 8 9 7 7 6 6 9 15 — 123
serogroup B 9 6 13 7 11 1 — 4 7 9 6 16 — 89
other serogroups 3 4 2 3 — 2 — 3 1 2 3 2 — 25
unknown serogroup 23 27 21 14 20 18 7 14 13 15 11 13 — 196
Mumps 26 52 168 335 242 99 48 48 22 29 47 107 — 1,223
Novel influenza A virus infection — — — — — — — 2 — 1 — — — 3
Pertussis 1,984 1,925 2,375 2,236 3,755 3,238 3,073 3,358 2,142 2,038 3,199 3,648 — 32,971
Plague — — — 1 — — 5 1 1 — 1 1 — 10
Psittacosis — — 1 — — — — — 1 2 3 1 — 8
Q fever, total 11 9 19 18 19 13 11 24 12 10 7 15 — 168
acute 9 8 13 14 15 12 10 16 11 5 5 14 — 132
chronic 2 1 6 4 4 1 1 8 1 5 2 1 — 36
Rabies 
animal¶¶ 267 292 394 573 515 449 511 756 675 567 292 277 420 5,988
human — — — — — — — — 1 — — — — 1
Rubella — — 2 — 1 1 — — — — 1 1 — 6
Rubella, congenital syndrome — — — 1 — — — — — — — — — 1
Salmonellosis 1,981 2,122 2,691 2,652 4,264 4,538 5,538 7,954 5,837 5,085 4,936 3,857 — 51,455
Shiga toxin-producing E. coli (STEC) 195 193 354 369 541 624 839 948 604 455 543 514 — 6,179
Shigellosis 939 825 1,179 1,163 1,980 1,838 2,032 2,132 1,875 2,077 2,319 2,386 — 20,745
Spotted fever rickettsiosis, total 39 30 77 105 426 745 612 633 339 235 301 215 — 3,757
confirmed 1 1 2 1 12 23 26 17 8 8 12 4 — 115
probable 38 28 75 104 414 722 583 612 331 227 289 211 — 3,634
Streptococcal toxic shock syndrome 29 26 36 26 23 24 18 13 10 6 17 31 — 259
Syphilis, total, all stages¶,*** 4,143 4,464 6,056 4,795 6,090 5,153 4,935 6,269 5,086 5,223 5,604 5,632 — 63,450
primary and secondary¶ 1,349 1,377 1,805 1,449 1,902 1,635 1,558 2,040 1,622 1,640 1,773 1,849 — 19,999
congenital¶ 39 36 37 26 36 36 32 48 48 43 38 39 — 458
Tetanus 2 2 1 2 3 3 4 3 — 2 — 3 — 25
Toxic shock syndrome 
(other than streptococcal)
7 2 6 3 6 1 10 3 6 1 8 6 — 59
Trichinellosis — 1 — — 3 1 3 1 — — 2 2 — 13
Tuberculosis††† 503 535 726 879 786 796 775 879 779 777 714 1,272 — 9,421
Tularemia 1 — 1 6 19 31 41 25 16 19 10 11 — 180
Typhoid fever 23 28 36 25 36 31 34 46 40 19 9 22 — 349
Vancomycin-intermediate 
Staphylococcus aureus (VISA)
13 18 20 20 17 16 16 20 28 12 17 15 — 212
Varicella (Chickenpox)
morbidity 603 676 972 869 1,270 843 580 726 913 877 1,008 835 — 10,172
mortality§§§ — — — — — 1 — 1 — 1 1 — — 4
Vibriosis 20 19 36 30 68 106 162 343 197 130 77 73 — 1,261
Viral hemorrhagic fevers — — — 1 — — — — — 4 — — — 5
Yellow fever§ — — — — — — — — — — — — — —
 * No cases of anthrax; dengue hemorrhagic fever (and dengue shock syndrome), eastern equine encephalitis, nonneuroinvasive disease; poliomyelitis, paralytic; poliovirus infection, 
nonparalytic; severe acute respiratory syndrome-associated Coronavirus disease (SARS-CoV); smallpox; vancomycin-resistant Staphylococcus aureus (VRSA); western equine encephalitis, 
neuroinvasive and nonneuroinvasive disease; or yellow fever were reported in the United States during 2014.
 † Month is defined using MMWR week http://wwwn.cdc.gov/nndss/document/MMWR_Week_overview.pdf. MMWR week calendars can be found at http://wwwn.cdc.gov/nndss/script/
downloads.aspx.
 § Totals reported to the Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases (ArboNET Surveillance), as of July 1, 2015.
 ¶ Totals reported to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), as of June 10, 2015.
 ** Reportable in <25 states.
 †† Total number of HIV diagnoses reported to the Division of HIV/AIDS Prevention, NCHHSTP through December 31, 2014.
  §§ Totals reported to the Influenza Division, National Center for Immunization and Respiratory Diseases (NCIRD), as of June 30, 2015.
 ¶¶ Totals reported to the National Center for Emerging and Zoonotic Infectious Diseases, Division of High Consequence Pathogens and Pathology, as of October 30, 2015.
 *** Includes the following categories: primary, secondary, latent (including early latent, late latent, and latent syphilis of unknown duration), neurosyphilis, late (including late syphilis with 
clinical manifestations other than neurosyphilis), and congenital syphilis. Totals reported to the Division of STD Prevention, NCHHSTP, as of June 10, 2015.
 ††† Totals reported to the Division of Tuberculosis Elimination, NCHHSTP, as of July 15, 2015.
 §§§ Totals reported to the Division of Viral Diseases, NCIRD, as of June 30, 2015.
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United States 318,856 85 11 8 7 1 6 4 1,347 858
New England 14,681 2 — 4 4 — — — 8 4
Connecticut 3,597 — — — — — — — 3 3
Maine 1,330 — — 1 — — — — — —
Massachusetts 6,745 2 — — 4 — — — 5 1
New Hampshire 1,327 — — 3 — — — — — —
Rhode Island 1,055 — — — — — — — — —
Vermont 627 — — — — — — — —
Mid. Atlantic 41,471 — — 2 1 1 — — 36 11
New Jersey 8,938 — — — 1 — — — 6 2
New York (upstate) 11,255 — — 2 — 1 — — 7 4
New York City 8,491 — — — — — — — 12 3
Pennsylvania 12,787 — — — — — — — 11 2
E.N. Central 46,740 37 6 1 2 — — — 59 13
Illinois 12,881 — 1 — — — — — 36 8
Indiana 6,597 2 — — — — — — 9 1
Michigan 9,910 — — 1 — — — — 1 —
Ohio 11,594 30 1 — — — — — 10 1
Wisconsin 5,758 5 4 — 2 — — — 3 3
W.N. Central 21,006 6 2 — — — — — 104 221
Iowa 3,107 — — — — — — — 5 10
Kansas 2,904 — — — — — — — 18 36
Minnesota 5,457 6 2 — — — — — 6 15
Missouri 6,064 — — — — — — — 10 3
Nebraska 1,882 — — — — — — — 41 101
North Dakota 739 — — — — — — — 12 11
South Dakota 853 — — — — — — — 12 45
S. Atlantic 62,513 28 2 — — — 2 — 38 11
Delaware 936 — — — — — — — — —
District of Columbia 659 — — — — — — — 1 2
Florida 19,893 1 — — — — 2 — 12 5
Georgia 10,097 1 1 — — — — — 11 2
Maryland 5,976 — — — — — — — 6 —
North Carolina 9,944 23 — — — — — — — —
South Carolina 4,832 — — — — — — — 3 —
Virginia 8,326 2 — — — — — — 5 2
West Virginia 1,850 1 1 — — — — — — —
E.S. Central 18,805 12 1 1 — — 3 — 38 24
Alabama 4,849 — — 1 — — 1 — — 2
Kentucky 4,413 — — — — — — — — 1
Mississippi 2,994 — 1 — — — 2 — 26 17
Tennessee 6,549 12 — — — — — — 12 4
W.S. Central 38,451 — — — — — 1 3 332 201
Arkansas 2,966 — — — — — — — 9 2
Louisiana 4,650 — — — — — — — 61 64
Oklahoma 3,878 — — — — — — — 9 9
Texas 26,957 — — — — — 1 3 253 126
Mountain 23,197 — — — — — — 1 157 126
Arizona 6,731 — — — — — — 1 80 27
Colorado 5,356 — — — — — — — 46 72
Idaho 1,634 — — — — — — — 6 13
Montana 1,024 — — — — — — — 2 3
Nevada 2,839 — — — — — — — 3 —
New Mexico 2,086 — — — — — — — 19 5
Utah 2,943 — — — — — — — 1 1
Wyoming 584 — — — — — — — — 5
See table footnotes on next page.
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Pacific 51,992 — — — — — — — 575 247
Alaska 737 — — — — — — — — —
California 38,803 — — — — — — — 561 240
Hawaii 1,420 — — — — — — — — 1
Oregon 3,970 — — — — — — — 7 1
Washington 7,062 — — — — — — — 7 5
Territories
American Samoa 55 — — — — — — — — —
C.N.M.I. 51 — — — — — — — — —
Guam 161 — — — — — — — — —
Puerto Rico 3,621 — — — — — — — — —
U.S. Virgin Islands 104 — — — — — — — — —
* No cases of anthrax; dengue hemorrhagic fever; eastern equine encephalitis, nonneuroinvasive; poliomyelitis, paralytic; poliovirus infection, nonparalytic; severe 
acute respiratory syndrome-associated coronavirus disease (SARS-CoV); smallpox; Vancomycin-resistant Staphylococcus aureus (VRSA); western equine encephalitis 
virus disease, neuroinvasive and nonneuroinvasive; and yellow fever were reported in the United States during 2014.
† Totals reported to the Division of Vector-Borne Diseases (DVBD), National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) (ArboNET Surveillance), 
as of July 1, 2015.
§ California serogroup viral diseases for 2014 include LaCrosse virus, Jamestown Canyon virus and California serogroup viruses not specified.
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TABLE 2b. Number of reported cases of notifiable diseases,* by region and reporting area — United States and U.S. territories, 2014 
Area
Babesiosis Botulism
BrucellosisTotal Confirmed Probable Total Foodborne Infant Other†
United States 1,760 1,472 288 161 15 127 19 92
New England 1,007 902 105 1 — 1 — 3
Connecticut 212 173 39 — — — — —
Maine 42 34 8 — — — — —
Massachusetts 537 510 27 — — — — 3
New Hampshire 41 36 5 — — — — —
Rhode Island 172 148 24 — — — — —
Vermont 3 1 2 1 — 1 — —
Mid. Atlantic 640 498 142 26 2 24 — 2
New Jersey 169 133 36 10 — 10 — 1
New York (upstate) 421 319 102 5 2 3 — —
New York City 50 46 4 2 — 2 — 1
Pennsylvania N N N 9 — 9 — —
E.N. Central 47 31 16 8 4 4 — 12
Illinois 1 1 — 1 1 — — 4
Indiana — — — 1 1 — — —
Michigan 2 1 1 1 — 1 — 2
Ohio 1 — 1 5 2 3 — 1
Wisconsin 43 29 14 — — — — 5
W.N. Central 50 32 18 4 — 4 — 4
Iowa N N N — — — N —
Kansas N N N — — — — 2
Minnesota 49 31 18 1 — 1 — 1
Missouri N N N 3 — 3 — —
Nebraska — — — — — — — 1
North Dakota — — — — — — — —
South Dakota 1 1 — — — — — —
S. Atlantic 6 3 3 18 — 17 1 19
Delaware 1 1 — 4 — 4 — —
District of Columbia N N N 1 — 1 — 2
Florida N N N — — — — 3
Georgia N N N 2 — 2 — 7
Maryland 2 — 2 10 — 9 1 —
North Carolina N N N — — — — 2
South Carolina 3 2 1 — — — — 1
Virginia N N N 1 — 1 — 1
West Virginia — — — — — — — 3
E.S. Central 1 — 1 2 — 2 — 2
Alabama 1 — 1 — — — — —
Kentucky N N N 1 — 1 — 1
Mississippi N N N — — — — —
Tennessee — — — 1 — 1 — 1
W.S. Central 1 1 — 11 — 8 3 16
Arkansas N N N 3 — 1 2 —
Louisiana — — — — — — — —
Oklahoma N N N — — — — 1
Texas 1 1 — 8 — 7 1 15
Mountain — — — 17 1 15 1 9
Arizona N N N 2 — 1 1 6
Colorado N N N 6 1 5 — 3
Idaho N N N — — — — —
Montana — — — 1 — 1 — —
Nevada N N N 1 — 1 — —
New Mexico N N N 1 — 1 — —
Utah — — — 6 — 6 — —
Wyoming — — — — — — — —
Pacific 8 5 3 74 8 52 14 25
Alaska N N N 7 7 — — —
California 3 2 1 63 — 49 14 20
Hawaii N N N — — — — 1
Oregon 1 — 1 1 1 — — 1
Washington 4 3 1 3 — 3 — 3
See table footnotes on next page.
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TABLE 2b. (Continued) Number of reported cases of notifiable diseases,* by region and reporting area — United States and U.S. territories, 2014 
Area
Babesiosis Botulism
BrucellosisTotal Confirmed Probable Total Foodborne Infant Other†
Territories
American Samoa U U U — — — — —
C.N.M.I. — — — — — — — —
Guam — — — — — — — —
Puerto Rico N N N — — — — —
U.S. Virgin Islands N N N — — — — —
* No cases of anthrax; dengue hemorrhagic fever; eastern equine encephalitis, nonneuroinvasive; poliomyelitis, paralytic; poliovirus infection, nonparalytic; severe 
acute respiratory syndrome-associated coronavirus disease (SARS-CoV); smallpox; Vancomycin-resistant Staphylococcus aureus (VRSA); western equine encephalitis 
virus disease, neuroinvasive and nonneuroinvasive; and yellow fever were reported in the United States during 2014.
† Includes cases reported as wound and unspecified botulism.
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United States 6 1,441,789 5 8,232 8,682 5,565 3,117 398
New England 1 48,355 1 5 318 282 36 26
Connecticut — 13,382 — N 45 45 — 8
Maine — 3,530 — N 51 34 17 N
Massachusetts 1 21,271 1 — 139 139 — 18
New Hampshire — 3,586 — 3 40 23 17 —
Rhode Island — 4,349 — 2 16 16 — —
Vermont — 2,237 — N 27 25 2 —
Mid. Atlantic — 179,254 — — 785 609 176 53
New Jersey — 29,904 — N 77 77 — 16
New York (upstate) — 38,845 — N 237 230 7 14
New York City — 59,969 — N 102 102 — 23
Pennsylvania — 50,536 — N 369 200 169 N
E.N. Central — 217,323 — 55 1,451 1,044 407 26
Illinois — 66,536 — N 158 79 79 14
Indiana — 28,519 — N 185 96 89 2
Michigan — 44,256 — 33 239 215 24 8
Ohio — 54,858 — 16 324 109 215 1
Wisconsin — 23,154 — 6 545 545 — 1
W.N. Central — 85,924 1 118 1,248 666 582 10
Iowa — 11,804 — N 264 61 203 —
Kansas — 11,116 — N 67 22 45 1
Minnesota — 19,907 1 90 338 244 94 5
Missouri — 27,981 — 19 167 81 86 1
Nebraska — 7,499 — 4 111 87 24 3
North Dakota — 3,451 — 5 148 143 5 N
South Dakota — 4,166 — N 153 28 125 —
S. Atlantic — 289,330 2 11 2,627 1,488 1,139 70
Delaware — 4,473 — — 8 6 2 —
District of Columbia — 5,293 — 1 5 5 — —
Florida — 84,194 2 N 1,905 1,031 874 33
Georgia — 51,945 — N 240 240 — 6
Maryland — 27,424 — 10 79 47 32 4
North Carolina — 47,147 — N 166 85 81 4
South Carolina — 28,087 — N 63 41 22 18
Virginia — 36,048 — N 152 32 120 4
West Virginia — 4,719 — N 9 1 8 1
E.S. Central — 97,072 — — 411 282 129 1
Alabama — 29,010 — N 147 67 80 N
Kentucky — 17,664 — N 80 50 30 N
Mississippi — 19,605 — N 66 66 — N
Tennessee — 30,793 — N 118 99 19 1
W.S. Central 1 196,441 — 3 804 436 368 201
Arkansas — 15,605 — — 56 55 1 1
Louisiana — 28,955 — 3 244 107 137 —
Oklahoma — 20,662 — N 88 23 65 N
Texas 1 131,219 — N 416 251 165 200
Mountain — 97,489 1 5,792 487 361 126 6
Arizona — 32,397 — 5,624 46 33 13 2
Colorado — 21,863 1 N 75 52 23 1
Idaho — 5,442 — N 100 87 13 N
Montana — 4,193 — 10 66 57 9 2
Nevada — 11,841 — 70 16 10 6 N
New Mexico — 11,558 — 40 86 80 6 —
Utah — 8,223 — 46 70 16 54 1
Wyoming — 1,972 — 2 28 26 2 —
Pacific 4 230,601 — 2,248 551 397 154 5
Alaska — 5,789 — N 4 3 1 —
California 4 176,308 — 2,243 357 346 11 2
Hawaii — 6,419 — N 3 3 — —
Oregon — 15,508 — 5 112 10 102 1
Washington — 26,577 — N 75 35 40 2
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American Samoa — — — N N N N N
C.N.M.I. — — — — — — — —
Guam — 839 — — — — — —
Puerto Rico — 4,899 — N — — — —
U.S. Virgin Islands — 791 — — — — — —
* No cases of anthrax; dengue hemorrhagic fever; eastern equine encephalitis, nonneuroinvasive; poliomyelitis, paralytic; poliovirus infection, nonparalytic; severe 
acute respiratory syndrome-associated coronavirus disease (SARS-CoV); smallpox; Vancomycin-resistant Staphylococcus aureus (VRSA); western equine encephalitis 
virus disease, neuroinvasive and nonneuroinvasive; and yellow fever were reported in the United States during 2014. 
† Totals reported to the Division of STD Prevention, NCHHSTP, as of June 10, 2015.
§ Notifiable in <25 states.
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Dengue Fever Ehrlichia chaffeensis Ehrlichia ewingii Undetermined
United States 680 1 2,800 1,475 17 196
New England 35 — 1,182 60 — 10
Connecticut 3 — 75 — — —
Maine 1 — 191 8 — 6
Massachusetts 17 — 621 20 — 1
New Hampshire 5 — 131 7 — 2
Rhode Island 5 — 97 24 — —
Vermont 4 — 67 1 — 1
Mid. Atlantic 160 — 547 177 — 26
New Jersey 84 — 69 54 — 10
New York (upstate) 28 — 421 109 — 11
New York City 42 — 32 9 — —
Pennsylvania 6 — 25 5 — 5
E.N. Central 34 1 507 62 — 96
Illinois 7 — 18 47 — —
Indiana 5 — — — — 49
Michigan 5 — 4 3 — —
Ohio 9 1 1 4 — 1
Wisconsin 8 — 484 8 — 46
W.N. Central 10 — 483 386 12 39
Iowa 4 — N N N N
Kansas 1 — 4 46 2 3
Minnesota 3 — 448 5 1 17
Missouri 2 — 24 328 9 19
Nebraska — — 1 6 — —
North Dakota — — 6 1 — —
South Dakota — — — — — —
S. Atlantic 126 — 41 299 3 10
Delaware 1 — 2 22 — —
District of Columbia 2 — — — — 1
Florida 84 — 7 29 — —
Georgia 4 — 1 14 — 1
Maryland 8 — 2 38 1 —
North Carolina 8 — 12 73 — —
South Carolina 2 — — 8 — —
Virginia 16 — 15 112 2 8
West Virginia 1 — 2 3 — —
E.S. Central 8 — 11 163 1 12
Alabama 3 — 7 10 — 2
Kentucky 1 — — 62 — —
Mississippi 2 — 1 4 — —
Tennessee 2 — 3 87 1 10
W.S. Central 41 — 24 328 1 —
Arkansas 4 — 15 236 1 —
Louisiana 3 — 2 3 — —
Oklahoma — — 4 77 — —
Texas 34 — 3 12 — —
Mountain 113 — — — — 1
Arizona 97 — — — — 1
Colorado 10 — N N N N
Idaho 1 — N N N N
Montana 2 — — — — —
Nevada 3 — — — — —
New Mexico — — N N N N
Utah — — — — — —
Wyoming — — — — — —
Pacific 153 — 5 — — 2
Alaska 4 — N N N N
California 130 — 5 — — 2
Hawaii 10 — N N N —
Oregon — — — — — N
Washington 9 — — — — —
See table footnotes on next page.
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Dengue Fever Ehrlichia chaffeensis Ehrlichia ewingii Undetermined
Territories
American Samoa — — N N N N
C.N.M.I. — — — — — —
Guam — — N N N N
Puerto Rico 525 — N N N N
U.S. Virgin Islands 19 — — — — —
* No cases of anthrax; dengue hemorrhagic fever; eastern equine encephalitis, nonneuroinvasive; poliomyelitis, paralytic; poliovirus infection, nonparalytic; severe 
acute respiratory syndrome-associated coronavirus disease (SARS-CoV); smallpox; Vancomycin-resistant Staphylococcus aureus (VRSA); western equine encephalitis 
virus disease, neuroinvasive and nonneuroinvasive; and yellow fever were reported in the United States during 2014.
† Total number of reported laboratory-positive dengue cases including all confirmed cases [by antidengue virus (DENV) molecular diagnostic methods or seroconversion 
of anti-DENV IgM] and all probable cases (by a single, positive anti-DENV IgM). Totals reported to the Division of Vector-Borne Diseases (DVBD), National Center for 
Emerging and Zoonotic Infectious Diseases (NCEZID) (ArboNET Surveillance), as of July 1, 2015.
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TABLE 2e. Number of reported cases of notifiable diseases,* by region and reporting area — United States and U.S. territories, 2014 
Area Giardiasis Gonorrhea†






Serotype b Nontypeable Non-b serotype
Unknown 
serotype
United States 14,554 350,062 3,541 40 128 38 266 88
New England 1,361 7,287 240 2 8 2 10 3
Connecticut 219 2,333 60 — — — 9 —
Maine 154 237 21 1 2 — — N
Massachusetts 709 3,817 104 1 4 1 — 3
New Hampshire 97 226 24 — 1 1 — —
Rhode Island 45 590 16 — 1 — 1 —
Vermont 137 84 15 — — — — N
Mid. Atlantic 2,931 40,104 598 9 15 2 31 10
New Jersey 384 6,636 149 — — — 14 —
New York (upstate) 951 6,616 148 3 5 — 1 N
New York City 874 14,142 120 — — — 12 10
Pennsylvania 722 12,710 181 6 10 2 4 —
E.N. Central 1,562 53,262 589 7 33 13 18 4
Illinois N 15,970 164 — 4 5 5 —
Indiana 167 7,289 102 2 5 1 3 —
Michigan 506 9,688 106 4 5 5 — 1
Ohio 385 16,237 128 — 15 2 4 2
Wisconsin 504 4,078 89 1 4 — 6 1
W.N. Central 1,501 18,714 304 2 1 1 41 2
Iowa 205 1,641 4 1 — — — —
Kansas 104 2,568 43 1 1 — 8 —
Minnesota 662 4,073 127 — — — 18 —
Missouri 228 7,387 97 — — — 8 2
Nebraska 131 1,459 25 — — — 6 —
North Dakota 39 694 8 — — 1 1 N
South Dakota 132 892 — — — — — —
S. Atlantic 2,663 75,743 854 4 14 10 62 13
Delaware 24 1,279 16 — — — 4 —
District of Columbia 78 1,883 10 — — 1 1 —
Florida 1,165 20,944 259 — — — 32 10
Georgia 656 13,770 138 1 5 8 4 1
Maryland 268 6,108 85 1 1 — 2 1
North Carolina N 14,415 146 — — — 16 —
South Carolina 150 8,253 63 1 1 — — —
Virginia 256 8,250 89 — 7 1 1 1
West Virginia 66 841 48 1 — — 2 N
E.S. Central 182 24,854 239 — 18 5 17 5
Alabama 182 7,677 65 — 7 3 3 —
Kentucky N 4,353 37 — 1 1 6 1
Mississippi N 5,625 36 — — — 5 4
Tennessee N 7,199 101 — 10 1 3 —
W.S. Central 393 55,000 204 7 9 — 8 27
Arkansas 113 4,539 50 — 4 — — 7
Louisiana 280 9,002 46 — — — 6 1
Oklahoma N 6,137 96 1 5 — 2 N
Texas N 35,322 12 6 N N N 19
Mountain 1,111 18,788 330 5 25 2 26 4
Arizona 119 7,750 101 — 8 — 12 —
Colorado 332 3,170 66 — 4 2 2 1
Idaho 154 443 18 — — — — —
Montana 89 434 14 1 — — 1 —
Nevada 65 3,188 17 — 2 — 1 1
New Mexico 101 2,246 49 2 4 — 6 —
Utah 225 1,441 59 2 7 — 3 2
Wyoming 26 116 6 — — — 1 —
See table footnotes on next page.
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TABLE 2e. (Continued) Number of reported cases of notifiable diseases,* by region and reporting area — United States and U.S. territories, 2014 
Area Giardiasis Gonorrhea†






Serotype b Nontypeable Non-b serotype
Unknown 
serotype
Pacific 2,850 56,310 183 4 5 3 53 20
Alaska 89 1,341 25 — 4 — 3 —
California 1,852 45,408 42 — — — 35 6
Hawaii 43 1,020 23 — — — 6 14
Oregon 351 2,320 84 — 1 — 7 N
Washington 515 6,221 9 4 — 3 2 N
Territories
American Samoa — — — — — — — —
C.N.M.I. — — — — — — — —
Guam 1 99 — — — — — 13
Puerto Rico 31 454 3 — — 1 — 2
U.S. Virgin Islands — 84 N N N N N —
* No cases of anthrax; dengue hemorrhagic fever; eastern equine encephalitis, nonneuroinvasive; poliomyelitis, paralytic; poliovirus infection, nonparalytic; severe 
acute respiratory syndrome-associated coronavirus disease (SARS-CoV); smallpox; Vancomycin-resistant Staphylococcus aureus (VRSA); western equine encephalitis 
virus disease, neuroinvasive and nonneuroinvasive; and yellow fever were reported in the United States during 2014. 
† Totals reported to the Division of STD Prevention, NCHHSTP, as of June 10, 2015.
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United States 32 250 1,239 2,791 12,400 47 2,204 162,863
New England — 11 88 59 411 1 272 11,227
Connecticut N 4 23 9 72 — 9 3,263
Maine — 1 8 12 44 — 31 1,423
Massachusetts — 6 43 30 233 1 228 5,639
New Hampshire — — 5 4 28 — N N
Rhode Island — — 8 U U — U U
Vermont — — 1 4 34 — 4 902
Mid. Atlantic — 7 191 240 3,669 11 308 33,947
New Jersey — 3 59 77 487 — 113 7,765
New York (upstate) — 3 38 38 496 1 113 8,448
New York City — 1 46 57 1,759 6 13 7,339
Pennsylvania — — 48 68 927 4 69 10,395
E.N. Central — 33 186 416 1,662 5 381 32,104
Illinois — 4 82 58 972 — 27 8,777
Indiana — 7 20 126 U — 122 U
Michigan — 6 45 50 475 2 78 7,572
Ohio — 9 32 171 214 2 105 15,755
Wisconsin — 7 7 11 1 1 49 —
W.N. Central 4 34 79 78 1,013 2 76 12,033
Iowa 2 6 12 9 66 — U —
Kansas — 10 7 11 116 — 28 1,560
Minnesota — 10 19 16 197 — 40 1,899
Missouri — 6 20 31 431 2 6 6,278
Nebraska — 1 9 8 110 — 2 926
North Dakota 2 — 9 — 83 — — 848
South Dakota — 1 3 3 10 — — 522
S. Atlantic — 31 225 848 2,874 4 423 49,338
Delaware — — 1 8 88 — U U
District of Columbia — — U U U U U U
Florida — 7 90 313 1,137 1 93 22,253
Georgia — 7 24 103 N — 57 4,237
Maryland — 6 27 40 498 — 42 7,041
North Carolina — 4 38 100 447 2 111 N
South Carolina — 1 6 37 145 — 4 3,586
Virginia — 6 27 61 341 1 54 5,590
West Virginia — — 12 186 218 — 62 6,631
E.S. Central — 21 49 561 625 2 334 —
Alabama N 1 15 117 N — 35 N
Kentucky — 4 19 164 N — 176 N
Mississippi N 2 3 48 N N U —
Tennessee — 14 12 232 625 2 123 N
W.S. Central 6 37 148 294 211 5 127 2,657
Arkansas — 8 2 28 N — 13 N
Louisiana — 2 5 87 125 1 22 2,116
Oklahoma 1 21 17 57 86 1 45 541
Texas 5 6 124 122 N 3 47 N
Mountain 19 30 86 100 449 — 112 10,299
Arizona 5 — 29 31 98 — U U
Colorado 4 6 23 29 144 — 33 3,644
Idaho — 10 7 6 51 — 6 932
Montana 1 5 5 — 26 — 13 1,413
Nevada — 1 5 21 N — 6 N
New Mexico 6 — 8 2 50 — 16 2,316
Utah 2 8 8 11 34 — 38 1,492
Wyoming 1 — 1 U 46 — U 502
Pacific 3 46 187 195 1,486 17 171 11,258
Alaska — — 1 3 U — N —
California 1 38 142 110 1,114 14 73 1,317
Hawaii — 2 5 6 182 N 1 11
Oregon 1 6 13 32 97 — 15 5,002
Washington 1 — 26 44 93 3 82 4,928
See table footnotes on next page.
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American Samoa N N — — N — — —
C.N.M.I. — — — — — — — —
Guam N — 5 9 47 — 5 63
Puerto Rico — N 8 19 5 — N 558
U.S. Virgin Islands — N — — — — — —
* No cases of anthrax; dengue hemorrhagic fever; eastern equine encephalitis, nonneuroinvasive; poliomyelitis, paralytic; poliovirus infection, nonparalytic; severe 
acute respiratory syndrome-associated coronavirus disease (SARS-CoV); smallpox; Vancomycin-resistant Staphylococcus aureus (VRSA); western equine encephalitis 
virus disease, neuroinvasive and nonneuroinvasive; and yellow fever were reported in the United States during 2014.
† Reported cases of chronic hepatitis B and hepatitis C past or present might not reflect unique case reports and might include both confirmed and probable case reports.
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Legionellosis Leptospirosis ListeriosisAll ages Age <5 years
United States 35,606 141 15,356 1,065 5,166 38 769
New England 887 3 1,136 51 270 1 57
Connecticut 248 — 241 9 60 N 15
Maine 40 1 137 6 19 — 8
Massachusetts 474 2 531 27 144 1 21
New Hampshire 29 — 98 4 12 N 2
Rhode Island 82 — 73 4 28 — 10
Vermont 14 — 56 1 7 — 1
Mid. Atlantic 5,315 16 2,009 116 1,173 1 136
New Jersey 1,029 6 519 34 199 — 17
New York (upstate) 910 1 842 48 422 — 36
New York City 2,282 6 648 34 228 1 37
Pennsylvania 1,094 3 N N 324 — 46
E.N. Central 3,449 10 2,600 128 1,108 4 100
Illinois 1,171 3 N — 249 — 30
Indiana 431 — 624 32 129 1 8
Michigan 703 2 614 34 229 1 20
Ohio 932 2 936 45 406 2 30
Wisconsin 212 3 426 17 95 — 12
W.N. Central 1,053 10 954 83 254 1 46
Iowa 98 1 N N 33 — 7
Kansas 112 3 136 N 19 N 6
Minnesota 245 5 487 41 59 — 17
Missouri 468 — N 23 106 1 11
Nebraska 81 1 153 14 23 — 4
North Dakota 24 — 88 5 4 N 1
South Dakota 25 — 90 N 10 N —
S. Atlantic 10,895 26 2,944 241 959 — 153
Delaware 105 — 41 1 20 — 1
District of Columbia 242 — 71 2 13 — 1
Florida 5,257 6 792 89 280 — 49
Georgia 1,401 1 925 62 93 — 15
Maryland 778 1 428 34 144 — 13
North Carolina 1,378 8 N N 187 — 30
South Carolina 741 2 421 23 45 — 10
Virginia 912 6 19 19 129 — 25
West Virginia 81 2 247 11 48 — 9
E.S. Central 1,944 9 1,430 101 352 1 34
Alabama 517 — 213 17 63 1 9
Kentucky 235 1 189 12 95 N 3
Mississippi 463 1 261 23 33 N 6
Tennessee 729 7 767 49 161 N 16
W.S. Central 5,649 34 2,205 208 394 — 34
Arkansas 283 2 290 26 38 N 4
Louisiana 1,400 6 353 27 64 — 9
Oklahoma 276 2 N 26 36 — 2
Texas 3,690 24 1,562 129 256 N 19
Mountain 1,651 10 1,902 116 208 2 50
Arizona 705 3 724 38 59 1 14
Colorado 361 1 471 21 65 N 10
Idaho 12 — N 7 17 — 3
Montana 15 — 40 2 4 — 1
Nevada 388 3 139 6 25 — 4
New Mexico 124 1 299 14 8 — 9
Utah 37 2 204 25 28 1 9
Wyoming 9 — 25 3 2 — —
Pacific 4,763 23 176 21 448 28 159
Alaska 41 — 87 10 2 — —
California 3,988 22 N N 351 5 114
Hawaii 82 — 89 11 7 23 5
Oregon 215 1 N N 33 — 16
Washington 437 — N N 55 — 24
See table footnotes on next page.
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Legionellosis Leptospirosis ListeriosisAll ages Age <5 years
Territories
American Samoa — — N — N — N
C.N.M.I. — — — — — — —
Guam — — — — — — —
Puerto Rico 489 — — — 13 69 —
U.S. Virgin Islands 16 — — — — — —
* No cases of anthrax; dengue hemorrhagic fever; eastern equine encephalitis, nonneuroinvasive; poliomyelitis, paralytic; poliovirus infection, nonparalytic; severe 
acute respiratory syndrome-associated coronavirus disease (SARS-CoV); smallpox; Vancomycin-resistant Staphylococcus aureus (VRSA); western equine encephalitis 
virus disease, neuroinvasive and nonneuroinvasive; and yellow fever were reported in the United States during 2014.
† Totals reported to the Influenza Division, National Center for Immunization and Respiratory Diseases (NCIRD), as of June 30, 2015.
§ Streptococcus pneumoniae, invasive disease. Since January 1, 2010, “Invasive pneumococcal disease (IPD)” has been nationally notifiable and separate notifications 
for “Drug resistant S. pneumoniae” and “IPD in children <5 years of age” have been discontinued.
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Total Confirmed Probable Total Indigenous Imported
United States 33,461 25,359 8,102 1,653 667 604 63
New England 11,292 8,168 3,124 120 13 6 7
Connecticut 2,360 1,719 641 15 5 4 1
Maine 1,401 1,169 232 7 — — —
Massachusetts 5,304 3,646 1,658 61 8 2 6
New Hampshire 724 622 102 11 — — —
Rhode Island 904 570 334 22 — — —
Vermont 599 442 157 4 — — —
Mid. Atlantic 14,509 11,912 2,597 427 38 30 8
New Jersey 3,286 2,589 697 79 3 1 2
New York (upstate) 2,887 2,285 602 59 5 2 3
New York City 849 568 281 204 27 25 2
Pennsylvania 7,487 6,470 1,017 85 3 2 1
E.N. Central 1,950 1,511 439 141 392 384 8
Illinois 233 233 — 55 2 1 1
Indiana 110 100 10 20 1 — 1
Michigan 127 93 34 17 5 3 2
Ohio 119 94 25 38 382 379 3
Wisconsin 1,361 991 370 11 2 1 1
W.N. Central 1,663 1,035 628 115 52 48 4
Iowa 194 110 84 17 — — —
Kansas 20 12 8 9 14 13 1
Minnesota 1,416 896 520 51 2 1 1
Missouri 10 7 3 15 27 25 2
Nebraska 7 6 1 9 1 1 —
North Dakota 14 2 12 9 — — —
South Dakota 2 2 — 5 8 8 —
S. Atlantic 3,678 2,557 1,121 421 3 1 2
Delaware 417 341 76 2 — — —
District of Columbia 40 35 5 18 — — —
Florida 155 85 70 52 — — —
Georgia 4 4 — 82 — — —
Maryland 1,373 957 416 146 — — —
North Carolina 170 27 143 36 1 — 1
South Carolina 37 20 17 6 — — —
Virginia 1,346 976 370 77 2 1 1
West Virginia 136 112 24 2 — — —
E.S. Central 127 48 79 46 5 3 2
Alabama 64 28 36 14 1 — 1
Kentucky 44 11 33 11 — — —
Mississippi 2 2 — 1 — — —
Tennessee 17 7 10 20 4 3 1
W.S. Central 42 20 22 143 10 7 3
Arkansas — — — 7 — — —
Louisiana 2 — 2 20 — — —
Oklahoma — — — 10 — — —
Texas 40 20 20 106 10 7 3
Mountain 59 38 21 79 8 6 2
Arizona 21 14 7 25 3 3 —
Colorado — — — 30 1 — 1
Idaho 9 8 1 3 — — —
Montana 7 5 2 2 — — —
Nevada 6 4 2 11 — — —
New Mexico — — — 3 1 1 —
Utah 13 5 8 5 3 2 1
Wyoming 3 2 1 — — — —
Pacific 141 70 71 161 146 119 27
Alaska 8 5 3 4 — — —
California 73 54 19 95 92 75 17
Hawaii N N N 4 15 10 5
Oregon 45 3 42 17 6 5 1
Washington 15 8 7 41 33 29 4
See table footnotes on next page.
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Total Confirmed Probable Total Indigenous Imported
Territories
American Samoa N N N — — — —
C.N.M.I. — — — — — — —
Guam — — — — 2 2 —
Puerto Rico N N N 1 2 2 —
U.S. Virgin Islands N N N — — — —
* No cases of anthrax; dengue hemorrhagic fever; eastern equine encephalitis, nonneuroinvasive; poliomyelitis, paralytic; poliovirus infection, nonparalytic; severe 
acute respiratory syndrome-associated coronavirus disease (SARS-CoV); smallpox; Vancomycin-resistant Staphylococcus aureus (VRSA); western equine encephalitis 
virus disease, neuroinvasive and non-neuroinvasive; and yellow fever were reported in the United States during 2014.
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United States 433 123 89 25 196 1,223 3 32,971
New England 18 11 4 2 1 10 — 1,199
Connecticut 3 3 — — — 3 — 100
Maine 2 1 — 1 — — — 557
Massachusetts 12 6 4 1 1 5 — 308
New Hampshire — — — — — 2 — 84
Rhode Island 1 1 — — — — — 108
Vermont — — — — — — — 42
Mid. Atlantic 51 7 11 3 30 193 — 2,223
New Jersey 9 — — — 9 39 — 387
New York (upstate) 8 2 5 1 — 12 — 901
New York City 18 — — — 18 123 — 122
Pennsylvania 16 5 6 2 3 19 — 813
E.N. Central 50 19 21 3 7 805 3 5,658
Illinois 12 7 4 1 — 142 — 764
Indiana 4 — 4 — — 25 — 492
Michigan 12 4 5 — 3 20 — 1,424
Ohio 12 7 2 — 3 552 2 1,463
Wisconsin 10 1 6 2 1 66 1 1,515
W.N. Central 22 3 3 — 16 41 — 2,689
Iowa 2 1 1 — — 10 — 222
Kansas 1 1 — — — 2 — 431
Minnesota 7 — — — 7 22 — 950
Missouri 8 — — — 8 6 — 558
Nebraska — — — — — — — 366
North Dakota 2 1 1 — — 1 — 52
South Dakota 2 — 1 — 1 — — 110
S. Atlantic 102 17 22 5 58 47 — 3,002
Delaware 1 — 1 — — — — 205
District of Columbia 1 — 1 — — 16 — 22
Florida 50 — — — 50 1 — 719
Georgia 14 7 2 1 4 2 — 408
Maryland 7 2 4 1 — 3 — 203
North Carolina 13 6 5 — 2 2 — 752
South Carolina 5 — 3 1 1 2 — 170
Virginia 10 2 6 1 1 20 — 505
West Virginia 1 — — 1 — 1 — 18
E.S. Central 19 9 3 — 7 8 — 983
Alabama 7 4 1 — 2 2 — 285
Kentucky 3 — — — 3 2 — 300
Mississippi 1 — — — 1 — — 68
Tennessee 8 5 2 — 1 4 — 330
W.S. Central 40 15 8 6 11 21 — 3,094
Arkansas 1 1 — — — 1 — 286
Louisiana 7 — — — 7 1 — 90
Oklahoma 10 3 4 3 — 4 — 142
Texas 22 11 4 3 4 15 — 2,576
Mountain 33 17 6 4 6 49 — 4,176
Arizona 9 4 4 1 — 12 — 517
Colorado 9 5 1 2 1 4 — 1,282
Idaho 5 2 1 1 1 26 — 367
Montana 4 4 — — — 1 — 494
Nevada 3 — — — 3 2 — 144
New Mexico 2 2 — — — 2 — 370
Utah 1 — — — 1 2 — 940
Wyoming — — — — — — — 62
Pacific 98 25 11 2 60 49 — 9,947
Alaska 3 3 — — — 1 — 169
California 57 — — — 57 37 — 8,723
Hawaii 2 1 — 1 — 1 — 38
Oregon 19 11 5 — 3 1 — 416
Washington 17 10 6 1 — 9 — 601
See table footnotes on next page.
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American Samoa — — — — — — — —
C.N.M.I. — — — — — — — —
Guam — — — — — — — —
Puerto Rico — — — — — — — 17
U.S. Virgin Islands — — — — — — — —
* No cases of anthrax; dengue hemorrhagic fever; eastern equine encephalitis, nonneuroinvasive; poliomyelitis, paralytic; poliovirus infection, nonparalytic; severe 
acute respiratory syndrome-associated coronavirus disease (SARS-CoV); smallpox; Vancomycin-resistant Staphylococcus aureus (VRSA); western equine encephalitis 
virus disease, neuroinvasive and nonneuroinvasive; and yellow fever were reported in the United States during 2014. 
† Totals reported to the Influenza Division, National Center for Immunization and Respiratory Diseases (NCIRD), as of June 30, 2015.
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TABLE 2j. Number of reported cases of notifiable diseases,* by region and reporting area — United States and U.S. territories, 2014 
Area Plague Psittacosis
Q fever Rabies
RubellaTotal Acute Chronic Animal† Human
United States 10 8 168 132 36 5,988 1 6
New England — — 1 — 1 479 — —
Connecticut — N — — — 183 — —
Maine — — — — — 43 — —
Massachusetts — — 1 — 1 148 — —
New Hampshire — — N N N 23 — —
Rhode Island — — — — — 27 — —
Vermont — — N — — 55 — —
Mid. Atlantic — 1 18 13 5 1,136 — 1
New Jersey — 1 4 3 1 349 — —
New York (upstate) — — 6 6 — 372 — —
New York City — — 2 — 2 12 — —
Pennsylvania — — 6 4 2 403 — 1
E.N. Central — — 18 8 10 150 — 1
Illinois — — 4 2 2 40 — 1
Indiana — — 2 2 — 12 — —
Michigan — — 2 1 1 43 — —
Ohio — — 4 — 4 28 — —
Wisconsin — — 6 3 3 27 — —
W.N. Central — 5 15 14 1 204 1 1
Iowa — — N N N 15 — —
Kansas — — 2 2 — 70 — —
Minnesota — — 3 3 — 33 — —
Missouri — — 1 1 — 26 1 —
Nebraska — 5 2 2 — 21 — 1
North Dakota — — 2 2 — 18 — —
South Dakota — — 5 4 1 21 — —
S. Atlantic — 1 11 10 1 1,833 — —
Delaware — — — — — 9 — —
District of Columbia — — N — — 40 — —
Florida — 1 1 1 — 95 — —
Georgia — — — — — 272 — —
Maryland — — — — — 344 — —
North Carolina — — 3 3 — 355 — —
South Carolina — — — — — 140 — —
Virginia — — 4 3 1 528 — —
West Virginia — — 3 3 — 50 — —
E.S. Central — — 4 4 — 137 — —
Alabama — — 2 2 — 86 — —
Kentucky — — — — — 10 — —
Mississippi — — — — — 1 — —
Tennessee — — 2 2 — 40 — —
W.S. Central — — 22 14 8 1,396 — —
Arkansas — — 5 5 N 152 — —
Louisiana — — 1 1 — 5 — —
Oklahoma — — 4 2 2 106 — —
Texas — N 12 6 6 1,133 — —
Mountain 10 — 34 24 10 422 — 1
Arizona — — 9 6 3 157 — —
Colorado 8 — 6 4 2 131 — —
Idaho — — 4 4 — 12 — —
Montana — — 4 2 2 16 — —
Nevada — — — — — 14 — —
New Mexico 2 — 2 2 — 12 — —
Utah — — 9 6 3 22 — 1
Wyoming — — — — — 58 — —
Pacific — 1 45 45 — 231 — 2
Alaska — — — — — 3 — —
California — — 35 35 — 200 — 2
Hawaii — — — — — U — —
Oregon — — 9 9 — 13 — —
Washington — 1 1 1 — 15 — —
See table footnotes on next page.
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TABLE 2j. (Continued) Number of reported cases of notifiable diseases,* by region and reporting area — United States and U.S. territories, 2014 
Area Plague Psittacosis
Q fever Rabies
RubellaTotal Acute Chronic Animal† Human
Territories
American Samoa — N N N N U U —
C.N.M.I. — — — — — — — —
Guam — — N N N — — —
Puerto Rico — N — — — 45 — —
U.S. Virgin Islands — — — — — — — —
* No cases of anthrax; dengue hemorrhagic fever; eastern equine encephalitis, nonneuroinvasive; poliomyelitis, paralytic; poliovirus infection, nonparalytic; severe acute respiratory syndrome-
associated coronavirus disease (SARS-CoV); smallpox; Vancomycin-resistant Staphylococcus aureus (VRSA); western equine encephalitis virus disease, neuroinvasive and nonneuroinvasive; 
and yellow fever were reported in the United States during 2014.
† Totals reported to the National Center for Emerging and Zoonotic Infectious Diseases, Division of High-consequence Pathogens and Pathology, as of December 14, 2015.
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Spotted Fever Rickettsiosis§ Streptococcal 
toxic shock 
syndromeTotal Confirmed Probable
United States 1 51,455 6,179 20,745 3,757 115 3,634 259
New England — 2,231 223 335 19 1 18 46
Connecticut — 457 60 67 6 — 6 19
Maine — 127 33 29 3 — 3 18
Massachusetts — 1,223 95 187 8 — 8 6
New Hampshire — 191 16 14 2 1 1 —
Rhode Island — 140 4 34 — — — 1
Vermont — 93 15 4 — — — 2
Mid. Atlantic — 4,968 577 1,224 86 2 84 50
New Jersey — 1,170 124 297 58 — 58 37
New York (upstate) — 1,320 200 281 20 1 19 13
New York City — 1,008 70 443 1 — 1 —
Pennsylvania — 1,470 183 203 7 1 6 —
E.N. Central 1 5,672 871 3,475 148 2 146 78
Illinois 1 1,778 195 840 89 1 88 52
Indiana — 725 117 1,362 36 — 36 12
Michigan — 1,053 133 310 — — — 4
Ohio — 1,199 204 606 12 — 12 9
Wisconsin — 917 222 357 11 1 10 1
W.N. Central — 3,038 1,013 2,615 411 8 403 11
Iowa — 527 224 208 10 — 10 —
Kansas — 428 90 55 110 — 110 2
Minnesota — 727 332 95 7 — 7 8
Missouri — 839 180 1,395 265 2 263 1
Nebraska — 259 107 220 13 3 10 —
North Dakota — 88 39 21 3 2 1 —
South Dakota — 170 41 621 3 1 2 —
S. Atlantic — 14,163 514 4,768 1,002 56 946 35
Delaware — 157 14 74 24 — 24 —
District of Columbia — 64 5 118 — — — —
Florida — 6,019 117 2,396 29 2 27 N
Georgia — 2,242 97 1,021 37 37 — —
Maryland — 894 74 260 6 2 4 4
North Carolina — 2,057 51 510 496 10 486 20
South Carolina — 1,399 15 162 32 1 31 1
Virginia — 1,151 121 214 373 4 369 10
West Virginia — 180 20 13 5 — 5 —
E.S. Central — 3,738 323 1,893 881 25 850 4
Alabama — 1,165 41 516 220 8 206 —
Kentucky — 585 97 344 53 — 53 4
Mississippi — 990 31 199 50 4 46 N
Tennessee — 998 154 834 558 13 545 —
W.S. Central — 7,821 843 3,791 1,155 3 1,152 2
Arkansas — 668 89 770 824 — 824 —
Louisiana — 1,210 18 139 18 — 18 2
Oklahoma — 798 124 139 219 3 216 N
Texas — 5,145 612 2,743 94 — 94 N
Mountain — 2,933 627 749 37 10 25 33
Arizona — 1,046 98 376 16 6 10 4
Colorado — 616 168 80 5 1 4 2
Idaho — 174 116 12 1 — 1 1
Montana — 146 39 44 4 1 3 —
Nevada — 173 36 36 1 — 1 12
New Mexico — 333 47 64 2 1 1 —
Utah — 370 91 41 8 1 5 13
Wyoming — 75 32 96 — — — 1
Pacific — 6,891 1,188 1,895 18 8 10 —
Alaska — 68 — 4 N N N N
California — 5,358 691 1,655 11 5 6 N
Hawaii — 323 25 29 N N N —
Oregon — 401 185 50 5 2 3 N
Washington — 741 287 157 2 1 1 N
See table footnotes on next page.
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American Samoa — — — — N N N N
C.N.M.I. — — — — — — — —
Guam — 13 — 4 N N N —
Puerto Rico N 832 5 26 N N N N
U.S. Virgin Islands — — — — N N N —
* No cases of anthrax; dengue hemorrhagic fever; eastern equine encephalitis, nonneuroinvasive; poliomyelitis, paralytic; poliovirus infection, nonparalytic; severe 
acute respiratory syndrome-associated coronavirus disease (SARS-CoV); smallpox; Vancomycin-resistant Staphylococcus aureus (VRSA); western equine encephalitis 
virus disease, neuroinvasive and nonneuroinvasive; and yellow fever were reported in the United States during 2014.
† Includes E. coli O157:H7; shiga toxin-positive, serogroup non-O157; and shiga toxin positive, not serogrouped.
§ Total case count includes eight unknown case status reports.
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United States 63,450 19,999 458 25 59 13
New England 1,256 515 3 — 2 —
Connecticut 169 86 — — N —
Maine 23 16 — — — —
Massachusetts 813 301 3 — — —
New Hampshire 79 36 — — — —
Rhode Island 160 71 — — 1 —
Vermont 12 5 — — 1 —
Mid. Atlantic 9,825 2,556 27 2 7 —
New Jersey 1,172 297 — — 2 —
New York (upstate) 1,341 401 3 — 4 —
New York City 5,788 1,326 19 — — —
Pennsylvania 1,524 532 5 2 1 —
E.N. Central 5,880 2,106 65 3 17 2
Illinois 2,796 863 27 — 2 —
Indiana 475 168 8 1 — 1
Michigan 1,095 421 15 — 4 —
Ohio 1,229 568 15 1 9 1
Wisconsin 285 86 — 1 2 —
W.N. Central 2,083 857 6 2 6 —
Iowa 239 72 1 — 1 —
Kansas 200 60 — — — —
Minnesota 631 257 — 2 5 —
Missouri 771 352 1 — — —
Nebraska 96 50 1 — — —
North Dakota 51 13 — — — —
South Dakota 95 53 3 — — —
S. Atlantic 14,857 4,886 93 3 9 1
Delaware 110 47 — — 1 —
District of Columbia 281 116 — — — —
Florida 6,102 1,740 47 2 N —
Georgia 3,384 1,234 17 — 4 N
Maryland 1,475 449 16 1 N —
North Carolina 1,998 733 6 — 2 —
South Carolina 750 250 5 — 1 —
Virginia 702 289 2 — N 1
West Virginia 55 28 — — 1 —
E.S. Central 2,541 745 9 1 6 —
Alabama 475 161 3 — — —
Kentucky 447 158 3 — 1 —
Mississippi 642 189 1 1 N —
Tennessee 977 237 2 — 5 —
W.S. Central 10,780 2,483 132 6 2 2
Arkansas 389 121 6 — 2 N
Louisiana 2,173 575 46 1 — —
Oklahoma 414 151 6 1 N —
Texas 7,804 1,636 74 4 N 2
Mountain 3,201 1,317 20 — 7 2
Arizona 1,459 577 13 — 2 —
Colorado 355 186 — — 4 1
Idaho 46 12 — — — —
Montana 9 8 — — — —
Nevada 894 357 6 — — —
New Mexico 283 126 1 — — —
Utah 149 47 — — 1 1
Wyoming 6 4 — — — —
Pacific 13,027 4,534 103 8 3 6
Alaska 45 15 — 1 N 2
California 11,440 3,835 99 4 3 2
Hawaii 106 68 — — N —
Oregon 582 272 2 — N —
Washington 854 344 2 3 N 2
See table footnotes on next page.
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American Samoa — — — — N N
C.N.M.I. — — — — — —
Guam 13 7 — — — —
Puerto Rico 960 484 — — N N
U.S. Virgin Islands 6 2 — — — —
* No cases of anthrax; dengue hemorrhagic fever; eastern equine encephalitis, nonneuroinvasive; poliomyelitis, paralytic; poliovirus infection, nonparalytic; severe 
acute respiratory syndrome-associated coronavirus disease (SARS-CoV); smallpox; Vancomycin-resistant Staphylococcus aureus (VRSA); western equine encephalitis 
virus disease, neuroinvasive and nonneuroinvasive; and yellow fever were reported in the United States during 2014.
† Includes the following categories: primary, secondary, latent (including early latent, late latent, and latent syphilis of unknown duration), neurosyphilis, late (including 
late syphilis with clinical manifestations other than neurosyphilis), and congenital syphilis.
§ Totals reported to the Division of STD Prevention, NCHHSTP, as of June 10, 2015.
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TABLE 2m. Number of reported cases of notifiable diseases,* by region and reporting area — United States and U.S. territories, 2014 
Area Tuberculosis† Tularemia Typhoid fever
Vancomycin-intermediate 
Staphylococcus aureus (VISA)
United States 9,421 180 349 212
New England 307 4 19 2
Connecticut 60 — 1 —
Maine 14 — — 1
Massachusetts 199 3 15 —
New Hampshire 11 — 1 N
Rhode Island 21 — 2 1
Vermont 2 1 — —
Mid. Atlantic 1,304 4 85 62
New Jersey 308 1 21 7
New York (upstate) 202 3 10 31
New York City 585 — 39 20
Pennsylvania 209 — 15 4
E.N. Central 736 12 38 17
Illinois 320 7 15 3
Indiana 108 2 5 —
Michigan 105 2 9 3
Ohio 156 1 7 9
Wisconsin 47 — 2 2
W.N. Central 381 63 15 106
Iowa 54 1 1 N
Kansas 40 27 1 —
Minnesota 147 — 6 —
Missouri 79 20 5 104
Nebraska 38 6 — —
North Dakota 15 4 2 —
South Dakota 8 5 — 2
S. Atlantic 1,667 2 56 16
Delaware 22 — 4 —
District of Columbia 32 — — —
Florida 595 1 13 4
Georgia 335 — 10 3
Maryland 198 — 16 1
North Carolina 195 — 4 4
South Carolina 79 — — 1
Virginia 198 — 9 3
West Virginia 13 1 — —
E.S. Central 438 3 4 3
Alabama 133 — 2 2
Kentucky 80 1 — —
Mississippi 74 — — —
Tennessee 151 2 2 1
W.S. Central 1,542 60 23 5
Arkansas 93 42 1 —
Louisiana 121 1 — —
Oklahoma 59 17 2 —
Texas 1,269 — 20 5
Mountain 431 24 21 1
Arizona 193 — 4 —
Colorado 64 16 6 N
Idaho 11 — — N
Montana 6 1 3 —
Nevada 74 — 3 —
New Mexico 50 5 1 N
Utah 31 1 4 1
Wyoming 2 1 — —
Pacific 2,615 8 88 —
Alaska 62 — — N
California 2,145 — 66 N
Hawaii 136 — 4 —
Oregon 77 4 3 N
Washington 195 4 15 N
See table footnotes on next page.
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TABLE 2m. (Continued) Number of reported cases of notifiable diseases,* by region and reporting area — United States and U.S. territories, 2014 




American Samoa 1 — — N
C.N.M.I. 23 — — —
Guam 56 — — —
Puerto Rico 44 — 1 —
U.S. Virgin Islands — — — —
* No cases of anthrax; dengue hemorrhagic fever; eastern equine encephalitis, nonneuroinvasive; poliomyelitis, paralytic; poliovirus infection, nonparalytic; severe 
acute respiratory syndrome-associated coronavirus disease (SARS-CoV); smallpox; Vancomycin-resistant Staphylococcus aureus (VRSA); western equine encephalitis 
virus disease, neuroinvasive and nonneuroinvasive; and yellow fever were reported in the United States during 2014.
† Totals reported to the Division of Tuberculosis Elimination, NCHHSTP, as of July 1, 2015.
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TABLE 2n. Number of reported cases of notifiable diseases,* by region and reporting area — United States and U.S. territories, 2014 
Area
Varicella
Vibriosis Viral hemorrhagic fever§Morbidity Mortality†
United States 10,172 4 1,261 5
New England 1,147 — 86 —
Connecticut 186 — 15 —
Maine 207 — 9 —
Massachusetts 470 N 51 —
New Hampshire 112 — 5 —
Rhode Island 54 — 6 —
Vermont 118 — — —
Mid. Atlantic 1,151 — 70 1
New Jersey 317 — 34 —
New York (upstate) N N N —
New York City — — 17 1
Pennsylvania 834 — 19 —
E.N. Central 2,498 — 63 —
Illinois 596 — 24 —
Indiana 220 — 6 —
Michigan 728 — 7 —
Ohio 535 N 12 —
Wisconsin 419 — 14 —
W.N. Central 855 — 38 1
Iowa N N N —
Kansas 294 — 2 —
Minnesota 297 — 25 1
Missouri 201 — 8 —
Nebraska 19 — 2 —
North Dakota 21 — 1 —
South Dakota 23 — N —
S. Atlantic 1,282 3 326 —
Delaware 15 — 5 —
District of Columbia — — 1 —
Florida 570 1 166 —
Georgia 64 1 18 —
Maryland N — 42 —
North Carolina N N 14 —
South Carolina 151 — 18 —
Virginia 324 1 59 —
West Virginia 158 N 3 —
E.S. Central 111 — 55 —
Alabama 107 — 20 —
Kentucky N N 9 —
Mississippi 4 N 11 —
Tennessee N — 15 —
W.S. Central 1,943 1 130 3
Arkansas 254 N N —
Louisiana 42 — 50 —
Oklahoma N N 2 —
Texas 1,647 1 78 3
Mountain 1,059 — 57 —
Arizona 300 — 36 —
Colorado 386 N 13 —
Idaho N N N —
Montana 72 — 2 —
Nevada N N 2 —
New Mexico 75 N 1 —
Utah 215 — 2 —
Wyoming 11 N 1 —
Pacific 126 — 436 —
Alaska 31 — 5 —
California 43 — 272 —
Hawaii 52 — 38 —
Oregon N N 29 —
Washington N — 92 —
See table footnotes on next page.
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TABLE 2n. (Continued) Number of reported cases of notifiable diseases,* by region and reporting area — United States and U.S. territories, 2014 
Area
Varicella
Vibriosis Viral hemorrhagic fever§Morbidity Mortality†
Territories
American Samoa N N N —
C.N.M.I. — — — —
Guam 33 N — —
Puerto Rico 231 — — —
U.S. Virgin Islands — — — —
* No cases of anthrax; dengue hemorrhagic fever; eastern equine encephalitis, nonneuroinvasive; poliomyelitis, paralytic; poliovirus infection, nonparalytic; severe 
acute respiratory syndrome-associated coronavirus disease (SARS-CoV); smallpox; Vancomycin-resistant Staphylococcus aureus (VRSA); western equine encephalitis 
virus disease, neuroinvasive and nonneuroinvasive; and yellow fever were reported in the United States during 2014.
† Totals reported to the Division of Viral Diseases, National Center for Immunization and Respiratory Diseases (NCIRD), as of June 30, 2015.
§ In addition to the four cases of Ebola Virus Disease diagnosed in the United States in 2014, six patients were medically evacuated to the United States for care after 
being diagnosed with Ebola Virus Disease in West Africa. In total, 11 VHF cases were reported for 2014, 10 confirmed infections with Ebola virus and one confirmed 
infection with Lassa virus.
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TABLE 3. Number of reported cases of notifiable diseases* and rates per 100,000 population, by age group, excluding U.S. territories — 
United States, 2014 
Disease
<1 yr 1–4 yrs 5–14 yrs 15–24 yrs 25–39 yrs 40—64 yrs ≥65 yrs Age not stated
No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Total
Arboviral diseases†
California serogroup viruses
neuroinvasive 2 (0.05) 12 (0.08) 59 (0.14) 2 (0.00) 2 (0.00) 3 (0.00) 5 (0.01) — 85
nonneuroinvasive — (0.00) — (0.00) 4 (0.01) 2 (0.00) 2 (0.00) 1 (0.00) 2 (0.00) — 11
Eastern equine encephalitis virus
neuroinvasive — (0.00) — (0.00) — (0.00) — (0.00) 1 (0.00) 4 (0.00) 3 (0.01) — 8
Powassan virus
neuroinvasive — (0.00) — (0.00) — (0.00) 1 (0.00) — (0.00) 2 (0.00) 4 (0.01) — 7
nonneuroinvasive — (0.00) — (0.00) — (0.00) — (0.00) — (0.00) — (0.00) 1 (0.00) — 1
St. Louis encephalitis virus
neuroinvasive — ( 0.00) — (0.00) — (0.00) — (0.00) 2 (0.00) 4 (0.00) — (0.00) — 6
nonneuroinvasive — ( 0.00) — (0.00) — (0.00) — (0.00) — (0.00) 2 (0.00) 2 (0.00) — 4
West Nile virus
neuroinvasive 2 (0.05) — (0.00) 26 (0.06) 54 (0.12) 150 (0.24) 633 (0.61) 481 (1.04) 1 1,347
nonneuroinvasive — (0.00) 3 (0.02) 13 (0.03) 53 (0.12) 137 (0.22) 432 (0.41) 220 (0.48) — 858
Babesiosis, total 1 (0.04) 10 (0.09) 33 (0.12) 48 (0.17) 144 (0.34) 700 (1.03) 816 (2.80) 8 1,760
confirmed 1 (0.04) 8 (0.08) 23 (0.08) 30 (0.10) 114 (0.27) 575 (0.84) 715 (2.46) 6 1,472
probable — (0.00) 2 (0.02) 10 (0.04) 18 (0.06) 30 (0.07) 125 (0.18) 101 (0.35) 2 288
Botulism, total 127 (3.22) 1 (0.01) 1 (0.00) 4 (0.01) 6 (0.01) 18 (0.02) 4 (0.01) — 161
foodborne 1 (0.03) — (0.00) 1 (0.00) 3 (0.01) 1 (0.00) 6 (0.01) 3 (0.01) — 15
Infant 126 (3.19) 1 (0.01) — (0.00) — (0.00) — (0.00) — (0.00) — (0.00) — 127
other (wound 
and unspecified)
— (0.00) — (0.00) — (0.00) 1 (0.00) 5 (0.01) 12 (0.01) 1 (0.00) — 19
Brucellosis — (0.00) 3 (0.02) 2 (0.00) 13 (0.03) 18 (0.03) 32 (0.03) 22 (0.05) 2 92
Chancroid§ — (0.00) — (0.00) — (0.00) 3 (0.01) 2 (0.00) 1 (0.00) — (0.00) — 6
Chlamydia trachomatis, 
infection§
— (0.00) — (0.00) — (0.00) 948,102 (2155.77) 419,569 (61.38) 58,726 (56.40) 1,449 (3.13) 1,753 1,441,789**
Cholera — (0.00) 1 (0.01) — (0.00) — (0.00) 1 (0.00) 3 (0.00) — (0.00) — 5
Coccidioidomycosis¶ 4 (0.26) 27 (0.43) 256 (1.58) 720 (4.14) 1,532 (6.13) 3,434 (8.47) 2,232 (12.54) 27 8,232
Cryptosporidiosis, total 158 (4.00) 1,313 (8.24) 1,201 (2.92) 1,262 (2.87) 1,975 (3.11) 1,873 (1.80) 883 (1.91) 17 8,682
confirmed 90 (2.28) 923 (5.79) 817 (1.98) 862 (1.96) 1,272 (2.01) 1,133 (1.09) 457 (0.99) 11 5,565
probable 68 (1.72) 390 (2.45) 384 (0.93) 400 (0.91) 703 (1.11) 740 (0.71) 426 (0.92) 6 3,117
Cyclosporiasis — (0.00) 2 (0.01) 1 (0.00) 21 (0.05) 74 (0.13) 214 (0.23) 85 (0.20) 1 398
Dengue fever† 1 (0.03) 1 (0.01) 28 (0.07) 86 (0.20) 167 (0.26) 312 (0.30) 83 (0.18) 2 680




— (0.00) 10 (0.07) 99 (0.25) 127 (0.30) 245 (0.40) 1,241 (1.25) 1,072 (2.42) 6 2,800
Ehrlichia chaffeensis 1 (0.03) 9 (0.06) 36 (0.09) 85 (0.20) 151 (0.25) 657 (0.66) 526 (1.19) 10 1,475
Ehrlichia ewingii — (0.00) — (0.00) — (0.00) — (0.00) 4 (0.01) 7 (0.01) 6 (0.01) — 17
undetermined — (0.00) 1 (0.01) 8 (0.02) 17 (0.04) 25 (0.04) 75 (0.08) 69 (0.16) 1 196
Giardiasis 103 (3.37) 1,720 (13.95) 1,960 (6.15) 1,823 (5.29) 2,891 (5.81) 4,493 (5.44) 1,489 (4.00) 75 14,554
Gonorrhea§ — (0.00) — (0.00) — (0.00) 184,668 (419.89) 128,783 (203.01) 32,558 (31.27) 911 (1.97) 485 350,062**
Haemophilus influenzae, invasive disease
all ages, serotypes 277 (7.02) 195 (1.22) 97 (0.24) 80 (0.18) 211 (0.33) 876 (0.84) 1,800 (3.89) 5 3,541
age <5 yrs  
serotype b 25 (0.63) 15 (0.09) — (0.00) — (0.00) — (0.00) — (0.00) — (0.00) — 40
nontypeable 86 (2.42) 42 (0.25) — (0.00) — (0.00) — (0.00) — (0.00) — (0.00) — 128
non-b serotype 20 (1.52) 18 (0.10) — (0.00) — (0.00) — (0.00) — (0.00) — (0.00) — 38
unknown serotype 146 (4.10) 120 (0.83) — (0.00) — (0.00) — (0.00) — (0.00) — (0.00) — 266
Hansen’s disease — (0.00) — (0.00) 3 (0.01) 7 (0.02) 22 (0.04) 22 (0.02) 19 (0.05) 15 88
Hantavirus pulmonary 
syndrome




6 (0.15) 117 (0.73) 87 (0.21) 12 (0.03) 2 (0.00) 16 (0.02) 8 (0.02) 2 250
Hepatitis,virus
A acute 2 (0.05) 13 (0.08) 68 (0.17) 181 (0.41) 344 (0.54) 407 (0.39) 217 (0.47) 7 1,239
B acute — (0.00) 1 (0.01) 1 (0.00) 102 (0.23) 1,080 (1.72) 1,436 (1.39) 157 (0.34) 14 2,791
B chronic 13 (0.41) 28 (0.22) 79 (0.24) 821 (2.30) 4,316 (8.39) 5,705 (6.67) 1,064 (2.75) 374 12,400
B infection perinatal 24 (0.62) 23 (0.15) — (0.00) — (0.00) — (0.00) — (0.00) — (0.00) — 47
C acute 11 (0.30) 3 (0.02) 1 (0.00) 502 (1.21) 1,139 (1.90) 482 (0.49) 38 (0.09) 28 2,204





34 (0.90) 24 (0.20) 95 (0.20) 7,723 (17.60) 14,927 (23.50) 12,059 (11.60) 744 (1.60) — 35,606
See table footnotes on page 62.
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TABLE 3. (Continued) Number of reported cases of notifiable diseases* and rates per 100,000 population, by age group, excluding U.S. 
territories — United States, 2014 
Disease
<1 yr 1–4 yrs 5–14 yrs 15–24 yrs 25–39 yrs 40—64 yrs ≥65 yrs Age not stated
No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Total
Influenza-associated 
pediatric mortality§§
33 (0.84) 31 (0.19) 61 (0.15) 16 (0.13) — (0.00) — (0.00) — (0.00) — 141
Invasive pneumococcal disease
all ages 363 (13.42) 660 (6.05) 372 (1.32) 262 (0.87) 1,161 (2.69) 6,407 (8.95) 6,103 (19.06) 28 15,356
age <5 yrs 378 (12.78) 687 (5.75) — (0.00) — (0.00) — (0.00) — (0.00) — (0.00) — 1,065
Legionellosis 1 (0.03) — (0.00) 2 (0.00) 37 (0.08) 335 (0.53) 2,374 (2.28) 2,185 (4.73) 232 5,166
Leptospirosis — (0.00) — (0.00) 2 (0.01) 11 (0.03) 9 (0.02) 11 (0.01) 2 (0.01) 3 38
Listeriosis 48 (1.22) 2 (0.01) 5 (0.01) 19 (0.04) 67 (0.11) 187 (0.18) 438 (0.95) 3 769
Lyme disease, total 36 (0.92) 1,263 (7.97) 5,649 (13.77) 3,337 (7.62) 4,092 (6.48) 11,968 (11.54) 6,310 (13.71) 806 33,461
confirmed 26 ( 0.66) 1,100 (6.94) 4,502 (10.97) 2,384 (5.44) 3,019 (4.78) 9,115 (8.79) 4,543 (9.87) 670 25,359
probable 10 (0.25) 163 (1.03) 1,147 (2.80) 953 (2.18) 1,073 (1.70) 2,853 (2.75) 1,767 (3.84) 136 8,102
Malaria 6 (0.15) 49 (0.31) 128 (0.31) 255 (0.58) 512 (0.81) 584 (0.56) 115 (0.25) 4 1,653
Measles, total 49 (1.24) 102 (0.64) 150 (0.36) 156 (0.35) 134 (0.21) 75 (0.07) 1 (0.00) — 667
Indigenous 41 (1.04) 90 (0.57) 146 (0.35) 142 (0.32) 120 (0.19) 64 (0.06) 1 (0.00) — 604
Imported 8 (0.20) 12 (0.08) 4 (0.01) 14 (0.03) 14 (0.02) 11 (0.01) — (0.00) — 63
Meningococcal disease
all serogroups 42 (1.06) 40 (0.25) 18 (0.04) 63 (0.14) 68 (0.11) 119 (0.11) 83 (0.18) — 433
serogroups ACWY 6 (0.15) 11 (0.07) 4 (0.01) 6 (0.01) 21 (0.03) 40 (0.04) 35 (0.08) — 123
serogroup B 16 (0.41) 12 (0.08) 5 (0.01) 24 (0.05) 10 (0.02) 16 (0.02) 6 (0.01) — 89
other serogroups 6 (0.15) — (0.00) 1 (0.00) 7 (0.02) 2 (0.00) 7 (0.01) 2 (0.00) — 25
unknown serogroup 14 (0.35) 17 (0.11) 8 (0.02) 26 (0.06) 35 (0.06) 56 (0.05) 40 (0.09) — 196
Mumps 6 (0.15) 62 (0.39) 118 (0.29) 481 (1.09) 242 (0.38) 269 (0.26) 44 (0.10) 1 1,223
Novel influenza A 
virus infection
— (0.00) — (0.00) 2 (0.00) — (0.00) — (0.00) — (0.00) — (0.00) 1 3
Pertussis 4,155 (105.23) 4,418 (27.74) 12,945 (31.43) 6,027 (13.70) 1,820 (2.87) 2,734 (2.63) 750 (1.62) 122 32,971
Plague — (0.00) — (0.00) — (0.00) 1 (0.00) 4 (0.01) 5 (0.00) — (0.00) — 10
Psittacosis — (0.00) — (0.00) — (0.00) 1 (0.00) 1 (0.00) 4 (0.00) 2 (0.00) — 8
Q fever, total — (0.00) — (0.00) 1 (0.00) 7 (0.02) 22 (0.04) 92 (0.09) 42 (0.09) 4 168
acute — (0.00) — (0.00) 1 (0.00) 7 (0.02) 21 (0.03) 73 (0.07) 27 (0.06) 3 132
chronic — (0.00) — (0.00) — (0.00) — (0.00) 1 (0.00) 19 (0.02) 15 (0.03) 1 36
Rabies, human — (0.00) — (0.00) — (0.00) — (0.00) — (0.00) 1 (0.00) — (0.00) — 1
Rubella — (0.00) — (0.00) — (0.00) 3 (0.01) 2 (0.00) 1 (0.00) — (0.00) — 6
Rubella, 
congenital syndrome
— (0.00) 1 (0.01) — (0.00) — (0.00) — (0.00) — (0.00) — (0.00) — 1
Salmonellosis 5,135 (130.05) 7,357 (46.19) 6,173 (14.99) 5,136 (11.68) 7,093 (11.18) 12,337 (11.85) 7,929 (17.15) 295 51,455
Shiga toxin-producing 
E. coli (STEC)
205 (5.19) 1,433 (9.00) 1,208 (2.93) 1,041 (2.37) 855 (1.35) 830 (0.80) 569 (1.23) 38 6,179
Shigellosis 309 (7.83) 5,600 (35.16) 6,303 (15.30) 1,566 (3.56) 3,203 (5.05) 2,866 (2.75) 779 (1.68) 119 20,745
Spotted fever 
rickettsiosis, total
5 (0.13) 38 (0.23) 175 (0.43) 293 (0.66) 650 (1.03) 1,745 (1.68) 838 (.82) 13 3,757
confirmed 1 (0.03) 5 (0.03) 6 (0.01) 10 (0.02) 18 (0.03) 46 (0.04) 29 (0.06) — 115
probable 4 (0.10) 33 (0.20) 169 (0.41) 282 (0.64) 630 (1.00) 1,695 (1.63) 808 (1.76) 13 3,634
Streptococcal toxic 
shock syndrome
1 (0.04) 5 (0.05) 10 (0.04) 16 (0.05) 40 (0.10) 117 (0.16) 70 (0.22) — 259
Syphilis, total, 
all stages§,¶¶
— (0.00) — (0.00) — (0.00) 13,653 (31.04) 27,286 (43.01) 20,572 (19.76) 1,404 (3.04) 18 63,450**
primary and 
secondary§
— (0.00) — (0.00) — (0.00) 5,160 (11.73) 9,024 (14.22) 5,621 (5.40) 176 (0.38) 6 19,999**
congenital§ — (0.00) — (0.00) — (0.00) — (0.00) — (0.00) — (0.00) — (0.00) — 458**
Tetanus — (0.00) 1 (0.01) 3 (0.01) 1 (0.00) 5 (0.01) 5 (0.00) 5 (0.01) 5 25
Toxic shock syndrome 
(other than 
streptococcal)
— (0.00) 2 (0.02) 18 (0.06) 22 (0.07) 3 (0.01) 10 (0.01) — (0.00) 4 59
Trichinellosis — (0.00) — (0.00) 1 (0.00) — (0.00) 5 (0.01) 5 (0.01) 2 (0.00) — 13
Tuberculosis*** 45 (1.14) 217 (1.36) 198 (0.48) 961 (2.19) 2,150 (3.39) 3,634 (3.49) 2,216 (4.79) — 9,421
Tularemia 2 (0.05) 6 (0.04) 30 (0.07) 16 (0.04) 12 (0.02) 68 (0.07) 44 (0.10) 2 180





1 (0.03) 1 (0.01) — (0.00) 11 (0.03) 20 (0.04) 110 (0.13) 65 (0.17) 4 212
Vibriosis 1 (0.03) 9 (0.06) 108 (0.28) 93 (0.23) 239 (0.40) 550 (0.56) 254 (0.59) 7 1,261
Viral hemorrhagic 
fevers
— (0.00) — (0.00) — (0.00) — (0.00) 3 (0.01) 1 (0.00) — (0.00) 1 5
Yellow fever† — (0.00) — (0.00) — (0.00) — (0.00) — (0.00) — (0.00) — (0.00) — —
See table footnotes on page 62.
62 MMWR / Published October 14, 2016, for 2014 / Vol. 63 / No. 54
Morbidity and Mortality Weekly Report
US Department of Health and Human Services/Centers for Disease Control and Prevention
TABLE 3. (Continued) Number of reported cases of notifiable diseases* and rates per 100,000 population, by age group, excluding U.S. 
territories — United States, 2014 
 * No cases of anthrax; dengue hemorrhagic fever (and dengue shock syndrome), eastern equine encephalitis, nonneuroinvasive disease; poliomyelitis, paralytic; poliovirus infection, 
nonparalytic; severe acute respiratory syndrome-associated Coronavirus disease (SARS-CoV); smallpox; vancomycin-resistant Staphylococcus aureus (VRSA); western equine encephalitis, 
neuroinvasive and nonneuroinvasive disease; or yellow fever were reported in the United States during 2014. 
 † Totals reported to the Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases (ArboNET Surveillance), as of July 1, 2015.
 § Cases among persons aged <15 years are not shown because some might not be caused by sexual transmission; totals reported to the Division of STD Prevention, National Center for 
HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), as of June 10, 2015.
 ¶ Reportable in <25 states.
 ** The row totals do not sum to total column. Data are suppressed for those aged <15 years. The total reflects the total count across all age groups.
 †† Total number of HIV diagnoses reported to the Division of HIV/AIDS Prevention, NCHHSTP through December 31, 2014.
 §§ Totals reported to the Influenza Division, National Center for Immunization and Respiratory Diseases (NCIRD) as of June 30, 2015.
 ¶¶ Includes the following categories: primary, secondary, latent (including early latent, late latent, and latent syphilis of unknown duration), neurosyphilis, late (including late syphilis with 
clinical manifestations other than neurosyphilis), and congenital syphilis. Totals reported to the Division of STD Prevention, NCHHSTP, as of June 10, 2015.
 *** Totals reported to the Division of Tuberculosis Elimination, NCHHSTP, as of July 15, 2015.
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TABLE 4. Number of reported cases of notifiable diseases* and rates per 100,000 population, by sex, excluding U.S. territories — United States, 2014
Disease
Male Female Sex not stated
No. Rate No. Rate No. Total
Arboviral diseases†
California serogroup viruses
neuroinvasive 42 (0.03) 43 (0.03) — 85
nonneuroinvasive 6 (0.00) 5 (0.00) — 11
Eastern equine encephalitis virus
neuroinvasive 4 (0.00) 4 (0.00) — 8
Powassan virus 
neuroinvasive 5 (0.00) 2 (0.00) — 7
nonneuroinvasive 1 (0.00) — (0.00) — 1
St. Louis encephalitis virus
neuroinvasive 3 (0.00) 3 (0.00) — 6
nonneuroinvasive 1 (0.00) 3 (0.00) — 4
West Nile virus
neuroinvasive 881 (0.57) 466 (0.29) — 1,347
nonneuroinvasive 522 (0.33) 336 (0.21) — 858
Babesiosis, total 1,138 (1.11) 616 (0.58) 6 1,760
confirmed 969 (0.94) 498 (0.47) 5 1,472
probable 169 (0.16) 118 (0.11) 1 288
Botulism, total 93 (0.06) 68 (0.04) — 161
foodborne 7 (0.00) 8 (0.00) — 15
infant 71 (3.52) 56 (2.90) — 127
other (wound and unspecified) 15 (0.01) 4 (0.00) — 19
Brucellosis 58 (0.04) 34 (0.02) — 92
Chancroid§ 4 (0.00) 2 (0.00) — 6
Chlamydia trachomatis, infection§ 433,325 (276.11) 1,006,441 (621.56) 2,023 1,441,789
Cholera 4 (0.00) 1 (0.00) — 5
Coccidioidomycosis¶ 4,283 (6.96) 3,940 (6.24) 9 8,232
Cryptosporidiosis, total 4,289 (2.73) 4,361 (2.69) 32 8,682
confirmed 2,775 (1.77) 2,763 (1.71) 27 5,565
probable 1,514 (0.96) 1,598 (0.99) 5 3,117
Cyclosporiasis 179 (0.12) 218 (0.15) 1 398
Dengue fever† 324 (0.21) 356 (0.22) — 680
Diphtheria — (0.00) 1 (0.00) — 1
Ehrlichiosis/Anaplasmosis
Anaplasma phagocytophilum 1,714 (1.14) 1,079 (0.70) 7 2,800
Ehrlichia chaffeensis 874 (0.58) 596 (0.39) 5 1,475
Ehrlichia ewingii 11 (0.01) 6 (0.00) — 17
undetermined 113 (0.08) 83 (0.05) — 196
Giardiasis 8,652 (7.00) 5,712 (4.48) 190 14,554
Gonorrhea§ 186,943 (119.12) 162,608 (100.42) 511 350,062
Haemophilus influenzae, invasive disease 
all ages, serotypes 1,651 (1.05) 1,868 (1.15) 22 3,541
age <5 yrs 
serotype b 19 (0.19) 21 (0.22) — 40
nontypeable 74 (0.73) 53 (0.55) 1 128
non-b serotype 24 (0.24) 13 (0.13) 1 38
unknown serotype 157 (1.55) 104 (1.07) 5 266
Hansen’s disease 48 (0.03) 25 (0.02) 15 88
Hantavirus pulmonary syndrome 25 (0.02) 7 (0.00) — 32
Hemolytic uremic syndrome postdiarrheal 99 (0.06) 151 (0.09) — 250
Hepatitis, virus
A acute 645 (0.41) 591 (0.37) 3 1,239
B acute 1,778 (1.14) 1,001 (0.62) 12 2,791
B chronic 6,782 (5.30) 5,473 (4.14) 145 12,400
B infection perinatal 25 (0.02) 22 (0.01) — 47
C acute 1,173 (0.79) 1,029 (0.67) 2 2,204
C past or present 98,372 (80.68) 63,550 (50.46) 941 162,863
Human immunodeficiency virus (HIV) diagnoses** 28,806 (18.40) 6,800 (4.20) — 35,606
Influenza-associated pediatric mortality†† 69 (0.18) 72 (0.20) — 141
Invasive pneumococcal disease 
all ages 7,967 (7.41) 7,321 (6.58) 68 15,356
age <5 yrs 567 (7.44) 443 (6.08) 55 1,065
Legionellosis 3,050 (1.94) 2,112 (1.30) 4 5,166
Leptospirosis 30 (0.02) 8 (0.01) — 38
Listeriosis 368 (0.23) 399 (0.25) 2 769
See table footnotes on next page.
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TABLE 4. (Continued) Number of reported cases of notifiable diseases* and rates per 100,000 population, by sex, excluding U.S. territories — 
United States, 2014
Disease
Male Female Sex not stated
No. Rate No. Rate No. Total
Lyme disease, total 19,180 (12.28) 13,841 (8.59) 440 33,461
confirmed 14,526 (9.30) 10,485 (6.50) 348 25,359
probable 4,654 (2.98) 3,356 (2.08) 92 8,102
Malaria 1,048 (0.67) 598 (0.37) 7 1,653
Measles, total 357 (0.23) 310 (0.19) — 667
indigenous 319 (0.20) 285 (0.18) — 604
imported 38 (0.02) 25 (0.02) — 63
Meningococcal disease
all serogroups 223 (0.14) 210 (0.13) — 433
serogroups ACWY 61 (0.04) 62 (0.04) — 123
serogroup B 50 (0.03) 39 (0.02) — 89
other serogroups 12 (0.01) 13 (0.01) — 25
unknown serogroup 100 (0.06) 96 (0.06) — 196
Mumps 598 (0.38) 624 (0.39) 1 1,223
Novel influenza A virus infection — (0.00) 3 (0.00) — 3
Pertussis 15,378 (9.80) 17,406 (10.75) 187 32,971
Plague 4 (0.00) 6 (0.00) — 10
Psittacosis 3 (0.00) 5 (0.00) — 8
Q fever, total 117 (0.08) 51 (0.03) — 168
acute 92 (0.06) 40 (0.03) — 132
chronic 25 (0.02) 11 (0.01) — 36
Rabies, human 1 (0.00) (0.00) — 1
Rubella 3 (0.00) 3 (0.00) — 6
Rubella, congenital syndrome — (0.00) 1 (0.00) — 1
Salmonellosis 23,965 (15.27) 27,086 (16.73) 404 51,455
Shiga toxin-producing E. coli (STEC) 2,810 (1.79) 3,348 (2.07) 21 6,179
Shigellosis 10,051 (6.40) 10,368 (6.40) 326 20,745
Spotted fever rickettsiosis, total 2,610 (1.66) 1,140 (0.70) 7 3,757
confirmed 90 (0.06) 24 (0.01) 1 115
probable 2,515 (1.60) 1,113 (0.68) 6 3,634
Streptococcal toxic shock syndrome 139 (0.13) 120 (0.11) — 259
Syphilis, total, all stages§,§§ 51,774 (32.99) 11,180 (6.90) 496 63,450
primary and secondary§ 18,146 (11.56) 1,840 (1.14) 13 19,999
congenital§ 23 (1.14) 19 (0.98) 416 458
Tetanus 9 (0.01) 16 (0.01) — 25
Toxic shock syndrome (other than streptococcal) 19 (0.02) 40 (0.03) — 59
Trichinellosis 9 (0.01) 4 (0.00) — 13
Tuberculosis¶¶ 5,840 (3.72) 3,578 (2.21) 3 9,421
Tularemia 113 (0.07) 67 (0.04) — 180
Typhoid fever 183 (0.12) 165 (0.10) 1 349
Vancomycin-intermediate Staphylococcus aureus (VISA) 111 (0.09) 101 (0.08) — 212
Vibriosis 862 (0.59) 393 (0.26) 6 1,261
Viral hemorrhagic fevers 3 (0.00) 2 (0.00) — 5
Yellow fever† — (0.00) — (0.00) — —
 * No cases of anthrax; dengue hemorrhagic fever (and dengue shock syndrome), eastern equine encephalitis, nonneuroinvasive disease; poliomyelitis, paralytic; 
poliovirus infection, nonparalytic; severe acute respiratory syndrome-associated Coronavirus disease (SARS-CoV); smallpox;  vancomycin-resistant Staphylococcus 
aureus (VRSA); western equine encephalitis, neuroinvasive and nonneuroinvasive disease; or yellow fever  were  reported in the United States during 2014.
 † Totals reported to the Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases (ArboNET Surveillance), as of July 15, 2015.
 § Totals reported to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), as of June 10, 2015.
 ¶ Reportable in <25 states.
 ** Total number of HIV diagnoses reported to the Division of HIV/AIDS Prevention, NCHHSTP through December 31, 2014.
 †† Totals reported to the Division of Influenza, National Center for Immunization and Respiratory Diseases, as of June 30, 2015.
 §§ Includes the following categories: primary, secondary, latent (including early latent, late latent, and latent syphilis of unknown duration), neurosyphilis, late (including 
late syphilis with clinical manifestations other than neurosyphilis), and congenital syphilis. Totals reported to the Division of STD Prevention, NCHHSTP, as 
of June 10, 2015. 
 ¶¶ Totals reported to the Division of Tuberculosis Elimination, NCHHSTP, as of June 15, 2015.
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TotalNo. Rate No. Rate No. Rate No. Rate No. No.
Arboviral diseases†
California serogroup viruses
neuroinvasive 5 (0.11) 1 0.01) 4 (0.01) 68 (0.03) 0 7 85
West Nile virus
neuroinvasive 7 (0.15) 17 (0.09) 78 (0.18) 806 (0.32) 114 325 1,347
nonneuroinvasive 5 (0.11) 10 (0.05) 21 (0.05) 571 (0.23) 39 212 858
Babesiosis, total 6 (0.20) 51 (0.35) 31 (0.12) 1,021 (0.62) 30 621 1,760
confirmed 5 (0.17) 48 (0.32) 28 (0.10) 841 (0.51) 28 522 1,472
probable 1 (0.03) 3 (0.02) 3 (0.01) 180 (0.11) 2 99 288
Botulism, total 5 (0.11) 9 (0.05) 5 (0.01) 108 (0.04) 2 32 161
infant 1 (1.28) 8 (3.23) 3 (0.44) 91 (3.09) 1 23 127
Brucellosis — (0.00) 2 (0.01) 4 (0.01) 54 (0.02) 13 19 92
Chlamydia trachomatis, infection§ 18,205 (402.86) 21,794 (112.35) 436,045 (984.09) 477,720 (190.61) 62,704 425,321 1,441,789
Coccidioidomycosis¶ 127 (5.68) 139 (1.48) 229 (1.69) 2,024 (2.03) 260 5,453 8,232
Cryptosporidiosis, total 80 (1.77) 96 (0.49) 826 (1.86) 5,919 (2.36) 309 1,452 8,682
confirmed 48 (1.06) 59 (0.30) 530 (1.20) 3,676 (1.47) 203 1,049 5,565
probable 32 (0.71) 37 (0.19) 296 (0.67) 2,243 (0.89) 106 403 3,117
Cyclosporiasis 1 (0.03) 7 (0.04) 16 (0.04) 292 (0.13) 5 77 398
Dengue fever† 3 (0.07) 67 (0.34) 36 (0.06) 345 (0.14) 35 203 680
Ehrlichiosis/Anaplasmosis
Anaplasma phagocytophilum 30 (0.75) 17 (0.09) 21 (0.05) 1,928 (0.81) 47 757 2,800
Ehrlichia chaffeensis 12 (0.30) 12 (0.07) 40 (0.09) 971 (0.41) 21 419 1,475
undetermined 3 (0.07) 1 (0.01) 2 (0.00) 136 (0.06) 18 36 196
Giardiasis 79 (2.26) 670 (4.01) 1,161 (3.46) 6,718 (3.40) 652 5,274 14,554
Gonorrhea§ 4,404 (97.46) 3,761 (19.39) 157,302 (355.01) 99,200 (39.58) 12,939 72,456 350,062
Haemophilus influenzae, invasive disease
all ages, serotypes 42 (0.93) 68 (0.35) 414 (0.93) 2,295 (0.92) 91 631 3,541
age <5 yrs 
serotype b 2 (0.52) 1 (0.08) — (0.00) 30 (0.20) — 7 40
nontypeable 6 (1.55) 2 (0.16) 27 (0.80) 67 (0.45) 8 18 128
non-b serotype — (0.00) 1 (0.08) 10 (0.29) 18 (0.12) 2 7 38
unknown serotype 10 (2.59) 12 (0.96) 58 (1.71) 116 (0.78) 15 55 266
Hansen’s disease 1 (0.03) 24 (0.13) 3 (0.01) 36 (0.02) 3 21 88
Hantavirus pulmonary syndrome 7 (0.16) 1 (0.01) — (0.00) 20 (0.01) — 4 32
Hemolytic uremic syndrome postdiarrheal 2 (0.04) 9 (0.05) 3 (0.01) 189 (0.08) 8 39 250
Hepatitis, virus 
A acute 4 (0.09) 137 (0.71) 85 (0.19) 710 (0.28) 57 246 1,239
B acute 23 (0.51) 55 (0.28) 345 (0.79) 1,817 (0.73) 61 490 2,791
B chronic 24 (0.60) 2,780 (16.36) 1,555 (4.55) 1,801 (0.88) 492 5,748 12,400
B infection perinatal — (0.00) 21 (0.11) 6 (0.01) 8 (0.00) 1 11 47
C acute 29 (0.74) 11 (0.06) 78 (0.19) 1,655 (0.70) 62 369 2,204
C past or present 1,331 (38.26) 1,189 (7.13) 12,128 (35.10) 55,561 (28.76) 5,970 86,684 162,863
Human immunodeficiency virus (HIV) 
diagnoses**
205 (8.70) 813 (4.80) 15,843 (40.10) 10,116 (5.10) 8,629 — 35,606
Influenza-associated pediatric mortality†† 2 (0.17) 6 (0.14) 20 (0.17) 95 (0.19) 1 17 141
Invasive pneumococcal disease 
all ages 216 (7.99) 185 (1.75) 2,294 (6.75) 9,054 (5.28) 382 3,225 15,356
age <5 yrs 19 (7.02) 42 (5.42) 224 (7.92) 466 (4.22) 42 272 1,065
Legionellosis 21 (0.46) 69 (0.36) 901 (2.03) 3,155 (1.26) 122 898 5,166
Leptospirosis — (0.00) 2 (0.01) 1 (0.00) 9 (0.00) 4 22 38
Listeriosis 8 (0.18) 70 (0.36) 66 (0.15) 498 (0.20) 25 102 769
Lyme disease, total 102 (2.26) 376 (2.04) 349 (0.79) 19,745 (7.89) 987 11,902 33,461
confirmed 74 (1.64) 259 (1.40) 255 (0.58) 14,791 (5.91) 804 9,176 25,359
probable 28 (0.62) 117 (0.63) 94 (0.21) 4,954 (1.98) 183 2,726 8,102
Malaria 3 (0.07) 103 (0.53) 823 (1.86) 261 (0.10) 56 407 1,653
Measles, total 4 (0.09) 86 (0.44) 2 (0.00) 509 (0.20) 4 62 667
indigenous 4 (0.09) 58 (0.30) 1 (0.00) 484 (0.19) 3 54 604
imported — (0.00) 28 (0.14) 1 (0.00) 25 (0.01) 1 8 63
Meningococcal disease
all serogroups 7 (0.15) 9 (0.05) 53 (0.12) 296 (0.12) 10 58 433
serogroups ACY and W-135 5 (0.11) — (0.00) 13 (0.03) 86 (0.03) 3 16 123
serogroup B 1 (0.02) 1 (0.01) 12 (0.03) 64 (0.03) 1 10 89
other serogroups — (0.00) 2 (0.01) 5 (0.01) 15 (0.01) — 3 25
unknown serogroup 1 (0.02) 6 (0.03) 23 (0.05) 131 (0.05) 6 29 196
See table footnotes on next page.
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TotalNo. Rate No. Rate No. Rate No. Rate No. No.
Mumps 4 (0.09) 39 (0.20) 104 (0.23) 781 (0.31) 24 271 1,223
Pertussis 211 (4.67) 560 (2.89) 1,460 (3.30) 23,466 (9.36) 1,074 6,200 32,971
Q fever, total 3 (0.07) 7 (0.04) 8 (0.02) 112 (0.05) 9 29 168
acute 3 (0.07) 6 (0.03) 7 (0.02) 92 (0.04) 6 18 132
chronic — (0.00) 1 (0.01) 1 (0.00) 20 (0.01) 3 11 36
Salmonellosis 401 (8.87) 1,829 (9.43) 4,522 (10.21) 32,194 (12.85) 2,099 10,410 51,455
Shiga toxin-producing E. coli (STEC) 56 (1.24) 145 (0.75) 244 (0.55) 4,256 (1.70) 210 1,268 6,179
Shigellosis 684 (15.14) 280 (1.44) 5,511 (12.44) 10,049 (4.01) 885 3,336 20,745
Spotted fever rickettsiosis, total 53 (1.21) 22 (0.11) 95 (0.21) 2,597 (1.04) 35 955 3,757
confirmed 1 (0.02) 1 (0.01) 4 (0.01) 77 (0.03) 1 31 115
probable 52 (1.18) 21 (0.11) 90 (0.20) 2,515 (1.01) 34 922 3,634
Streptococcal toxic shock syndrome 1 (0.04) 5 (0.05) 36 (0.11) 162 (0.10) 14 41 259
Syphilis, total, all stages§,§§ 436 (9.65) 1,576 (8.12) 24,281 (54.80) 28,144 (11.23) 4,122 4,891 63,450
primary and secondary§ 187 (4.14) 483 (2.49) 7,381 (16.66) 9,682 (3.86) 1,083 1,183 19,999
congenital§ 5 (6.42) 18 (7.27) 227 (33.45) 175 (5.94) 17 16 458
Tetanus — (0.00) 1 (0.01) — (0.00) 17 (0.01) — 7 25
Toxic shock syndrome (other than 
streptococcal)
— (0.00) 3 (0.02) 5 (0.02) 45 (0.02) — 6 59
Tuberculosis¶¶ 131 (2.90) 3,006 (15.50) 2,078 (4.69) 3,864 (1.54) 254 88 9,421
Tularemia 9 (0.20) — (0.00) 1 (0.00) 143 (0.06) 1 26 180
Typhoid fever 2 (0.04) 200 (1.03) 18 (0.04) 50 (0.02) 31 48 349
Vancomycin-intermediate 
Staphylococcus aureus (VISA)
1 (0.03) 1 (0.01) 51 (0.13) 121 (0.06) — 38 212
Vibriosis 6 (0.14) 51 (0.27) 55 (0.13) 860 (0.37) 30 259 1,261
Yellow fever† — (0.00) — (0.00) — (0.00) — (0.00) — — —
 * Conditions for which <25 cases were reported for the year are not included in the table. No cases of anthrax; dengue hemorrhagic fever (and dengue shock syndrome), 
eastern equine encephalitis, nonneuroinvasive disease; poliomyelitis, paralytic; poliovirus infection, nonparalytic; severe acute respiratory syndrome-associated Coronavirus 
disease (SARS-CoV); smallpox; vancomycin-resistant Staphylococcus aureus (VRSA); western equine encephalitis, neuroinvasive and nonneuroinvasive disease; or yellow 
fever were reported in the United States during 2014.
 † Totals reported to the Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases (ArboNET Surveillance), as of June 1, 2014.
 § Totals reported to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), as of June 10, 2015.
 ¶ Reportable in <25 states.
 ** Total number of HIV diagnoses reported to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) 
through December 31, 2014.
 †† Totals reported to the Division of Influenza, National Center for Immunization and Respiratory Diseases, as of June 30, 2015.
 §§ Includes the following categories: primary, secondary, latent (including early latent, late latent, and latent syphilis of unknown duration), neurosyphilis, late (including 
late syphilis with clinical manifestations other than neurosyphilis), and congenital syphilis. Totals reported to the Division of STD Prevention, NCHHSTP, as 
of June 10, 2015.
 ¶¶ Totals reported to the Division of Tuberculosis Elimination, NCHHSTP, as of July 15, 2015.
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TABLE 6. Number of reported cases of notifiable diseases* and rates per 100,000 population, by ethnicity, excluding U.S. territories — 
United States, 2014
Disease
Hispanic Non-Hispanic Ethnicity not stated
No. Rate No. Rate No. Total
Arboviral diseases†
California serogroup viruses
neuroinvasive 2 (0.00) 69 (0.03) 14 85
West Nile virus 
neuroinvasive 251 (0.45) 713 (0.27) 383 1,347
nonneuroinvasive 75 (0.14) 520 (0.20) 263 858
Babesiosis, total 76 (0.18) 842 (0.51) 842 1,760
confirmed 68 (0.17) 692 (0.41) 712 1,472
probable 8 (0.02) 150 (0.09) 130 288
Botulism, total 38 (0.07) 86 (0.03) 37 161
infant 31 (3.06) 69 (2.35) 27 127
Brucellosis 49 (0.09) 31 (0.01) 12 92
Chlamydia trachomatis, infection§ 201,171 (363.21) 711,693 (270.12) 528,925 1,441,789
Coccidioidomycosis¶ 936 (1.69) 1,737 (0.66) 5,559 8,232
Cryptosporidiosis, total 631 (1.14) 5,789 (2.20) 2,262 8,682
confirmed 434 (0.78) 3,617 (1.37) 1,514 5,565
probable 197 (0.36) 2,172 (0.82) 748 3,117
Cyclosporiasis 60 (0.11) 252 (0.10) 86 398
Dengue fever† 272 (0.49) 248 (0.09) 160 680
Ehrlichiosis/Anaplasmosis 
Anaplasma phagocytophilum 31 (0.06) 1,705 (0.68) 1,064 2,800
Ehrlichia chaffeensis 21 (0.04) 1,044 (0.41) 410 1,475
undetermined 2 (0.00) 150 (0.06) 44 196
Giardiasis 1,151 (2.81) 7,347 (3.49) 6,056 14,554
Gonorrhea§ 38,672 (69.82) 210,362 (79.84) 101,028 350,062
Haemophilus influenzae, invasive disease 
all ages, serotypes 216 (0.39) 2,148 (0.82) 1,177 3,541
age <5 yrs 
serotype b 5 (0.10) 23 (0.16) 12 40
nontypeable 24 (0.47) 66 (0.45) 38 128
non-b serotype 5 (0.10) 27 (0.18) 6 38
unknown serotype 43 (0.84) 139 (0.94) 84 266
Hansen’s disease 12 (0.02) 48 (0.02) 28 88
Hantavirus pulmonary syndrome 4 (0.01) 21 (0.01) 7 32
Hemolytic uremic syndrome postdiarrheal 25 (0.05) 178 (0.07) 47 250
Hepatitis, virus
A acute 211 (0.38) 730 (0.28) 298 1,239
B acute 158 (0.29) 1,883 (0.72) 750 2,791
B chronic 319 (0.76) 4,605 (2.11) 7,476 12,400
B infection perinatal 2 (0.00) 34 (0.01) 11 47
C acute 127 (0.24) 1,421 (0.57) 656 2,204
C past or present 5,086 (12.79) 44,360 (21.32) 113,417 162,863
Human immunodeficiency virus (HIV) diagnoses** 7,927 (14.30) 27,679 (10.50) — 35,606
Influenza-associated pediatric mortality†† 44 (0.25) 84 (0.15) 13 141
Invasive pneumococcal disease
all ages 1,005 (2.94) 8,503 (4.61) 5,848 15,356
age <5 yrs 153 (4.50) 572 (4.97) 340 1,065
Legionellosis 280 (0.51) 3,577 (1.36) 1,309 5,166
Leptospirosis 1 (0.00) 16 (0.01) 21 38
Listeriosis 117 (0.21) 498 (0.19) 154 769
Lyme disease, total 650 (1.18) 13,839 (5.28) 18,972 33,461
confirmed 469 (0.85) 10,244 (3.91) 14,646 25,359
probable 181 (0.33) 3,595 (1.37) 4,326 8,102
Malaria 33 (0.06) 1,264 (0.48) 356 1,653
Measles, total 38 (0.07) 534 (0.20) 95 667
indigenous 38 (0.07) 479 (0.18) 87 604
Imported 0 (0.00) 55 (0.02) 8 63
Meningococcal disease 
all serogroups 69 (0.12) 278 (0.11) 86 433
serogroups ACWY 21 (0.04) 76 (0.03) 26 123
serogroup B 2 (0.00) 58 (0.02) 29 89
other serogroups 1 (0.00) 19 (0.01) 5 25
unknown serogroup 45 (0.08) 125 (0.05) 26 196
See table footnotes on next page.
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TABLE 6. (Continued) Number of reported cases of notifiable diseases* and rates per 100,000 population, by ethnicity, excluding U.S. territories — 
United States, 2014
Disease
Hispanic Non-Hispanic Ethnicity not stated
No. Rate No. Rate No. Total
Mumps 66 (0.12) 859 (0.33) 298 1,223
Pertussis 6,799 (12.28) 19,531 (7.41) 6,641 32,971
Q fever, total 22 (0.04) 111 (0.04) 35 168
acute 20 (0.04) 90 (0.03) 22 132
chronic 2 (0.00) 21 (0.01) 13 36
Salmonellosis 7,181 (12.97) 29,707 (11.28) 14,567 51,455
Shiga toxin-producing E. coli (STEC) 776 (1.40) 3,903 (1.48) 1,500 6,179
Shigellosis 4,091 (7.39) 11,989 (4.55) 4,665 20,745
Spotted fever rickettsiosis, total 124 (0.22) 2,494 (0.94) 1,139 3,757
confirmed 6 (0.01) 73 (0.03) 36 115
probable 118 (0.21) 2,415 (0.91) 1,101 3,634
Streptococcal toxic shock syndrome 26 (0.11) 150 (0.08) 83 259
Syphilis, total, all stages§,§§ 15,348 (27.71) 43,029 (16.33) 5,073 63,450
primary and secondary§ 4,036 (7.29) 14,700 (5.58) 1,263 19,999
congenital§ 110 (10.86) 322 (10.97) 26 458
Tetanus 4 (0.01) 12 (0.00) 9 25
Toxic shock syndrome (other than streptococcal) 3 (0.01) 41 (0.02) 15 59
Tuberculosis¶¶ 2,758 (4.98) 6,653 (2.53) 10 9,421
Tularemia 7 (0.01) 148 (0.06) 25 180
Typhoid fever 28 (0.05) 271 (0.10) 50 349
Vancomycin-intermediate Staphylococcus aureus (VISA) 13 (0.04) 145 (0.07) 54 212
Vibriosis 142 (0.27) 802 (0.33) 317 1,261
Yellow fever† — (0.00) — (0.00) — —
 * Conditions for which <25 cases were reported for the year are not included in the table. No cases of anthrax; dengue hemorrhagic fever (and dengue shock 
syndrome), eastern equine encephalitis, nonneuroinvasive disease; poliomyelitis, paralytic; poliovirus infection, nonparalytic; severe acute respiratory syndrome-
associated Coronavirus disease (SARS-CoV); smallpox;    vancomycin-resistant Staphylococcus aureus (VRSA); western equine encephalitis, neuroinvasive and 
nonneuroinvasive disease; or yellow fever  were  reported in the United States during 2014.
 † Totals reported to the Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases (ArboNET Surveillance), as of July 1, 2015.
 § Totals reported to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), as of June 10, 2015.
 ¶ Reportable in <25 states.
 ** Total number of HIV diagnoses reported to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) 
through December 31, 2014.
 †† Totals reported to the Division of Influenza, National Center for Immunization and Respiratory Diseases, as of June 30, 2015.
 §§ Includes the following categories: primary, secondary, latent (including early latent, late latent, and latent syphilis of unknown duration), neurosyphilis, late (including 
late syphilis with clinical manifestations other than neurosyphilis), and congenital syphilis. Totals reported to the Division of STD Prevention, NCHHSTP, as of 
June 10, 2015.
 ¶¶ Totals reported to the Division of Tuberculosis Elimination, NCHHSTP, as of July 15, 2015.
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TABLE 7. Rate of notifiable diseases,* excluding U.S. territories, by year — United States, 2004–2014
Disease 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014*
AIDS 15.28 14 12.87 12.53 13 † † † † † †
Anthrax — — 0 0 0 0 0 0 0 0 0
Arboviral diseases§
California serogroup virus disease 
neuroinvasive — 0.02 0.02 0.02 0.02 0.02 0.02 0.04 0.02 0.03 0.03
nonneuroinvasive ¶ 0 0 0 0 0 0 0.01 0 0.01 0
Eastern equine encephalitis virus disease
neuroinvasive — 0 0 0 0 0 0 0 0 0 0
nonneuroinvasive ¶ 0 0 0 0 0 — — — — —
Powassan virus disease
neuroinvasive — 0 0 0 0 0 0 0 0 0 0
nonneuroinvasive ¶ 0 0 0 0 — — 0 0 0 0
St. Louis encephalitis virus disease
neuroinvasive — 0 0 0 0 0 0 0 0 0 0
nonneuroinvasive ¶ 0 0 0 0 0 0 0 0 0 0
West Nile virus disease
neuroinvasive — 0.45 0.5 0.41 0.23 0.13 0.2 0.16 0.92 0.4 0.42
nonneuroinvasive ¶ 0.58 0.94 0.8 0.22 0.11 0.13 0.07 0.9 0.38 0.27
Western equine encephalitis virus disease
neuroinvasive — — — — — — — — — — —
nonneuroinvasive ¶ — — — — — — — — — —
Babesiosis, total** 
confirmed ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ 0.22 0.77 0.71
probable ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ 0.06 0.16 0.14
Botulism, total 0.02 0.01 0.02 0.05 0.05 0.04 0.04 0.01 0.05 0.05 0.05
foodborne 0.01 0.01 0.01 0.01 0.01 0 0 0.01 0.01 0 0
infant 2.12 2.09 2.35 2.05 2.56 1.92 1.88 2.34 3.1 3.45 3.22
other (wound and unspecified) — — — — — — — — 0.01 0 0.01
Brucellosis 0.04 0.04 0.04 0.04 0.03 0.04 0.04 0.03 0.04 0.03 0.03
Chancroid†† 0 0.01 0.01 0.01 0.01 0.01 0.01 0 0 0 0
Chlamydia trachomatis infections†† 319.61 332.51 347.8 370.2 401.34 409.19 426.01 457.14 456.69 446.65 452.17
Cholera 0 0 0 0 0 0 0 0.01 0.01 0 0
Coccidioidomycosis§§ 4.14 6.24 6.79 14.39 7.76 13.24 § 16.49 12.97 7.82 6.6
Cryptosporidiosis, total 1.23 1.93 2.05 3.73 3.02 2.52 2.91 3 2.56 2.89 2.72
confirmed ¶ ¶ ¶ ¶ ¶ 2.43 2.73 1.98 1.68 1.82 1.75
probable ¶ ¶ ¶ ¶ ¶ 0.09 0.19 1.01 0.87 1.06 0.98
Cyclosporiasis 0.14 0.24 0.06 0.04 0.05 0.05 0.07 0.05 0.04 0.28 0.14
Dengue virus infection§
Dengue fever ¶ ¶ ¶ ¶ ¶ ¶ 0.22 0.08 0.17 0.27 0.21
Dengue hemorrhagic fever ¶ ¶ ¶ ¶ ¶ ¶ 0 0 0 0 0
Diphtheria — — — — — — — — — — 0
Ehrlichiosis
human granulocytic (HGE) 0.2 0.28 0.23 0.31 ¶ ¶ ¶ ¶ ¶ ¶ ¶
human monocytic (HME) 0.12 0.18 0.2 0.3 ¶ ¶ ¶ ¶ ¶ ¶ ¶
human (other and unspecified)¶¶ — 0.04 0.08 0.12 ¶ ¶ ¶ ¶ ¶ ¶ ¶
Ehrlichiosis/Anaplasmosis
Ehrlichia chaffeensis ¶ ¶ ¶ ¶ 0.35 0.34 0.26 0.29 0.38 0.51 0.48
Ehrlichia ewingii ¶ ¶ ¶ ¶ 0 0 0 0 0.01 0.01 0.01
Anaplasma phagocytophilum ¶ ¶ ¶ ¶ 0.43 0.42 0.61 0.88 0.81 0.93 0.92
undetermined ¶ ¶ ¶ ¶ 0.06 0.06 0.04 0.05 0.06 0.07 0.06
Encephalitis/meningitis, arboviral ***
California serogroup virus 0 ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶
Eastern equine virus 0 ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶
Powassan virus 0 ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶
St. Louis virus 0 ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶
West Nile virus 0.43 ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶
Western equine virus — ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶
Enterohemorrhagic Escherichia coli
O157:H7 0.87 0.89 ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶
non-O157 0.13 0.19 ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶
not serogrouped 0.13 0.16 ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶
Giardiasis 8.35 7.82 7.28 7.66 7.41 7.37 7.64 6.42 5.87 5.8 5.79
Gonorrhea†† 113.52 115.64 120.9 118.9 111.64 99.05 100.76 104.14 107.46 106.09 109.79
See table footnotes on next page.
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TABLE 7. (Continued) Rate of notifiable diseases,* excluding U.S. territories, by year — United States, 2004–2014
Disease 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014*
Haemophilus influenzae, invasive disease
all ages, serotypes 0.72 0.78 0.82 0.85 0.96 0.99 1.03 1.15 1.1 1.21 1.11
age <5 yrs 
serotype b 0.03 0.04 0.14 0.11 0.14 0.18 0.11 0.06 0.15 0.16 0.2
non-b serotype* 0.04 0.67 0.86 0.97 1.18 1.17 0.94 0.57 1.02 1.11 ¶
unknown serotype 0.97 1.08 0.88 0.88 0.79 0.79 1.05 0.89 1.04 0.93 1.03
nontypeable ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ 0.64
Hansen’s disease (Leprosy) 0.04 0.03 0.03 0.04 0.03 0.04 0.04 0.03 0.03 0.03 0.03
Hantavirus pulmonary syndrome 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Hemolytic uremic syndrome postdiarrheal 0.07 0.08 0.11 0.1 0.12 0.09 0.09 0.1 0.09 0.11 0.08
Hepatitis, viral, acute
A acute 1.95 1.53 1.21 1 0.86 0.65 0.54 0.45 0.5 0.57 0.39
B acute 2.14 1.78 1.62 1.51 1.34 1.12 1.1 0.94 0.93 0.97 0.88
B chronic ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ 4.76
B perinatal infection — — — — — — — — 0.01 0.02 0.01
C acute 0.31 0.23 0.26 0.28 0.29 0.27 0.29 0.42 0.59 0.71 0.73
C past and present ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ 65.7
Human immunodeficiency virus (HIV) diagnoses — — — — — 12.13 11.64 11.32 11.26 11.06 11.2
Influenza-associated pediatric mortality††† § 0.02 0.07 0.1 0.12 0.48 0.08 0.17 0.07 0.22 0.19
Invasive pneumococcal disease, all ages¶¶¶¶ — — — — — — — — 7.72 8.3 7.02
age <5 years — — — — — — — — 8.35 7.8 7.14
Legionellosis 0.71 0.78 0.96 0.91 1.05 1.16 1.09 1.36 1.19 1.58 1.62
Leptospirosis ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ ¶ 0.01
Listeriosis 0.32 0.31 0.3 0.27 0.25 0.28 0.27 0.28 0.23 0.23 0.24
Lyme disease, total§§§ ¶ ¶ ¶ ¶ 11.67 12.71 9.86 10.78 9.96 11.62 10.54
confirmed 6.84 7.94 6.75 9.21 9.59 9.85 7.38 7.92 7.1 8.71 7.99
probable ¶ ¶ ¶ ¶ 2.08 2.8 2.49 2.84 2.84 2.91 2.55
Malaria 0.51 0.51 0.5 0.47 0.42 0.48 0.58 0.56 0.48 0.51 0.52
Measles, total 0.01 0.02 0.02 0.01 0.05 0.02 0.02 0.06 0.02 0.06 0.21
indigenous — — — — — — — — 0.01 0.04 0.19
imported — — — — — — — — 0.01 0.02 0.02
Meningococcal disease, invasive¶¶¶
all serogroups 0.47 0.42 0.4 0.36 0.39 0.32 0.27 0.25 0.18 0.18 0.14
serogroups ACWY ¶ 0.1 0.11 0.11 0.11 0.1 0.09 0.08 0.05 0.05 0.04
serogroup B ¶ 0.05 0.07 0.06 0.06 0.06 0.04 0.05 0.04 0.03 0.03
other serogroup ¶ 0.01 0.01 0.01 0.01 0.01 0 0.01 0.01 0.01 0.01
serogroup unknown ¶ 0.26 0.22 0.18 0.2 0.16 0.13 0.1 0.08 0.09 0.06
Mumps 0.09 0.11 2.22 0.27 0.15 0.65 0.85 0.13 0.07 0.19 0.38
Novel influenza A virus infections § § § 0 0 14.37 0 0 0.1 0.1 0
Pertussis 8.88 8.72 5.27 3.49 4.4 5.54 8.97 6.06 15.49 9.12 10.34
Plague 0 0 0.01 0 0 0 0 0 0 0 0
Poliomyelitis, paralytic 0 0 0 — — 0 — — — — —
Poliovirus infection, nonparalytic ¶ ¶ ¶ — — — — — — — —
Psittacosis 0 0.01 0.01 0 0 0 0 0 0 0 0
Q Fever, total**** 0.03 0.05 0.06 0.06 0.04 0.04 0.04 0.04 0.04 0.05 0.05
acute ¶ ¶ ¶ ¶ 0.04 0.03 0.04 0.04 0.04 0.04 0.04
chronic ¶ ¶ ¶ ¶ 0 0.01 0.01 0.01 0.01 0.01 0.01
Rabies
animal 0 0 0 0 0 0 0 0 1.48 1.41 1.98
human 0 0 0 0 0 0 0 0 0 0 0
Rubella 0 0 0 0 0.01 0 0 0 0 0 0
Rubella, congenital syndrome 0 0 0 0 — — 0 — 0 0 0
Salmonellosis 14.47 15.43 15.45 16.03 16.92 16.18 17.73 16.79 17.27 16.13 16.14
SARS-CoV†††† — — — — — — — — — — —
Shiga toxin-producing E. coli (STEC) ¶ ¶ 1.71 1.62 1.76 1.53 1.78 1.96 2.08 2.13 1.94
Shigellosis 4.99 5.51 5.23 6.6 7.5 5.24 4.82 4.32 4.9 4.06 6.51
Spotted Fever Rickettsiosis, total§§§§ ¶ ¶ ¶ ¶ 0.85 0.6 0.65 0.91 1.44 1.08 1.18
confirmed 0.6 0.66 0.8 0.77 0.06 0.05 0.05 0.08 0.06 0.06 0.04
probable ¶ ¶ ¶ ¶ 0.78 0.55 0.59 0.83 1.38 1.02 1.14
Smallpox — — — — — — — — — — —
Streptococcal disease, invasive, group A 1.82 2 2.24 1.89 2.3 2.13 § § § § §
Streptococcal, toxic shock syndrome 0.06 0.07 0.06 0.06 0.07 0.08 0.07 0.09 0.1 0.11 0.12
See table footnotes on next page.
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TABLE 7. (Continued) Rate of notifiable diseases,* excluding U.S. territories, by year — United States, 2004–2014
Disease 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014*
Streptococcus pneumoniae invasive disease (IPD)¶¶¶¶
all ages ¶ ¶ ¶ ¶ ¶ ¶ 8.83 8.52 — — —
age < 5 yrs ¶ ¶ ¶ ¶ ¶ ¶ 14.15 7.64 — — —
Streptococcus pneumoniae invasive disease¶¶¶¶
drug resistant, all ages 1.49 1.42 2.19 1.49 1.6 1.75 ¶ ¶ ¶ ¶ ¶
age <5 yrs — — — 3.73 3.51 4.54 ¶ ¶ ¶ ¶ ¶
nondrug resistant, age <5 yrs 8.22 8.21 11.93 13.59 13.36 12.93 ¶ ¶ ¶ ¶ ¶
Syphilis††
all stages 11.94 11.33 12.46 13.67 15.34 14.74 14.93 14.9 16.02 17.99 19.9
congenital 9.12 8.24 9.07 10.46 10.12 9.9 8.85 8.68 8.12 8.83 11.6
primary and secondary 2.71 2.97 3.29 3.83 4.48 4.6 4.49 4.52 5.03 5.54 6.27
Tetanus 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Toxic shock syndrome 0.04 0.04 0.05 0.04 0.03 0.03 0.04 0.03 0.03 0.03 0.03
Trichinellosis 0 0.01 0.01 0 0.01 0 0 0.01 0.01 0.01 0
Tuberculosis***** 5.09 4.8 4.65 4.44 4.28 3.8 3.64 3.41 3.19 3.05 2.95
Tularemia 0.05 0.05 0.03 0.05 0.04 0.03 0.04 0.05 0.05 0.06 0.06
Typhoid fever 0.11 0.11 0.12 0.14 0.15 0.13 0.15 0.13 0.11 0.11 0.11
Vancomycin-intermediate Staphylococcus aureus — 0 0 0.02 0.03 0.03 0.04 0.04 0.06 0.1 0.08
Vancomycin-resistant Staphylococcus aureus 0 0 0 0 0 0 0 — — — —
Varicella (chickenpox morbidity) 18.41 19.64 28.65 18.68 13.56 8.71 6.46 5.79 5.33 4.62 3.94
Varicella (chickenpox mortality) — — — — — — — — 0 0 0
Vibriosis ¶ ¶ ¶ 0.25 0.24 0.3 0.3 0.29 0.39 0.43 0.42
Viral hemorrhagic fevers ¶ ¶ ¶ ¶ ¶ ¶ 0 0 0 0 0
Yellow fever§,††††† — — — — — — — — — — —
 *  Per 100,000 population. No cases of anthrax; dengue hemorrhagic fever (and dengue shock syndrome), eastern equine encephalitis, nonneuroinvasive disease; 
poliomyelitis, paralytic; poliovirus infection, nonparalytic; severe acute respiratory syndrome-associated Coronavirus disease (SARS-CoV); smallpox; vancomycin-
resistant Staphylococcus aureus (VRSA); western equine encephalitis, neuroinvasive and nonneuroinvasive disease; or yellow fever were reported in the United States 
during 2014. 
 † In 2008 CDC published a revised HIV case definition. This combined separate surveillance case definitions for HIV infection and AIDS into a single case definition 
for HIV infection that includes AIDS (and incorporates the HIV infection classification system). The revised HIV case definition provides a more complete presentation 
of the HIV epidemic on a population level. Please see the Centers for Disease Control and Prevention revised surveillance case definitions for HIV infection among 
adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years—United States, 2008. MMWR 
Recomm Rep 2008;57(No. RR-10). These case counts can be found under “HIV Diagnoses” in this table. The total number of HIV Diagnoses includes all cases 
reported to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), through December 31, 2012. 
AIDS: Acquired Immunodeficiency Syndrome. HIV: Human Immunodeficiency Virus.
 § Totals reported to the Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases (ArboNET Surveillance), as of July 1, 2015.
 ¶ Not nationally notifiable.
 ** Revision of National Surveillance Case Definition distinguishing between confirmed and probable cases for annual report only (weekly reports contain total cases).
 †† Total reported to the Division of STD Prevention, NCHHSTP, as of June 10, 2015.
 §§ Reportable in <25 states.
 ¶¶  As of 2008, these categories were replaced with codes for Anaplasma phagocytophilum. Refer to Ehrlichiosis/Anaplasmosis.
 *** In 2005, the arboviral disease surveillance case definitions and categories were revised. The nationally notifiable arboviral encephalitis and meningitis conditions 
continued to be nationally notifiable in 2005 and 2006, but under the category of arboviral neuroinvasive disease.
 ††† Totals reported to the Division of Influenza, National Center for Immunization and Respiratory Diseases, as of December 28, 2014.
 §§§ The National surveillance case definition was revised in 2008; probable cases not previously reported.
 ¶¶¶  To help public health specialists monitor the impact of the new meningococcal conjugate vaccine (Menactra®, licensed in the United States in January 2005), 
the data display for meningococcal disease was modified to differentiate the fraction of the disease that is vaccine preventable (serogroups A,C,Y, W-135) from 
the nonpreventable fraction of disease (serogroup B and others). 
 **** In 2008, Q fever acute and chronic reporting categories were recognized as a result of revision to the Q fever case definition. Before that time, case counts were 
not differentiated relative to acute and chronic Q fever cases.
 †††† Severe acute respiratory syndrome-associated coronavirus disease.
 §§§§ Revision of the National Surveillance Case Definition distinguishing between confirmed and probable cases; total case count includes eight case reports with 
unknown case status in 2014.
 ¶¶¶¶ Streptococcus pneumoniae invasive disease drug resistant (all ages) (11720) and nondrug resistant age <5 years (11717) became Streptococcus pneumoniae 
invasive disease (IPD) (11723) from 2010 through 2011 and finally simply invasive pneumococcal disease (IPD) (11723) starting in 2012.
 ***** Totals reported to the Division of Tuberculosis Elimination, NCHHSTP, as of July 15, 2015.
 ††††† The last indigenous case of yellow fever was reported in 1911; all other case reports since 1911 have been imported.
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TABLE 8. Number of deaths from selected nationally notifiable infectious diseases — United States, 2008–2014*
Cause of death
ICD-10†  
Cause of death code
No. of Deaths  
2008 2009 2010 2011 2012 2013 2014
Anthrax A22 0 0 0 0 0 0 0
Babesiosis B60.0 7 6 4 5 4 6 7
Botulism, foodborne A05.1 4 3 0 0 1 1 2
Brucellosis A23.0–A23.9 0 1 0 1 0 1 0
Cholera (toxigenic Vibrio cholerae O1 or O139) A00 0 1 0 0 0 1 0
Coccidioidomycosis B38 72 87 92 88 70 56 68
Cryptosporidiosis A07.2 3 2 4 4 2 0 1
Cyclosporiasis A07.8 0 0 0 0 0 0 0
Dengue Fever A90 0 1 2 0 1 3 2
Dengue Hemorrhagic Fever A91 0 0 1 0 1 0 0
Diphtheria A36.0–A36.3, A36.9 0 0 0 0 0 0 0
Ehrlichiosis/Anaplasmosis (Anaplasma phagocytophilum, 
Ehrlichia chaffeensis, Ehrlichia ewingii, undetermined human 
Ehrlichiosis/Anaplasmosis)
A77.8, A79 6 7 5 5 13 9 13
Giardiasis A07.1 1 0 1 1 0 0 1
Haemophilus influenzae infection A41.3, A49.2, G00.0, J14, J20.1 61 57 47 68 70 65 69
Hansen’s disease (leprosy) A30 2 1 4 1 0 0 0
Hantavirus Pulmonary Syndrome (HPS) B33.4 9 0 2 8 4 4 5
Hemolytic uremic syndrome, postdiarrheal D59.3 32 25 20 25 23 22 38
Hepatitis A, viral (acute) B15 37 26 29 25 23 24 26
Hepatitis B, viral (acute, chronic, perinatal) B16, B17.0, B18.0, B18.1 671 597 588 614 581 573 535
Hepatitis C, viral (acute, chronic) B17.1, B18.2 6,834 6,981 6,844 7,048 7,292 7,366 7,349
Human immunodeficiency virus (HIV) infection B20–B24 10,285 9,406 8,369 7,683 7,216 6,955 6,721
Invasive pneumococcal disease, all ages A40.3, G00.1 203 228 191 181 156 199 152
Legionellosis A48.1, A48.2 92 104 104 111 124 131 132
Leptospirosis A27.0, A27.8, A27.9 2 2 0 0 1 2 0
Listeriosis A32, P37.2 30 29 28 52 47 32 36
Lyme disease A69.2, L90.4 10 12 10 6 11 5 15
Measles B05 0 2 2 0 2 0 0
Meningococcal disease A39.0 31 28 14 26 11 9 10
Mumps B26 2 2 1 0 0 1 0
Pertussis A37.0 6 1 5 1 4 2 7
Plague A20 0 1 0 0 0 0 0
Poliomyelitis, paralytic A80 0 0 0 0 0 0 0
Psittacosis A70 0 0 0 0 0 0 0
Q Fever A78 0 1 0 2 0 2 3
Rabies, human A82 2 4 1 4 1 0 1
Rubella B06 0 1 1 1 0 0 0
Rubella, congenital syndrome P35.0 5 4 8 5 8 6 4
Salmonellosis A02 42 26 28 44 44 40 45
Shiga toxin-producing E. coli (STEC) A04.3 0 1 0 0 1 0 0
Shigellosis A03 3 4 2 3 2 5 3
Spotted Fever Rickettsiosis A77.0–A77.3, A77.9 4 8 8 6 4 7 8
Smallpox B03 0 0 0 0 0 0 0
Tetanus A33, A34, A35 3 6 3 6 4 3 1
Trichinellosis B75 1 0 0 0 0 0 0
Tuberculosis A16–A19 585 529 569 539 510 555 493
Tularemia A21 1 3 0 0 0 2 1
Typhoid fever A01.0 2 0 0 0 0 0 0
Varicella (chickenpox mortality) B01 18 22 15 14 16 8 4
Vibriosis A05.3§ 1 0 0 0 0 0 0
Viral hemorrhagic fevers
Crimean-Congo hemorrhagic fever A98.0 0 0 0 0 0 0 0
Ebola virus A98.4 0 0 0 0 0 0 1
Lassa virus A96.2 0 0 0 0 0 0 0
Lujo virus A98.8 0 0 0 0 0 0 0
Marburg virus A98.3 0 0 0 0 0 0 0
New World Arenavirus-Guanarito virus A96.8 0 0 0 0 0 0 0
New World Arenavirus-Junin virus A96.0 0 0 0 0 0 0 0
New World Arenavirus-Machupo virus A96.1 0 0 0 0 0 0 0
New World Arenavirus-Sabia virus A96.8 0 0 0 0 0 0 0
Yellow fever A95.0, A95.1, A95.9 0 0 0 0 0 0 0
See table footnotes on next page.
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TABLE 8. (Continued) Number of deaths from selected nationally notifiable infectious diseases — United States, 2008–2014*
Source: CDC. CDC WONDER Detailed Mortality files (http://wonder.cdc.gov/) provided by the National Center for Health Statistics, National Vital Statistics System, 
1999–2014. Underlying causes of death are classified according to ICD-10. Data are limited by the accuracy of the information regarding the underlying cause of 
death indicated on death certificates and reported to the National Vital Statistics System.
* List of Nationally Notifiable Conditions in 2014.
† World Health Organization. International Statistical Classification of Disease and Related Health Problems. Tenth Revision, 1992.
§ The mortality code listed (A05.3) specifies cause of death as “foodborne Vibrio parahaemolyticus intoxication” and might not accurately reflect mortality from other 
vibrio species.
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PART 2  
Graphs and Maps for Selected Notifiable Diseases 
in the United States, 2014
Abbreviations and Symbols Used in Graphs and Maps
U  Data not available.
N  Not reportable (i.e., report of disease not required in that jurisdiction).
DC  District of Columbia 
NYC  New York City 
AS  American Samoa
CNMI   Commonwealth of Northern Mariana Islands
GU  Guam
PR  Puerto Rico
VI  U.S. Virgin Islands
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ANTHRAX. Number* of reported cases, by year — United States, 1959–2014 
* One epizootic-associated cutaneous case was reported in 2001 from Texas.
In 2014, anthrax epizootics were reported in North Dakota, South Dakota, and Texas. Epizootics involved 
domestic and wildlife bovine, caprine, and cervid species. No human anthrax cases were reported in 2014 
from zoonotic or other causes.
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ARBOVIRAL DISEASES. Number* of reported cases of neuroinvasive disease, by year — United States, 
2005–2014
* Data from the Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases 
(ArboNET Surveillance). Only reported cases of neuroinvasive diseases are shown.
During 2005–2014, an average of 69 La Crosse virus neuroinvasive disease cases were reported each year. 
La Crosse virus was the most common cause of neuroinvasive arboviral disease among children. During that 
same time period, Jamestown Canyon virus caused an average of two neuroinvasive disease cases per year. 
Starting in 2013, following the implementation of routine antibody testing for Jamestown Canyon virus disease, 
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ARBOVIRAL DISEASES, WEST NILE VIRUS. Incidence* of reported cases of neuroinvasive disease, by 
age group — United States, 2014
* Per 100,000 population. Data from the Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic 
Infectious Diseases (ArboNET Surveillance).
In 2014, West Nile virus neuroinvasive disease incidence increased with increasing age, ranging from 0.03 per 












0–9 10–19 20–29 30–39 40–49 50–59 60–69 ≥70
MMWR / Published October 14, 2016, for 2014 / Vol. 63 / No. 54 79
Morbidity and Mortality Weekly Report
US Department of Health and Human Services/Centers for Disease Control and Prevention
ARBOVIRAL DISEASES, WEST NILE VIRUS. Incidence* of reported cases of neuroinvasive disease — 
United States and U.S. territories, 2014
* Per 100,000 population. Data from the Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic 
Infectious Diseases (ArboNET Surveillance).
In 2014, the states with the highest reported incidence of West Nile virus (WNV) neuroinvasive disease were 
Nebraska (2.2 per 100,000), North Dakota (1.6), California (1.4), South Dakota (1.4), Louisiana (1.3), and Arizona 
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ARBOVIRAL DISEASES, WEST NILE VIRUS. Incidence* of reported cases of neuroinvasive disease, by 
year — United States, 2005–2014
* Per 100,000 population. Data from the Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic 
Infectious Diseases (ArboNET Surveillance).
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BABESIOSIS. Number of reported cases, by county — United States, 2014
Abbreviation: N = not reportable.
Babesiosis, a tickborne parasitic disease, became a nationally notifiable condition in 2011. In 2014, babesiosis 
was reportable in 31 states. Twenty-two of the 31 states reported at least one case; however, 1,636 (94%) of 
the 1,744 reported cases occurred in residents of seven of the states in which tickborne transmission of Babesia 
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BOTULISM, FOODBORNE. Number of reported cases, by year — United States, 1994–2014
The number of foodborne botulism cases, caused by ingestion of preformed toxin, increased slightly from 
2013 but remains below the average of the preceding 20 years. Pruno, which caused the 2011 and 2012 
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Infant botulism remains the most common transmission category of botulism in the United States and 
accounted for most botulism cases in 2014. Reported cases have increased since 2010, but declined slightly 
from 2013 to 2014.
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BOTULISM, OTHER. Number* of reported cases, by year — United States, 2004–2014
* Includes wound and unspecified.
Annual number of cases of wound botulism and of botulism in “unspecified” transmission categories have 
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BRUCELLOSIS. Number of reported cases — United States and U.S. territories, 2014
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BRUCELLOSIS. Number of reported cases, by year — United States, 1984–2014
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CHLAMYDIA. Incidence* of reported cases among women aged 15–24 years — United States and 
U.S. Territories, 2014
* Per 100,000 population.
Among women aged 15–24 years, the population targeted for chlamydia screening, the overall rate of reported 
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CHOLERA. Number of reported cases — United States and U.S. territories, 2014
 
In 2014, five travel-associated cases of cholera were reported from four states.
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COCCIDIOIDOMYCOSIS. Number of reported cases — United States and U.S. territories, 2014
Abbreviation: N = not reportable.
In the United States, coccidioidomycosis is endemic in Southwestern states. However, the fungus that causes 
coccidioidomycosis also was recently found in south-central Washington. Cases reported from states outside 
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CRYPTOSPORIDIOSIS. Incidence* of reported cases, by year — United States, 2003–2014
* Per 100,000 population.
The incidence of reported cryptosporidiosis after 2007 remains elevated (>2.5 cases per 100,000 population) 
relative to the baseline observed before 2005 (<1.5). Whether this increase reflects a change in the true incidence 
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CRYPTOSPORIDIOSIS. Incidence* of reported cases — United States and U.S. territories, 2014
Abbreviation: N = not reportable.
* Per 100,000 population.
Cryptosporidiosis is widespread geographically in the United States. Although incidence appears to be consistently 
higher in certain states, differences in reported incidence among states might reflect differences in risk factors; 
the number of cases associated with outbreaks; or the capacity to detect, investigate, and report cases. 
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CYCLOSPORIASIS. Number of reported cases — United States and U.S. territories, 2014
Abbreviation: N = not reportable.
In 2014, a total of 398 cases (356 confirmed and 42 probable) were reported from 30 states and New York City. 
Of these, 275 (69%) were domestically acquired (i.e., they occurred in persons with no known history of travel 
outside the United States and Canada during the 14-day incubation period), at least 244 (89%) of which 
occurred in persons with onset of illness during May–August. A vehicle of infection (fresh cilantro from Mexico) 
was identified for 26 cluster-associated cases in Texas.
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DENGUE VIRUS INFECTION. Number* of reported cases, by age group — United States, 2014
* Data from the Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases 
(ArboNET Surveillance). Three age unknown cases of dengue fever. No cases of dengue hemorrhagic fever were 
reported in 2014 in travelers or residents of U.S. territories.
All age groups were affected by dengue.
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DENGUE FEVER AND DENGUE HEMORRHAGIC FEVER. Number* of reported cases, by location of 
residence — United States and U.S. territories, 2014
* Number of dengue fever cases/dengue hemorrhagic fever cases. Data from the Division of Vector-Borne Diseases, 
National Center for Emerging and Zoonotic Infectious Diseases (ArboNET Surveillance). The District of Columbia 
reported 2/0 cases, New York City 42/0, and U.S. Virgin Islands 19/0.
California, New Jersey, and Arizona reported the most dengue cases. No cases of dengue hemorrhagic fever 
were reported in 2014 in travelers or residents of U.S. states and territories.
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DIPHTHERIA. Number of reported cases, by year — United States, 1984–2014
Reported diphtheria is rare in the United States; no more than one case per year has been reported since 2003.
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EHRLICHIOSIS AND ANAPLASMOSIS, ANAPLASMA PHAGOCYTOPHILUM. Number of reported cases, 
by county — United States, 2014
Cases are reported primarily from the Upper Midwest and coastal New England, reflecting both the range of 
the primary tick vector species, Ixodes scapularis, which is also known to transmit Lyme disease and babesiosis, 
and the range of preferred animal hosts for tick feeding.
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EHRLICHIOSIS AND ANAPLASMOSIS, EHRLICHIA CHAFFEENSIS. Number of reported cases, by county — 
United States, 2014
Ehrlichia chaffeensis is the most common type of ehrlichiosis infection in the United States. This tickborne 
pathogen is transmitted by Amblyomma americanum, the lone star tick, whose geographic range extends 
from the Southeast into parts of the Northeast and Midwest. The majority of cases of E. chaffeensis ehrlichiosis 
are reported from the Midwest, South, and Northeast regions.
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EHRLICHIOSIS AND ANAPLASMOSIS, EHRLICHIA EWINGII. Number of reported cases, by county — 
United States, 2014
Ehrlichia ewingii is the least common cause of ehrlichiosis. Ehrlichia ewingii is carried by Amblyomma americanum, 
the tick, which is the same vector that transmits E. chaffeensis and whose geographic range extends from the 
Southeast into parts of the Northeast and Midwest. No serologic tests are used to distinguish between the 
two species, and differentiation can only be made by molecular genotyping.
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EHRLICHIOSIS AND ANAPLASMOSIS, UNDETERMINED. Number of reported cases, by county — 
United States, 2014
Cases of ehrlichiosis and anaplasmosis caused by an undetermined species are reported across the United States 
but are more likely to be reported in the Midwest region and the Middle Atlantic division. This classification 
of “undetermined” is most often used in areas where no clear geographic boundary separates the individual 
tick vectors. In the Upper Midwest, some cases are likely caused by Ehrlichia muris-like agent, a recognized 
cause of ehrlichiosis in the United States. Because ehrlichiosis and anaplasmosis elicit some cross reactivity in 
antibody detection, this category can also be used when single, inappropriate diagnostic tests are performed 
that do not provide differentiation of etiology.
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GIARDIASIS. Incidence* of reported cases, by year — United States, 2003–2014
* Per 100,000 population.
The incidence of giardiasis decreased in 2014, continuing a general decrease that began in 2011 following 
several years of stable reporting. Factors contributing to this decrease might include a decrease in disease 


















2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
MMWR / Published October 14, 2016, for 2014 / Vol. 63 / No. 54 101
Morbidity and Mortality Weekly Report
US Department of Health and Human Services/Centers for Disease Control and Prevention
GONORRHEA. Incidence* of reported cases — United States and U.S. territories, 2014
* Per 100,000 population.
In 2014, rates of reported gonorrhea cases per 100,000 population ranged by state from 13.4 in Vermont to 
193.6 in Louisiana; the gonorrhea rate in the District of Columbia was 285.8.
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GONORRHEA. Incidence* of reported cases, by sex — United States, 1994–2014
* Per 100,000 population.
Since 2013, the rate of reported cases of gonorrhea among men was higher than the rate among women. 
During 2010-2014, the rate among men increased from 94.1 to 119.1 (26.5%) and the rate among women 
decreased from 106.5 to 100.4 (5.7%). During 2013-2014, the rate among men increased from 109.5 to 119.1 
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GONORRHEA. Incidence* of reported cases among women aged 15–24 years — United States and 
U.S. territories, 2014
* Per 100,000 population.
In 2014, rates per 100,000 population of reported gonorrhea cases continued to be highest among adolescents 
and young adults. For women, the highest rates were observed among those aged 20–24 years (531.0) and 
15–19 years (431.7).







104 MMWR / Published October 14, 2016, for 2014 / Vol. 63 / No. 54
Morbidity and Mortality Weekly Report
US Department of Health and Human Services/Centers for Disease Control and Prevention
HAEMOPHILUS INFLUENZAE, INVASIVE DISEASE. Incidence* of reported cases, by serotype among 
persons aged <5 years — United States, 2001–2014
* Per 100,000 population.
Rates of all invasive Haemophilus influenzae disease remain low; the majority of invasive disease in children aged 
<5 years is caused by nontypeable Haemophilus influenzae. Haemophilus influenzae Type b incidence remains below 
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HAEMOPHILUS INFLUENZAE, INVASIVE DISEASE. Incidence* of reported cases, by serotype among 
persons aged ≥5 years — United States, 2001–2014
* Per 100,000 population.
Rates of all invasive Haemophilus influenzae disease remain low; the majority of invasive disease in persons aged 
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HANSEN’S DISEASE (LEPROSY). Number of reported cases, by year — United States, 1994–2014
An annual average of 89 Hansen’s disease cases have been reported since 2000, with a low of 66 in 2006 and a high 
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HEMOLYTIC UREMIC SYNDROME, POSTDIARRHEAL. Number of reported cases — United States and 
U.S. territories, 2014
Abbreviation: N = not reportable.
In 2014, a total of 41 of 56 jurisdictions (states, districts, and territories) reported cases, and three jurisdictions did 
not report their data. Most cases of postdiarrheal hemolytic uremic syndrome are caused by Shiga toxin-producing 
Escherichia coli.
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HEPATITIS, ACUTE A. Incidence* of reported cases, by county — United States, 2014
* Per 100,000 population.
Although effective vaccines to prevent Hepatitis A infections have been available in the United States since 1995, in 
2014, at least one case occurred in each state. A total of 1,239 cases were reported, and nine counties in seven states 
reported incidence rates of ≥10 cases per 100,000 population.
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HEPATITIS B, PERINATAL INFECTION. Number of reported cases — United States and U.S. territories, 2014
Abbreviations: N = not reportable; U = data not available.
In 2014, a total of 16 states reported 47 cases of perinatal hepatitis B. Because of the asymptomatic nature of 
hepatitis B (HBV) in young children, lack of timely testing among exposed infants, and incomplete reporting of infants 
with hepatitis B, the reported number of cases of perinatal hepatitis B is considered low and probably represents 
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HEPATITIS, ACUTE C. Number of of reported cases, by year — United States, 2000–2014
After declining during 2000–2005, then remaining stable at approximately 800–1000 reported cases per year until 
2010, reported acute hepatitis C cases doubled during 2011–2014. The rate of increase has slowed, and the number 
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HUMAN IMMUNODEFICIENCY VIRUS DIAGNOSES. Percentage of diagnosed cases, by race/ethnicity — 
United States, 2014
Among persons with HIV infection diagnosed in 2014, the greatest percentage was among blacks/African Americans, 
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HUMAN IMMUNODEFICIENCY VIRUS DIAGNOSES. Diagnosis incidence* — United States and 
U.S. territories, 2014
* Per 100,000 population.
The highest rates (i.e., ≥15 diagnoses per 100,000 population) of HIV diagnoses were in certain states in the Southeast 
and Northeast as well as the District of Columbia and the U.S. Virgin Islands.
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INFLUENZA-ASSOCIATED PEDIATRIC MORTALITY. Incidence* of reported cases — United States and 
U.S. territories, 2014
* Per 100,000 population.
In 2014, New York City and 34 states reported 141 influenza-associated pediatric deaths for an overall incidence rate 
of 0.19 deaths per 100,000 children aged <18 years.
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LEGIONELLOSIS. Incidence* of reported cases, by year — United States, 1999–2014
* Per 100,000 population.
From 2013 to 2014, the incidence of legionellosis increased, continuing a general increase that began in 2003. 
Decreases since 2003 did not result in a lower incidence beyond the immediate past year. Factors potentially 
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LEPTOSPIROSIS. Number of reported cases, by year — United States and U.S. territories, 
1947–2014
In 2014, of 107 leptospirosis cases reported, 38 were from U.S. states and 69 were from Puerto Rico, demonstrating 
a substantial increase in cases reported in Puerto Rico compared to all previous years that leptospirosis was notifiable 
(1947–1994). Although leptospirosis was first notifiable starting in 1947, territories did not begin reporting cases 















1944 1949 1954 1959 1964 1969 1974 1979 1984 1989 1994 1999 2004 2009 2014
Not notiable from
1995-2013
116 MMWR / Published October 14, 2016, for 2014 / Vol. 63 / No. 54
Morbidity and Mortality Weekly Report
US Department of Health and Human Services/Centers for Disease Control and Prevention
LISTERIOSIS. Incidence* of reported cases — United States and U.S. territories, 2014
* Per 100,000 population.
In 2014, a total of 47 states, the District of Columbia, and New York City reported 769 cases of Listeriosis for an overall 
incidence rate of 0.24 infections per 100,000, which is unchanged from 2013.
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LYME DISEASE. Incidence* of reported confirmed cases, by county — United States, 2014
* Per 100,000 population.
Although it is one of the most common nationally notifiable diseases, Lyme disease does not occur nationwide. 
Approximately 95% of confirmed Lyme disease cases are reported from states in the Northeast, mid-Atlantic, and 
upper Midwest. Many cases reported from other states are associated with travel to areas where Lyme disease is 
common. A rash that can be confused with and might be reported as Lyme disease sometimes occurs following bites 
of the lone star tick (Amblyomma americanum). These ticks, which do not transmit the Lyme disease bacterium, are 
common human biting ticks in the southeastern United States.
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MALARIA. Number of reported cases — United States and U.S. territories, 2014
In 2014, cases of malaria were reported from almost every jurisdiction, and nearly all cases reported in the United 
States were imported. Cases in eight jurisdictions (California, Georgia, Maryland, New Jersey, New York City, 
Pennsylvania, Texas, and Virginia) accounted for 53% of the reported cases because of large immigrant populations 
and international travelers. 
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MEASLES. Incidence* of reported cases, by year — United States, 1979–2014
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MENINGOCOCCAL DISEASE. Incidence* of reported cases, by year — United States, 1984–2014
* Per 100,000 population.
In 2014, meningococcal disease incidence remained at an historic low in the United States. However, 
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MUMPS. Incidence* of reported cases, by year — United States, 1989–2014
* Per 100,000 population.
The widespread use of a second dose of mumps vaccine beginning in 1989 was followed by historically low morbidity 
until 2006, when the U.S. experienced the largest mumps outbreak in two decades. The 2006 outbreak of approximately 
6,000 cases primarily affected college students aged 18–24 years in the Midwest. A second large outbreak occurred 
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PERTUSSIS. Incidence* of reported cases, by age — United States, 2014
* Per 100,000 population.
In 2014, the incidence of pertusis among infants remained highest, and the increased incidence among adolescents 
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PERTUSSIS. Incidence* of reported cases, by year — United States, 1984–2014
* Per 100,000 population.
Although substantially lower than the incidence observed during the prevaccine era, overall pertussis incidence 
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Q FEVER, ACUTE AND CHRONIC. Number* of reported cases — United States and U.S. territories, 2014
Abbreviation: N = not reportable.
* Number of Q fever acute cases/number of Q fever chronic cases.
Q fever, caused by Coxiella burnetii, is reported throughout the United States. Human cases of Q fever most often 
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RABIES, ANIMAL. Number* of reported cases, by county — United States, 2014
* Data from the Division of High Consequence Pathogens and Pathology, National Center for Emerging and 
Zoonotic Infectious Diseases.
In 2014, rabid animals were reported in all jurisdictions except Hawaii. Because reporting is based on the number of 
animals tested, the burden of disease is likely underestimated.
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RUBELLA. Incidence* of reported cases, by year — United States, 1984–2014
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SHIGA TOXIN-PRODUCING ESCHERICHIA COLI (STEC). Incidence* of reported cases — United States
and U.S. territories, 2014
* Per 100,000 population.
Incidence rates for STEC infection were generally highest in northern states.
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SALMONELLOSIS AND SHIGELLOSIS. Incidence* of reported cases, by year — United States, 
1984–2014
* Per 100,000 population.
Although incidence rates of salmonellosis have remained relatively stable since the early 1990s, incidence rates of 
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SPOTTED FEVER RICKETTSIOSIS. Number of reported cases, by county — United States, 2014
In the United States the majority of cases of spotted fever rickettsiosis are attributed to infection with Rickettsia 
rickettsii, the causative agent of Rocky Mountain spotted fever (RMSF), but might also be from other agents such as 
Rickettsia parkeri and Rickettsia species 364D. RMSF is ubiquitous across the United States, which represents the 
widespread nature of the three tick vectors known to transmit RMSF: Dermacentor variabilis in the East, Dermacentor 
andersoni in the West, and Rhipicephalus sanguineus in parts of Arizona.
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SYPHILIS, CONGENITAL. Reported cases among infants, by year of birth and incidence* of primary 
and secondary syphilis among women — United States, 2005–2014
Abbreviations: CS = congenital syphilis; P&S = primary and secondary syphilis.
* Per 100,000 population.
After decreasing from 431 cases in 2008 to 322 cases in 2012, the number of reported congenital syphilis cases 
increased to 348 in 2013. From 2013 to 2014, reported cases increased 31.6% to 458 in 2014. As has been observed 
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SYPHILIS, PRIMARY AND SECONDARY. Rate* of reported cases, by sex and male-to-female rate ratio — 
United States, 2005–2014
* Per 100,000 population.
In 2014, the rate of reported primary and secondary (P&S) syphilis cases among men (11.6 cases per 100,000 males) 
was substantially higher than rates among women (1.1), and men accounted for the large majority (87.1%) of P&S 
syphilis cases with known sex. Among men, the rate of P&S syphilis has increased every year since 2000, and during 
2013–2014, the rate among men increased from 10.3 to 11.6 (12.6%).  In contrast, the P&S syphilis rate among women 
has fluctuated between 0.8 and 1.8 since 2000.  During 2013–2014, the P&S syphilis rate among women increased 
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SYPHILIS, PRIMARY AND SECONDARY. Incidence* of reported cases — United States and 
U.S. territories, 2014
* Per 100,000 population.
In 2014, rates of reported primary and secondary (P&S) syphilis cases per 100,000 population ranged by state from 
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TRICHINELLOSIS. Number of reported cases, by year — United States, 1984–2014
In 2014, a total of 13 trichinellosis cases were reported. One outbreak of two confirmed and two probable cases 
occurred in persons from four states who consumed meat from a black bear that was hunted in Alaska. Overall, a 
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TUBERCULOSIS. Incidence* of reported cases — United States and U.S. territories, 2014
* Per 100,000 population.
In 2014, eight states, New York City, and the District of Columbia had tuberculosis (TB) incidence rates above the 2013 
national average of 3.0 per 100,000 persons. The decline in the TB incidence rate in 2014 was the smallest in over 
two decades and there was not much change from 2013. 
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TUBERCULOSIS. Incidence* of reported cases, by race/ethnicity — United States, 2004–2014
* Per 100,000 population. Data from the Division of Tuberculosis Elimination, National Center for HIV/AIDS, 
Viral Hepatitis, STD, and TB Prevention.
Declines in tuberculosis (TB) incidence were reported in all race-ethnic groups in 2014 except Hispanics, which was 
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TUBERCULOSIS. Number* of reported cases among U.S.-born and foreign-born persons,† by year — 
United States, 2004–2014
* Number represented is in thousands. Data from the Division of Tuberculosis Elimination, National Center for 
HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.
† For 18 cases, origin of patients was unknown.
The proportion of tuberculosis cases in foreign-born persons continues to increase. In 2014, of 9,421 reported cases, 
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TULAREMIA. Number of reported cases — United States and U.S. territories, 2014
During 1990–2010, an average of 125 cases of tularemia were reported in the United States each year. Since 2011, 
the number of reported cases has been above this historical average. Most cases are reported from south-central 
states. In 2014, Colorado reported a much higher number of cases than in previous years.
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TYPHOID FEVER. Incidence* of reported cases, by year — United States, 1984–2014
* Per 100,000 population. 
In the United States, typhoid fever continues to occur primarily among travelers to countries where typhoid fever is 
endemic, for whom vaccination against typhoid fever is recommended. During the preceding 30 years, the annual 
number of typhoid fever cases peaked in 1990 (552 cases) and then declined to a low of 321 cases in 2002. Case 
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VARICELLA (CHICKENPOX). Number of reported cases — Illinois, Michigan, Texas, and West Virginia, 
1992–2014
In four states (Illinois, Michigan, Texas, and West Virginia), the number of varicella cases reported in 2014 was 19% 
lower than 2013, 85% lower than the average annual number reported during the mature 1-dose varicella vaccination 





















1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014
Vaccine licensed
 Universal second dose 
 recommended
140 MMWR / Published October 14, 2016, for 2014 / Vol. 63 / No. 54
Morbidity and Mortality Weekly Report
US Department of Health and Human Services/Centers for Disease Control and Prevention
VIBRIOSIS. Number of reported cases — United States and U.S. territories, 2014
Abbreviation: N = not reportable.
In 2014, a total of 1,261 cases of vibriosis were reported. California, Florida, Washington, and Texas reported the 
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